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Abstract
Otosclerosis is a relatively common hearing loss disorder characterized by abnormal bone
growth in the otic capsule leading to stapes fixation. In approximately half of cases, otosclerosis
is inherited as an autosomal dominant trait. Typically, gene discovery efforts rely on surgical
confirmation, audiometry and occasionally acoustic reflexes to identify affected cases of
otosclerosis within families, requiring that the otosclerosis was at an advanced stage to be
detected. This makes it difficult to identify individuals with early otosclerosis. The use of
advanced phenotyping to identify cases of otosclerosis was tested in an Ontario otosclerotic
population as well as in two large Newfoundland families, one with otosclerosis due to a newly
discovered deletion in the FOXL1 gene. Family history questionnaires revealed that
approximately two-thirds of Ontario probands had a significant family history of non-congenital
hearing loss with almost half of those probands reporting another family member with
otosclerosis. Furthermore, all Ontario probands were screened for the FOXL1 deletion identified
in the NL family, with one testing positive, providing evidence that FOXL1 may underlie cases
of otosclerosis in other populations.
The otosclerotic phenotype of prospective data obtained in a surgically-confirmed
Ontario cohort was quite variable with 30% of subjects presenting with unilateral otosclerosis
and 9% presenting with sensorineural hearing loss (SNHL) in their non-surgical ear. Results
suggest that distortion product otoacoustic emissions and acoustic reflex thresholds are absent in
all surgical ears, SNHL ears and ears with a conductive hearing loss. To further enhance the
advanced phenotyping of otosclerosis, power absorbance (PA) was analyzed to determine its
utility as a phenotyping tool. Results suggest that PA has a valid test-retest reliability, but that
instrument and stimulus effects are present.
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Advanced phenotyping was used to develop a predictive model for FOXL1-associated
otosclerosis suggesting a progressive mixed hearing loss. Phenotyping in a second large, nonFOXL1 family identified members with suspected early disease progression. Early identification
of otosclerosis, without having to wait for a surgical confirmation, will aid future gene discovery
research. Furthermore, insights gained from advanced phenotyping in sub-clinical gene carriers
can provide a deeper understanding of the natural history of otosclerosis.

Keywords
immittance, middle ear analysis, power absorbance, reflectance, wideband acoustic immittance,
genetics, phenotyping, advanced phenotyping, otosclerosis, hearing disorder
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Summary for Lay Audience
Otosclerosis is a heritable bone disorder characterized by abnormal bone growth within
the ear occurring later-in-life. When the abnormal bone growth invades the middle ear, it results
in a conductive hearing loss, however, it can cause a sensorineural hearing loss if the abnormal
bone growth invades the cochlea. Recently, the first causative gene (FOXL1) for the disorder was
identified in a large Newfoundland family. In an Ontario otosclerosis population, FOXL1 was
screened, and one subject was identified with the mutation, providing evidence that the FOXL1
mutation occurs outside of the family where it was originally found. Advanced phenotyping,
using clinical tools to measure the physiological changes of a trait, was used in an Ontario
otosclerotic population, as well as in two large families with otosclerosis. Results from the
Ontario otosclerotic population confirmed that the clinical presentation of otosclerosis is
variable. Subjects had hearing loss in one or both ears, as well as the conductive or sensorineural
form of the hearing loss, or a combination of the two referred to as a mixed hearing loss. A
normative study was conducted to investigate whether, power absorbance (PA), a measure of
how sound can travel through the middle ear, is a valid phenotyping tool for otosclerosis. Results
suggest that PA is different in otosclerotic ears compared to typical ears and could be used for
future phenotyping studies. Advanced phenotyping of a large Newfoundland family with family
members carrying the mutation in FOXL1 gene suggests that the clinical features of otosclerosis
can present quite variably even when the same gene is responsible for the hearing loss. A
predictive model of otosclerosis caused by FOXL1 was also created which suggests a progressive
mixed hearing loss in affected gene carriers. Finally, advanced phenotyping was conducted in a
separate large otosclerotic Newfoundland family of unknown genetic cause. Results suggest that
using an advanced phenotyping approach has the possibility of improving future genetic and
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clinical studies of otosclerosis by possibly identifying early indicators of otosclerosis
progression.
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Chapter 1

1

Overview of Thesis

1.1 Rationale
Otosclerosis (OTSC) is a common hearing disorder associated with abnormal sclerotic
bone growth within the otic capsule and is found in approximately 2.5% of the population
(Crompton et al., 2019; Declau et al., 2001; Sakihara & Parving, 1999). One feature of
otosclerosis is hearing loss due to the sclerotic bone growth around the stapes, causing stapes
fixation, or invading the cochlea causing sensorineural hearing loss (Batson & Rizzolo, 2017). In
many cases, both conductive hearing loss and sensorineural hearing loss can be present, a clinical
phenomenon called mixed hearing loss (Crompton et al., 2019; Ishai, Halpin, Shin, McKenna, &
Quesnel, 2016; Sakihara & Parving, 1999; Schuknecht & Barber, 1985). However, hearing loss
due to otosclerosis is not present in all cases with otosclerosis. Hearing loss caused by
otosclerosis is estimated to be present in 0.3-0.4% of the Caucasian population (Declau et al.,
2001), while the presence of histological otosclerosis without hearing loss is much higher,
around 3.5% as determined by post-mortem investigations of temporal bones (Declau et al.,
2001; Schuknecht & Barber, 1985). Otosclerosis is heritable in approximately half of all cases
and transmitted in an autosomal dominant manner, requiring one copy of the affected allele to
exhibit the hearing loss (Thys & Camp, 2009). Research into the genetic etiology of otosclerosis
has identified ten regions within the human genome, named OTSC 1-10, which may be
separately responsible for monogenic (caused by mutations in a single gene) forms of the
disorder. These genetic loci, OTSC1-10, have been identified in large multiplex families, where
multiple 1st and 2nd degree family members present with otosclerosis. Currently OTSC 6 and 9
are reserved but not yet published (Bel Hadj Ali et al., 2008; Brownstein, Goldfarb, Levi,
1

Frydman, & Avraham, 2006; Chen et al., 2002; Pauw et al., 2006; Schrauwen et al., 2011; Thys,
Van Den Bogaert, et al., 2007; Tomek et al., 1998; Van Den Bogaert et al., 2001). Despite years
of research, none of these OTSC loci yielded a causative gene until Abdelfatah (2014) identified
FOXL1, the first gene underlying autosomal dominant otosclerosis in a large Newfoundland
family.
It is important to characterize the phenotypic features of otosclerosis, both in genetic and
sporadic forms (unknown etiology). Currently, genetic studies of families with otosclerosis have
relied on surgical confirmation of otosclerotic bone growth or audiometric thresholds showing
significant conductive or mixed hearing loss, in order to identify family members affected by
otosclerosis (Bel Hadj Ali et al., 2008; Brownstein et al., 2006; Chen et al., 2002; Thys, Van Den
Bogaert, et al., 2007; Tomek et al., 1998; Van Den Bogaert et al., 2001; Weegerink et al., 2011),
with few considering additional phenotyping measurements of middle ear muscle reflexes or
otoacoustic emissions (Bel Hadj Ali et al., 2008; Van Den Bogaert, 2004; Weegerink et al.,
2011), or advanced temporal bone imaging (Bel Hadj Ali et al., 2008). Comprehensive
phenotyping beyond pure tone audiometry or surgical confirmation could facilitate the discovery
of other gene mutations causing otosclerosis. Physiological measures of auditory system
function, such as middle ear muscle reflexes or otoacoustic emissions (Bel Hadj Ali et al., 2008;
Van Den Bogaert, 2004; Weegerink et al., 2011) and temporal bone imaging using high
resolution computed tomography (Bel Hadj Ali et al., 2008), have been used clinically and in
otosclerosis research, but not systematically applied in genetic studies of otosclerosis.
Advanced phenotyping of otosclerosis can also have a significant impact on the discovery
of other genetic mutations responsible for the development of otosclerosis in families inheriting
an autosomal dominant form. This is achieved by identifying individuals with otosclerotic
2

hearing loss in the family versus those unaffected or with hearing loss due to another etiology.
The current gold standard for a confirmed diagnosis of otosclerosis is through corrective surgery
(Quesnel et al., 2013). However, not all cases of otosclerotic hearing loss require, or can be
resolved by corrective surgery, as is the case with cochlear otosclerosis (Cureoglu, Yildirim, &
Paparella, 2010; Doherty & Linthicum, 2004; Schuknecht & Kirchner, 1974). The use of
advanced phenotyping measurements promises to improve the accuracy of otosclerosis diagnosis
in families with suspected otosclerosis to ensure the proper diagnosis is given to each case.
Furthermore, the early identification of genetic mutations causing otosclerosis can
improve the clinician’s ability to identify individuals at risk of developing this progressive
disease. Once a causative genetic mutation is identified, a clinical genetic test could be
developed to identify whether the mutation is present within an individual or within a family
(Abdelfatah, 2014; Ealy & Smith, 2010; Ealy, 2011; Morrison, 1967). Advanced phenotyping
can be used in conjunction with genetic testing to determine whether carriers of the mutation
demonstrate any early indicators or sub-clinical features of the development of the hearing loss.
Since otosclerosis causes a later onset hearing loss, typically developing between the third and
fifth decade of life (Crompton et al., 2019; Gordon, 1989; Rudic et al., 2015), incorporating
advanced phenotyping with genetic testing could improve clinical care by monitoring the
progression of the disorder, and choosing the appropriate clinical interventions or future
treatments based on this progression.
As the genes underlying genetic forms of otosclerosis are identified, so too will the
creation and implementation of treatments to slow, stop or reverse hearing loss associated with
otosclerosis. Advanced phenotyping will aid in the early identification of patients with subclinical symptoms and be used to track progression of the disease, which are important for
3

patient management and monitoring treatment efficacy. In the case of known genetic mutations,
advanced phenotyping will contribute to our understanding of the natural history and clinical
course of the disorder.
Up to this point, the use of various treatments for otosclerosis have been investigated with
no substantial evidence of success. For example, fluoride was proposed as a treatment method to
slow the progression of otosclerosis-associated hearing loss due to its ability to decrease
osteoclast activation and therefore slow the bone resorption pathway (Cruise, Singh, & Quiney,
2010; House & Linthicum, 1974; Liktor, Szekanecz, Batta, Sziklai, & Karosi, 2013). With
advances in knowledge about the genetic etiology of otosclerosis and the underlying pathological
mechanisms of otosclerosis revealed, there will undoubtedly be new treatment options for
otosclerosis beyond a surgical one. Advanced phenotyping measures will be useful outcome
measures for investigating the efficacy of novel gene therapy or pharmaceutical treatments for
preventing or treating otosclerosis.
The main purpose of this research is to improve the advanced phenotyping of otosclerosis
in order to facilitate future gene discovery studies of otosclerosis and enhance our understanding
of the natural history and variability of otosclerosis.
The specific aims are to:
1. Investigate the value of advanced phenotyping features in genetic studies of otosclerosis,
by investigating a clinical population diagnosed with otosclerosis, and two families with
heritable forms of otosclerosis.
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2. Address whether the gene mutation causing otosclerosis in a large multigenerational
family in Newfoundland (NL) is present in a clinical population from Ontario (Canada).

1.2 Organization of Thesis
The thesis is organized into seven chapters including this introductory chapter. Chapter 2
reviews the literature covering relevant topics of this thesis. Relevant topics include the clinical
presentation of otosclerosis, middle ear measurements including wideband acoustic immittance
and the genetics of otosclerosis. The advanced phenotype, family history and genotype of
otosclerosis are explored in an Ontario population with clinical diagnosis of otosclerosis in
Chapter 3. In Chapter 4, wideband acoustic immittance (WAI) will be evaluated as a potential
phenotypic measurement of middle ear function, focusing on instrument and stimulus level
effects, and test-retest reliability, in a normal hearing population and an otosclerotic cohort. The
utility of WAI as an advanced phenotypic measurement in conjunction with other auditory
phenotyping tools will then be applied to two families with otosclerosis. The first family study,
the large NL family with the known mutation causing otosclerosis is presented in Chapter 5.
Phenotyping of this family will provide the natural history and clinical course of otosclerosis due
a known genetic mutation. The second family presented in Chapter 6 is another large family
from NL with heritable otosclerosis of unknown etiology. An advanced phenotyping approach
was used to characterize the auditory phenotype of family members to facilitate segregation for
the purpose of future gene discovery research.
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Chapter 2

2
2.1

Literature Review
Pathology of Otosclerosis
Otosclerosis, first described by Politzer (1894), is a bone remodeling disorder and is

characterized by the abnormal hardening of bone growth within the otic capsule. The term
otosclerosis can be broken down to the root words oto, meaning “in the ear”, and sclerosis,
referring to abnormal hardening of tissue. The hardened bone frequently occurs around the stapes
resulting in fixation of the stapes footplate causing an increase in the stiffness of the middle ear
system. The stiffening of the middle ear system is responsible for the characteristic conductive
hearing loss associated with the disorder (Cherukupally, Merchant, & Rosowski, 1998; Vittorio
Colletti, Fiorino, Sittoni, & Policante, 1993; Hannley, 1993; Shahnaz & Polka, 1997; Fei Zhao et
al., 2002), however there are variations to the profile of the disorder, which can include
sensorineural, mixed, or no hearing loss (Declau et al., 2001; Schuknecht & Barber, 1985;
Schuknecht & Kirchner, 1974; Uppal, Bajaj, Rustom, & Coatesworth, 2009). It was proposed by
Schuknecht & Kirchner (1974) that three separate definitions of otosclerosis be used. These
include clinical otosclerosis, cochlear otosclerosis and histological otosclerosis. Clinical
otosclerosis represents a form of the disease-causing stapes fixation resulting in conductive
hearing loss. Cochlear otosclerosis is the form of otosclerosis where the otosclerotic foci has
replaced a portion of the endosteal layer of bone of the cochlea resulting in a sensorineural
hearing loss (Cureoglu et al., 2010; Quesnel et al., 2013; Schuknecht & Kirchner, 1974;
Shambaugh, 1965). Finally, histological otosclerosis is the form where the sclerotic foci do not
invade the stapes or the cochlea, yet, there is one or more otosclerotic foci located in the bony
labyrinth. The cases with histological otosclerosis do not exhibit any associated hearing loss, or
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clinical symptoms, since the sclerotic foci are found in the bony labyrinth (McKenna &
Merchant, 2010; Schuknecht & Barber, 1985).
Otosclerosis is a common type of hearing loss with prevalence rates at 2.5% of the
general population with some form of histological otosclerosis (based on temporal bone
histology), and 0.30-0.38% of who exhibit the symptoms of clinical otosclerosis (Cawthorne,
1955; Declau et al., 2001; Shambaugh, 1965). The disorder is highly heritable, whereby it is
estimated that approximately 50% of cases are caused by an inherited genetic change (Crompton
et al., 2019; Shin et al., 2001). The average age of onset of otosclerosis is typically in the third
and fourth decade (Gordon, 1989), however, the actual age of onset is difficult to recognize due
to a number of factors. The progression of otosclerosis varies greatly between individuals, and
the onset of hearing loss can be sudden, or progress slowly over time (Crompton et al., 2019;
Sakihara & Parving, 1999). When the hearing loss progresses slowly over time, an individual
may be less likely to notice their hearing loss, and therefore delay diagnosis of clinical
otosclerosis until well after the first signs of hearing loss have appeared.
There is no observable osteoclast or osteoblast activity within the normal otic capsule,
suggesting slow bone resorption and slow bone turnover rates (Frisch & Overgaard, 2000).
However, in the case of otosclerosis, there is an imbalance to the normal bone resorption
pathway, resulting in an increase in osteoblast and osteoclast activity (Chole & McKenna, 2001;
Declau et al., 2001). The etiopathogenesis of otosclerosis remains a mystery. There are a number
of studies investigating the pathogenesis of the disorder, suggesting many contributing factors
which include genetic predisposition, autoimmune factors, hormonal pathways, metabolic
influences, and inflammatory mechanisms (Karosi & Sziklai, 2010).

9

The progression of otosclerosis has been described in three phases; early phase,
transitional phase and late phase (reviewed by Rudic et al., 2015). Early phase otosclerosis is
characterized as the active phase of the disease involving otospongiosis. Otospongiosis is the
formation of spongy bone in the bony labyrinth of the ear. The formation of spongy bone occurs
due to active osteoclasts resorbing bone, causing lesions around the otic capsule. The lesions
become highly vascularized which open the way for increased osteocyte activity (Karosi,
Csomor, & Sziklai, 2012; Parahy & Linthicum, 1984; Schuknecht & Barber, 1985). Areas of
highly vascularized lesions and increased osteocyte activity become deprived of mature collagen,
and thus give rise to spongy bone growth (Rudic et al., 2015).
The late phase of otosclerosis involves the formation of sclerotic or dense bone in the
previously spongy bone growth areas of the otic capsule which characterize early phase
otosclerosis (Rudic et al., 2015). The term sclerosis simply refers to the hardening of tissue. It is
the advancement of sclerotic bone that causes stapes fixation and the classic form of conductive
hearing loss associated with clinical otosclerosis. However, there is variation in the localization
of sclerotic bone within the otic capsule, resulting in different types of hearing loss (conductive,
mixed, sensorineural).
When the otosclerotic foci invade the cochlear endosteum, a sensorineural component to
the hearing loss can arise (Schuknecht & Kirchner, 1974). It is suggested that otosclerotic foci
can cause atrophy of the spiral ligament and stria vascularis, which can prevent ion recycling and
alter the endocochlear potential required for proper cochlear hair cell function (Doherty &
Linthicum, 2004; McKenna & Merchant, 2010). Therefore, when the invasion of otosclerotic
foci reach the cochlea, a sensorineural component to the hearing loss can arise, resulting in a
mixed or sensorineural hearing loss in patients with otosclerosis. It is estimated that cochlear
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otosclerosis is responsible for approximately 1% of pure sensorineural hearing losses (Quesnel et
al., 2013; Schuknecht & Kirchner, 1974).

2.2

Clinical Presentation of Otosclerosis
The diagnosis of otosclerosis can only be confirmed at the time of corrective surgery for

stapes fixation but can be inferred clinically based on clinical symptoms. However, other hearing
disorders can clinically mimic otosclerosis, such as superior canal dehiscence (Merchant,
Rosowski, & McKenna, 2007) or enlarged vestibular aqueduct syndrome (Wieczorek, Anderson,
Harris, & Mikulec, 2013). An inferred diagnosis of stapes fixation due to otosclerosis is based on
the profile of otoscopy, tympanometry, pure-tone hearing thresholds and acoustic reflexes
(Emmett, 1993).
Otoscopy is conducted by looking into the ear canal towards the tympanic membrane
using an otoscope. In otosclerosis, the tympanic membrane may appear normal, however early in
the progression of the disorder, a reddish hue may be seen through the tympanic membrane
(Figure 1). This reddish hue, sometimes referred to as the Schwartz sign, suggests increased
vascularization within the middle ear associated with early stages of otosclerosis (Emmett, 1993;
Hannley, 1993; Purohit, Hermans, & Op de beeck, 2014).
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Figure 1. Otoscopy image of the reddish hue referred to as the “Schwartz Sign”. Schwartz sign
is circled in red. Image edited from:
https://commons.wikimedia.org/wiki/File:Normal_Left_Tympanic_Membrane.jpg#globalusage

Otosclerotic ears tend to have the typical ‘A’ or a shallower ‘As’ shape tympanogram. An
‘A’ shape tympanogram suggests maximum tympanic membrane compliance, or mobility,
around 0 dekapascals, daPa, or equal pressure in the external and middle ear. An ‘As’
tympanogram may be present in otosclerotic ears suggesting stiffness of the middle ear system.
This increased stiffness can therefore translate to a shallower compliance peak. However,
conventional tympanometry using a 226 Hz stimulus is not sensitive enough to distinguish
otosclerotic ears from normal ears (Shahnaz, Bork, et al., 2009; Shahnaz & Polka, 1997).
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Early in the development of otosclerosis, a low frequency conductive loss may begin to
appear below 2 kHz (Emmett, 1993; Hannley, 1993; Meranger, David, Beigner, Charpiot, &
Tavernier, 2019). A conductive hearing loss is diagnosed when air-conduction thresholds are
elevated compared to bone-conduction thresholds. The difference between air-conduction
thresholds and bone-conduction thresholds are referred to as the air-bone gap (ABG). Clinically,
a conductive hearing loss is when the ABG is greater than 10 dB at three neighbouring
frequencies. Otosclerosis may also cause a mixed or a sensorineural hearing loss (SNHL)
depending on the histological presentation of the disorder which can progress into advanced
otosclerosis, with air-conduction thresholds reaching the profound level (Calmels et al., 2007).
Mixed hearing loss is diagnosed when there is an ABG of greater than 10 dB at three
neighbouring frequencies and the bone-conduction thresholds are elevated compared to normal,
above 20 dB HL. A SNHL occurs when there is no ABG or an ABG of less than 10 dB, however
the bone-conduction thresholds are above the normal threshold level of 20 dB HL. Clinical
otosclerosis can be present either bilaterally or unilaterally, with bilateral otosclerosis occurring
in between 47-76% of otosclerosis cases (Hueb, Goycoolea, Paparella, & Oliveira, 1991;
Khorsandi, Jalali, & Shoshi, 2018).
Otosclerotic ears fail to have a stapedius muscle contraction in the presence of a loud
stimulus because of the increased stiffness of the middle ear. This increase stiffness results in
absent or elevated acoustic reflex thresholds (ARTs) (Hannley, 1993; Keefe et al., 2017;
Terkildsen, Osterhammel, & Bretlau, 1973). ARTs are a measure of the movement of the
tympanic membrane in response to an ipsilateral or contralateral stimulus. When a loud stimulus
is presented (85-110 dB SPL), the stapedius muscle is stimulated, causing contraction.
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The variability of clinical features of otosclerosis has been well known for decades.
Extensive histological studies have demonstrated the variability of otosclerotic foci within large
populations of otosclerotic subjects (Lagleyre et al., 2009; Schuknecht & Barber, 1985;
Schuknecht & Kirchner, 1974). These histological variations have been linked to differences in
the clinical presentation of the disorder, where patients have demonstrated unilateral or bilateral
hearing loss, either as a purely conductive hearing loss, mixed hearing loss, or sensorineural
hearing loss (Cherukupally et al., 1998; Ramsay & Linthicum, 1994; Shambaugh, 1965). Reports
also indicate that the disorder can be present without any notable clinical features, described as
histological otosclerosis (Schuknecht & Barber, 1985). The accurate diagnosis of otosclerosis is
crucial for genetic studies of otosclerosis to appropriately identify affection status (affected
versus unaffected).
There is an approximate 2:1 ratio in the incidence of otosclerosis in females to males
(Cawthorne, 1955; Ishai et al., 2016; Khorsandi et al., 2018; Marchese et al., 2009). There is
evidence suggesting that hearing thresholds in females may become worse following pregnancy
(Cawthorne, 1955; Crompton et al., 2019; Morrison, 1967). The increased incidence of
otosclerosis in females, specifically following pregnancy, has led to the hypothesis that hormone
pathways may influence the etiology of the disorder (Crompton et al., 2019; Imauchi et al.,
2008). However, recent case-controlled cohort studies comparing hearing thresholds of
otosclerotic women with children to those without children found no effects of pregnancy on presurgical hearing thresholds (Lippy, Berenholz, Schuring, & Burkey, 2005) or pre and postoperative functional outcomes (Marchese et al., 2009). Furthermore, Crompton et al. (2019)
compared age of onset and hearing levels between a cohort of female otosclerosis patients who
had a history of pregnancy (n=313) and those who had no history of pregnancy (n=96). They
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found no significant difference between groups for age of onset or hearing levels, thus providing
further evidence that pregnancy does not elevate the risk of developing otosclerosis. Therefore,
while the reported number of women affected with otosclerosis is approximately 2:1 compared
to males, and there are reports of otosclerosis occurring post-pregnancy, the evidence is still
mixed. It is possible that there is a sub-group of otosclerotic females where the hormonal
changes associated with pregnancy may increase the progression of hearing loss. In this case,
genes involved in the hormone pathways may contribute to the development and progression of
otosclerosis. The genetics of sex-specific differences in otosclerosis development is an
interesting area for further study.

2.3 Genetics of Otosclerosis
Familial conductive hearing loss was first described in the 19th century by Toynbee
(1841). In familial cases, otosclerosis is usually reported as an autosomal dominant pattern. A
century after the initial investigation of otosclerosis by Toynbee, a retrospective study conducted
by Cawthorne (1955) revealed that 54% of British otosclerotic patients disclosed that they had
one or more family member affected by a similar type of hearing impairment. More recently,
24% of an otosclerotic cohort from France, comprised of 211 surgically-confirmed patients,
reported having a family history of otosclerosis (Shin et al., 2001). Patients were asked via a
questionnaire whether they had a family member who was also diagnosed with otosclerosis.
Another 27% of their cohort reported a family history of hearing loss of unknown pathology.
This would suggest that approximately half of otosclerosis cases would be sporadic.
Genome wide association studies have been used to identify genes associated with
sporadic cases and use a case-control approach to determine if there are significant differences in
variant frequencies between cases and controls. Several genes identified as potentially important
15

include: COL1A1, RELN, TGFB1, BMP2, BMP4, AGT and ACE (Rodríguez et al. 2004; Imauchi
et al. 2008; Schrauwen et al. 2009; Khalfallah et al. 2011; Schrauwen et al. 2012; Ealy et al.
2014; Sommen et al. 2014; Mowat et al. 2018). A summary of the associated genes of
otosclerosis are presented in Table 1 and are also reviewed by Ealy & Smith (2010) and Thys &
Van Camp (2009).
Table 1. Summary of associated genes of otosclerosis identified through genome-wide
association studies. Summary of review by Ealy & Smith (2010).
Associated
Gene
COL1A1

Replicated

Expression/Function

Reference

Yes

Codes for alpha-1 type 1 collagen protein which
is a component of type 1 collagen. Hypothesized
to change bone remodeling process in otic
capsule.

RELN

Yes

TGFB1

Yes

Codes protein called reelin. Reelin is an
extracellular matrix protein which is involved in
the regulation of interactions between neurons
and glia. Reelin is also hypothesized to be
important for varying cell adhesion.
Encodes TGFB1 protein which is involved in the
embryogenesis in the otic capsule. Involved in
stimulating matrix protein synthesis.

McKenna et al. 1998;
Rodríguez et al. 2004;
Khalfallah et al. 2011;
Schrauwen et al. 2012;
Ertugay et al. 2013; Mowat
et al. 2018
Schrauwen et al. 2009;
Sommen et al. 2014; Mowat
et al. 2018

BMP2

Yes

BMP4

Yes

AGT

No

ACE

No

Part of the TGF- superfamily. BMP2 involved
in the recruitment and activation of transcription
factors of the SMAD family. Expressed in the
otic vesicle
Part of the TGF- superfamily. BMP4 involved
in the recruitment and activation of transcription
factors of the SMAD family. Expressed in the
otic vesicle.
Part of the renin-angiotensin system. Codes for
protein termed angiotensinogen. Angiotensinogen
involved in the regulation of blood pressure and
body fluid salinity.
Part of the renin-angiotensin system. Codes for
an angiotensin-converting enzyme. involved in
the regulation of blood pressure and body fluid
salinity.

Schrauwen et al. 2008;
Khalfallah et al. 2011;
Sommen et al. 2014; Mowat
et al. 2018
Schrauwen et al. 2008;
Khalfallah et al. 2011;
Sommen et al. 2014; Mowat
et al. 2018
Schrauwen et al. 2008;
Khalfallah et al. 2011;
Sommen et al. 2014; Mowat
et al. 2018
Imauchi et al. 2008;
Schrauwen et al. 2009;
Sommen et al. 2014
Imauchi et al. 2008;
Schrauwen et al. 2009

Otosclerosis is reported as a heritable disorder in approximately half of otosclerosis cases
in French and British otosclerotic populations (Crompton et al., 2019; Shin et al., 2001). When a
trait is inherited in an autosomal dominant manner, only one copy of the affected allele is
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required in order to express the altered phenotype. A summary of the eight chromosomal regions
(loci) harboring candidate genes for monogenic forms is presented in Table 2.
Genetic variants in SERPINF1 were reported as causing otosclerosis in four otosclerotic
families: three of European descent and one of European and Caribbean descent (Ziff et al.,
2016). However, a re-evaluation of the pathogenic mutations of SERPINF1 by Valgaeren et al.,
(2019) using a larger otosclerotic population of 126 patients from 63 families yielded conflicting
results raising into the question the pathogenicity of mutations in SERPINF1.
Abdelfatah (2014) reported the first gene causing otosclerosis using a large
multigenerational family from Newfoundland, Canada. Seven family members with otosclerosis
(confirmed via corrective stapes surgery) inherited a 15bp in-frame deletion in FOXL1, predicted
to remove five highly conserved amino acids from the expressed protein. Functional analysis
revealed that the deletion caused down-regulation of several downstream genes, including ILIA,
CXCL10, IL29, IFNB1, IFIT1, FEN1 and SP4. The identification of the causative gene in
familial otosclerosis, FOXL1, provides supportive evidence that molecular pathways involved
with inflammation and immunity along with anti-angiogenic activity play a role in the
development of otosclerosis. Abdelfatah (2014) concluded that candidate genes involved in these
pathways should be considered in order to identify other otosclerosis genes.
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Table 2. Summary of a selection of candidate genes located within each genetic locus segregating with familial otosclerosis. Summary
table created from information reviewed by Ealy & Smith (2010) along with gene information from Ziff et al. (2016) and Abdelfatah
(2014).
Locus
OTSC1

Chromosomal
Location
15q26.1-qter

Population
India

# of Genes
in Loci
33

Candidate
Genes
aggrecan

OTSC2

7q34-q36

Belgium

152

TIFIa

OTSC3

6p21.3-22.3

Cyprus

488

PLOD3
HLA

COL11A2
OTSC4

16q21-23.2

Israel

74

COG8, COG4
DDX19,
DDX28, DHX38
ZNF19, ZNF23,
ZNRF1, ZFP1
PCOLCE2
CHST2

OTSC5

3q22-q24

Netherlands

59

OTSC7

6q13-16.1

66

COL12A1

OTSC8

9p13.1-9q21.11

Greek
Netherlands
Tunisia

24

OTSC10

1q41-44

Netherlands

306

TJP2
TRMP3
KLF9
TGFB2

AGT
Gene
SERPINF1

17p13.3

FOXL1

16q24.1

European/
EuropeanCaribbean
Canada

Expression/Function
Expressed in bony labyrinth, causes hearing loss in
mice.
Involved in bone remodeling.
Involved in collagen synthesis.
Human leukocyte antigen (HLA) is region of
chromosome 6 containing genes for major
histocompatibility complex (MHC). Involved in
immune system function.
Expressed in bony labyrinth and previously
associated with autosomal dominant hearing loss.
Involved with cell trafficking.
Involved in transcription and other RNA activity.

References
Yoo, Cho, & Yamada,
1991, Tomek et al. 1998
Van Den Bogaert et al.
2001
Ealy & Smith 2010

Chen et al. 2002
McGuirt et al. 1999
Brownstein et al. 2006

Genes coding zinc finger proteins. Zinc finger
proteins are multifunctional proteins.
Expressed in non-ossified cartilage of developing tissue.Van Den Bogaert et al.
Golgi-associated sulfotransferase. Role in intercellular 2004
communication.
Collagen type XII, expressed in the cochlea.
Thys et al., 2007
Encodes for a tight junction protein.
Involved in osteoclast function.
Believed to regulate cranial facial development.
Involved in bone remodeling pathway, previously
associated with otosclerosis.

Codes for PEDF protein which is involved in antiangiogenic activity. PEDF inhibits angiogenic
activity, reducing formation of new blood vessels.
Transcription factor. Deletion was found to cause
down-regulation of several genes involved with
cytokine regulation and inflammation.

Bel Hadj Ali et al. 2008

Schrauwen et al. 2011

Ziff et al., 2016

Abdelfatah, 2014
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2.3.1

Challenges in gene identification
Determining the genetic origin of otosclerosis has been difficult. One major reason for the

difficulty of identifying pathogenic mutations is the scarcity of multiplex families. Since linkage
analysis studies require large multiplex, multigenerational families, and otosclerosis typically
develops in the 3rd decade (Schrauwen & Van Camp 2010), identifying families with affected
individuals spanning multiple generations can be difficult.
There is also the challenge of penetrance, or the percentage of gene carriers which present
with the affected phenotype. When not all gene-carriers express the altered phenotype, such as
hearing loss, then the allele is defined as demonstrating incomplete penetrance. Early work by
Fowler (1966) studying the presence of otosclerosis in 40 pairs of monozygotic twins, suggests
incomplete penetrance as a result of his findings of two twin pairs where one twin does not
exhibit a hearing loss. Around the same time, Morrison (1967) calculated penetrance by
comparing family histories of otosclerosis and hearing loss of affected probands to the expected
number of affected family members assuming complete penetrance. His estimate is a penetrance
of approximately 40%. Further, more recent genetic studies have incorporated estimates of
penetrance in their analysis of large families with otosclerosis in order to account for the
potential reduced penetrance of otosclerosis (Brownstein et al., 2006; Van Den Bogaert et al.,
2001). Caution should be used when interpreting these estimates of penetrance of otosclerosis,
since the true penetrance level remains unknown until the pathogenic mutations are identified.
The challenge of penetrance is further complicated by the unknown variability of age. Since the
age of onset of otosclerosis, like many autosomal dominant conditions, can be variable,
calculations of penetrance should take into consideration the potential for a delayed onset of the
condition.
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A further complication affecting the identification of pathogenic mutations for
otosclerosis is the potential presence of phenocopies. Phenocopies refer to cases presenting the
same phenotype caused by a different etiology. In the case of otosclerosis, this may include
tympanosclerosis, Paget’s disease, osteogenesis imperfecta, superior canal dehiscence and
enlarged vestibular aqueduct syndrome. All of these disorders can present as a conductive
hearing loss with absent acoustic reflexes, which is also the standard clinical presentation for
otosclerosis. Therefore, most genetic family studies of otosclerosis favour surgical diagnosis to
confirm the presence or absence of the disorder, at which point the otosclerotic disease is at an
advanced stage (Tomek et al. 1998; Van Den Bogaert et al. 2001; Chen et al. 2002; Brownstein
et al. 2006; Pauw et al. 2006; Thys et al. 2007; Bel Hadj Ali et al. 2008; Schrauwen et al. 2011;
Weegerink et al. 2011; Abdelfatah 2014).
The variability of clinical presentation in patients with otosclerosis can also be
challenging for genetic studies of this disease. Since the location of otosclerotic foci can affect
both middle ear and cochlear function, a spectrum of different clinical features is possible. The
use of advanced phenotyping has the potential to improve the accuracy of identifying “affected”
versus “unaffected” individuals for the purpose of genetic discovery.

2.4 Phenotyping Measurements
2.4.1

Acoustic Immittance
The auditory system is a complex system, wherein physical acoustic stimuli must travel

through the external auditory canal, reach the tympanic membrane, pass through and be
amplified by the middle ear system. The stimuli are transmitted to the inner ear and transferred
into an electrical signal by the cochlea which then propagates through the brainstem and up to
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the auditory cortex for processing. The audiological test battery must therefore be sensitive
enough to test for deterioration of the auditory signal along the entirety of the auditory system,
including the peripheral structures. Distal to the auditory brainstem, the peripheral auditory
system can be subdivided into the external ear canal, middle ear and inner ear. The middle ear
cavity refers to the tympanic membrane and the ossicles; the incus, the malleus and the stapes.
The role of the middle ear is to transform vibrations of the air entering the ear canal into
vibrations of the fluid-filled cochlea. As sound travels through the ear canal, the physical
vibrations are collected by the tympanic membrane that then sets the ossicles in motion behind it.
The hinge-like movement of the ossicles then transmit the energy from the stapes footplate
through the oval window of the cochlea. The transmission of sound through the middle ear
system occurs in a frequency specific manner, with a maximum mean sound pressure gain of
approximately 24 dB at 1.2 kHz and gain slopes of 6 dB/octave below 1.2 kHz and -6 dB/octave
above 1.2 kHz (Aibara, Welsh, Puria, & Goode, 2001).
Immittance testing has been widely used for decades to measure the movement of the
tympanic membrane to acoustic stimuli (Sanford, Schooling, & Frymark, 2012; Terkildsen &
Thomsen, 1959; Wiley et al., 1996; Zwolan, 2010). Immittance is the general term of the
mobility of the tympanic membrane that includes impedance (Z), admittance (Y), reflectance (R)
and absorbance (A) (reviewed by Rosowski, Stenfelt, & Lilly, 2013). Acoustic impedance,
simply stated, refers to the amount of resistance the acoustic source will encounter as it flows
through the middle ear system. Alternatively, admittance is the inverse of impedance, and refers
to the ease of the acoustic signal to flow through the middle ear system. This concept can be
broken down further where acoustic admittance (Ya) is defined by the relationship Ya=Ga+jBa,
where Ga is the acoustic conductance, and Ba is the acoustic susceptance. Conductance refers to
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the ease with which the acoustic stimulus can pass through the system, while susceptance relates
to how susceptible the middle ear system is to receiving acoustic stimuli. There are two main
components to susceptance, mass susceptance (Bm) and stiffness susceptance (Bs). Mass
susceptance is the admittance within the middle ear system due to mass, while stiffness
susceptance is the admittance within the middle ear system due to stiffness (Shahnaz, 2007).
Tympanometry is the measure the admittance of the middle ear system. Since the probe is
placed within the ear canal, the admittance of the ear canal is also included in the measurement.
To overcome this issue, tympanometry is conducted by sweeping pressure, typically from
positive (+400 daPa) to negative (-400 daPa). Under extreme pressure situations, the tympanic
membrane becomes extremely stiff, causing a decrease in admittance. At these extreme
pressures, it is assumed that the measured admittance of the system is that of the ear canal
volume because the tympanic membrane acts as a hard wall cavity and the tympanic membrane
is not contributing to the overall admittance of the system (Shanks & Lilly, 1981). By subtracting
the admittance at extreme positive pressure, the peak compensated static admittance (Ytm), or
more simply static admittance is calculated. The static admittance is the admittance of the middle
ear system without the inclusion of admittance of air of the ear canal space.
Admittance of the middle ear system changes with respect to frequency. A tone of 226
Hz is typically used for tympanometry. The reason for this is that at 226 Hz a 1.0 cm3 hardwalled cavity has an admittance of 1.0 mmhos. Conventional 226 Hz tympanometry has been
used for decades, where the output of the tympanogram results in values of tympanometric peak
pressure (TPP), equivalent ear canal volume (ECV), static compensated acoustic admittance
(Ytm) and tympanometric shape as outlined by Jerger (1970) (Figure 2). Tympanograms can be
qualitatively described as falling into one of three categories; A, B or C. Type ‘A’ represents a
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tympanogram with “normal” admittance, and an observable peak within normal limits. Type ‘A’
tympanograms can be subdivided into types A, As, or Ad. ‘A’ would be classified as a normal
tympanogram, however As, would refer to a type ‘A’ looking tympanogram, just with a shallow
peak, below normal limits (Margolis & Heller, 1987). Type ‘Ad’ would also have a peak
pressure around normal limits with a normal peak, however, the admittance peak would extend
above normal limits. Type ‘B’ or a flat tympanogram, is typically characteristic of a middle ear
pathology involving fluid or infection. Due to the fluid in the middle ear, the tympanic
membrane is more immobile, and does not form the characteristic peak. Type ‘C’ tympanograms
have the characteristic peak, but the peak occurs in extreme negative pressure. This type of
tympanogram is typically associated with Eustachian tube dysfunction, as the TPP occurs at the
pressure which matches the pressure of the middle ear. Therefore, there is a significant negative
pressure found in the middle ear.
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Figure 2. Diagram demonstrating the various qualitative types of tympanograms as described by
Jerger (1970). “normal” type ‘A’ tympanogram, with TPP close to zero, and admittance within
normal limits. B) Flat type ‘B’ tympanogram with no observable peak. C) type ‘C’ tympanogram
with TPP in extreme negative range.
Conventional tympanometry using a 226 Hz probe tone is insensitive to many middle ear
pathologies, including otosclerosis (Colletti, 1975; Shahnaz & Polka, 1997). Over the past
several decades, wideband stimuli in the measurement of immittance have become more widely
used. Improvements to immittance procedures have demonstrated success, specifically in the
identification of otosclerosis (Feeney, Grant, & Marryott, 2003; Nakajima, Rosowski, Shahnaz,
& Voss, 2013; Ogut, Serbetcioglu, Kirazli, Kirkim, & Gode, 2008; Shahnaz, Bork, et al., 2009;
Shahnaz & Polka, 1997) and superior canal dehiscence (Nakajima et al., 2012).
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2.4.2

Multifrequency Tympanometry
Tympanometry has been conducted for decades using a probe tone of 226Hz (Lilly,

1984), however a single probe tone of 226Hz fails to capture differences between normal ears
and ears with middle ear pathologies affecting the ossicular chain (Lilly, 1984; Shahnaz & Polka,
1997). The use of multifrequency tympanometry has been proposed as a method to increase
sensitivity of tympanometric measurements to identify middle ear pathologies (Korres, 2014;
Shahnaz, Bork, et al., 2009; Shahnaz & Polka, 1997; Vanaja & Manjula, 2003). One of the
objectives of multifrequency tympanometry (MFT) is to measure resonance frequency (RF)
which is the frequency where stiffness and mass contribute equally to admittance of the middle
ear system. The use of MFT has been demonstrated as a method to differentiate pathologically
affected ears from normal ears. For example, in a sample of 68 normal hearing subjects, Shahnaz
& Polka (1997) calculated the resonance frequency using a sweep frequency positive tail
compensation strategy. They obtained a mean resonant frequency in normal ears of 0.894 kHz
(SD = 0.166), compared to 1.142 kHz (SD=0.393) in a group of 4 otosclerotic cases. Since
otosclerotic stapes fixation results in the increased stiffness of the middle ear system, the
otosclerotic population has an increased resonant frequency compared to the normal population,
albeit with a large overlap in values (Shahnaz & Polka, 1997).
Zhao et al. (2002) suggest that this overlap of resonant frequency values between
otosclerotic ears and normal ears occurs partly because of the development stage of otosclerosis.
When otosclerosis is in the early stage of spongy bone growth referred to otospongiosis, the
middle ear system is believed to have lower stiffness compared to later stage otosclerosis when
the spongy bone growth hardens to more stiff sclerotic bone. Zhao et al., (2002) discovered
approximately 10% of their otosclerotic ears fell into a low stiffness category, characterized by
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resonant frequency values of <800 Hz. This overlap of resonant frequency values between
otosclerotic ears and normal ears limits the clinical utility of multifrequency tympanometry as a
single technique for diagnosing otosclerosis.

2.4.3

Wideband Acoustic Immittance
Wideband acoustic immittance (WAI), like tympanometry is a measurement of acoustic

admittance of the middle ear system. However, it differs from tympanometry as it uses wideband
chirp or a click stimulus to simultaneously determine the physical properties of the middle ear
system across a broad range of sound frequencies. By treating the ear canal as a rigid tube, and
presenting a wideband stimulus, the impedance of the middle ear system can be quickly
calculated in either a static or dynamic pressure environment.
Power reflectance (PR), also known as energy reflectance, uses a probe placed in the
external ear canal to estimate acoustic vibration at the tympanic membrane when set in motion
by a wideband acoustic probe stimulus. The power is measured across the frequency range of the
wideband probe signal and is measured by the same ear canal probe. Overall, the basic premise
behind power reflectance is that residual acoustic energy measured in the ear canal represents the
acoustic energy not absorbed by the middle ear. Power reflectance therefore involves measuring
the reflected power of the acoustic stimulus across frequencies, and dividing it by the power of
the original acoustic stimulus introduced at the probe tip, giving the simple equation:
PR = Reflected power/Incident power
This is achieved by relating the measured impedance of the ear canal (Z) to the
characteristic impedance of the ear canal (Zo). The measured impedance is the impedance
measured by the probe tip, whereas the characteristic impedance is the impedance calculated by
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dividing the phase velocity of sound from the area of the tube (Keefe, 1992; Voss & Allen,
1994). The assumption with PR is that the ear canal between the probe tip and the tympanic
membrane is a rigid, hollow tube. The measured power reflectance results from the ratio between
the acoustic power of the wideband acoustic probe signal used to stimulate the middle ear
system, and the acoustic power that is reflected from the tympanic membrane and measured at
the probe tip. The PR is squared to avoid negative values, and a value between 0-1 is achieved.
The absolute amplitude of PR is defined as:
PR = ([(Z/Zo) – 1] / [(Z/Zo)+1])2
A value of 1 represents a situation where all acoustic power is reflected back into the ear
canal, whereas a value of 0 represents a situation where no acoustic power is reflected back into
the ear canal.
PR is related to power absorbance (PA), as PA=1-PR. PA then refers to the amount of
acoustic energy that is absorbed by the middle ear system. The remainder of this thesis will
utilize the term power absorbance when referring to reflectance/absorbance of the middle ear
system.
Similar to the case of tympanometry, WAI is the technique of using an acoustic stimuli
and movement of the TM to estimate the ability of the middle ear to move in response to the
stimulus, and thus help differentiate between various middle ear pathologies (Prieve, Feeney,
Stenfelt, & Shahnaz, 2013; Shahnaz, Bork, et al., 2009; Shahnaz, Longridge, & Bell, 2009).
Keefe, Ling, & Bulen (1992) developed a system to measure PA in humans based on a similar
system used by Allen (1986) in cats. Energy reflectance (or 1-PA), was measured at ambient
pressure using a wideband stimulus. These early studies set the stage for the two commercial
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systems currently available, the Mimosa HearID (Figure 3) and Interacoustics Titan (Figure 4).
The Titan allows users to conduct three-dimensional tympanometry measurements in a
pressurized environment. A tight-fitting rubberized tip is required with the Interacoustics Titan
ear canal probe in order to maintain a hermetic seal while pressurized ear canal measurements
are acquired. This system uses a wideband chirp stimulus to acquire WAI data across frequencies
of 0.26-8kHz, and across pressures from +200 to -300 daPa, including ambient or tympanometric
peak pressure. The Mimosa HearID system is a non-pressurized system capable of measuring PA
across the frequency spectrum but at ambient pressure only. The non-pressurized Mimosa
HearID system uses an ER-10C foam tip connected to the ear canal probe in order to deliver
chirp or tone stimuli and record responses.
When calculating absorbance of the middle ear, the Thévenin equivalent method is
adopted in both the Mimosa HearID and the Interacoustics Titan. This method has two main
assumptions: 1) there is no loss of acoustic energy along the length of the ear canal wall, and 2)
the cross-sectional area of the tympanic membrane at the end of the ear canal is known and does
not change. There is a slight difference in the Thévenin calibration process of the Mimosa
HearID and Interacoustics Titan. The HearID is conducted using 4 calibration tubes of known
length and diameter, whereas the Titan only uses 2. Another difference between the two systems
is the way they compensate for ear-canal area. The Mimosa HearID estimates ear-canal area by
the size of the probe used, whereas the Interacoustics Titan uses a human average value when
compensating for ear-canal area in PA measurements.
The Mimosa HearID system also allows the user to select a stimulus level for the WAI
measurement. This is useful for improving the signal-to-noise ratio (SNR) of the measurement
by increasing the level of stimulus, and therefore the level of the measured output. Theoretically,
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improving the SNR of the measurement should allow for a more reliable response by minimizing
the effect of noise on the WAI measurement which in turn could improve the accuracy of WAI.

Figure 3. Image of the Mimosa HearID hardware including the USB audiobox, processing unit,
MEPA calibration cavity set and Etymotic ER10C probe. Photo retrieved from
http://www.mimosaacoustics.com/product.html with permission from Mimosa Acoustics Inc.
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Figure 4. Interacoustics Titan hardware including the Titan handheld device, wideband
tympanometry probe attachment and Titan Suite software. Image retrieved from
http://www.interacoustics.com/titan with permission from Interacoustics Inc.
Because WAI is a relatively new tool, it is unclear whether the 2 WAI instruments
currently available, and their associated protocols yield similar results for the same subject.
Shahnaz et al. (2013) made wideband measurements using the Mimosa HearID system and the
Interacoustics wideband acoustic immittance tympanometry (WAIT) system, an older research
version of the Interacoustics Titan. Although differences in absorbance values between the two
systems were found, these were much smaller than changes caused by middle ear pathology. The
further investigation of instrument differences in WAI is important to determine whether WAI
results obtained with currently available commercial systems are comparable. WAI research
utilized different systems, either the clinically available instruments or modified research
prototypes. Inter-instrument investigations of WAI using the 2 commercial systems are needed to
determine their clinical utility of previous WAI research.
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2.4.4

Variability within WAI
The value of WAI is based on the assumption that this measure of middle ear physiology

will reflect changes caused by pathological processes that are greater than the normal variability
in WAI associated with ear canal size and middle ear mobility. Likewise, measurements in the
same individual should be stable across consecutive measurements despite minor procedural
changes like differences in insertion depth of the WAI probe in the ear canal. Voss et al. (2008)
investigated the effects of ear canal volume, probe placement, and ear-canal cross-sectional area
on PA measurements. Their findings suggest that middle-ear cavity volume had the largest effect
on PA, while ear-canal volume, probe placement, and area all had negligible effects on PA.
Age has been shown to be partially responsible for inter-subject variability of PA. In
three separate groups of adults, young (20-38 years), middle age (42-64 years) and older (65-82
years), Mazlan et al. (2015) demonstrated that between PA values between 0.4 and 0.56 kHz
were lowest in the younger group than the middle and older adults. In higher frequencies
between 2.24 and 5.04 kHz, PA in the young adults was higher than the middle age and older
groups. In a cross-sectional analysis, Feeney et al. (2014) found a minimal effect of age between
three age groups of 20-29 years (n=37), 30-39 years (n=118) and 40-59 years (n=32). Slight
differences in PA occurred between frequencies of 0.5 and 1.6 kHz. The youngest group had
significantly lower PA compared to the middle age group from 0.5 to 1.3 kHz, while the oldest
group had significantly lower PA compared to the middle group from 0.63 to 1.6 kHz. No
significant difference in PA between the young and older groups was reported. Therefore, it
appears as though in the low frequencies (0.5 to 1.6 kHz) PA tends to increase in the fourth
decade, before decreasing later in the life.
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There are conflicting reports on the effect of sex on WAI measurements. No significant
difference in PA between males and females was reported in adults (Werner, Levi, & Keefe,
2010) and children (Beers, Shahnaz, Westerberg, & Kozak, 2010; Hunter, Tubaugh, Jackson, &
Propes, 2008). However, pooled data of Shahnaz & Bork (2006) and the unpublished thesis of
Shaw (2009) reports a significantly lower PA between 4 and 5 kHz in males compared to
females in a sample of 186 adults (Shahnaz et al., 2013). In another large sample of 112 adults,
Feeney et al. (2014) reported that females had lower PA below 0.5 kHz and higher PA above 4
kHz than males. Although, of the 112 participants in their study, only 24 were female. A similar
result was found by Feeney & Sanford (2004), where PA was lower in females between 0.794-1
kHz, and higher in females above 5.04 kHz.

2.4.5

Test-retest Reliability of WAI
In order for PA measurements to be reliable at diagnosing middle ear pathologies, it is

important that they have good test-retest reliability. Test-retest reliability has been investigated in
WAI research instruments to determine how WAI measurements from the same instrument vary
over time. Vander Werff, Prieve, & Georgantas (2007) found good test-retest reliability in a
sample of 127 infants and 10 adults using a research reflectance system by Mimosa Acoustics
Inc. Following probe reinsertion, the mean absolute differences in reflectance measurements and
90th percentile were less than 0.1.
The test-retest reliability of the Mimosa HearID and earlier Reflectance Measurement
prototype systems have been investigated in a number of methods in normal hearing populations.
Vander Werff, Prieve, & Georgantas, (2007) calculated the absolute difference between two
trials in order to investigate the test-retest reliability of energy reflectance (1-PA) in a population
of adults (n=10) and infants (n=127). The mean absolute difference between two trials in a
32

sample of 10 adults was approximately 0.02 with the probe reinserted during the same testing
session, and slightly lower than 0.02 when the probe was left in place. They report no significant
difference between the two different probe conditions, suggesting similar test-retest reliability of
ER both when the probe is left in place and when measurements were recorded following probe
reinsertion.
Rosowski et al. (2012) tested the reliability of the Mimosa HearID system in a subset of 7
adults measured 4 times separated by 1 week between ear measurements. Mean absolute
difference in energy reflectance (inverse of PA) was below 0.1 at all frequencies, with the testretest standard deviation measured below the population standard deviation for energy
reflectance, suggesting the variation in repeated testing of an individual is less than the variation
in energy reflectance of the broader population. Werner et al. (2010) also investigated the testretest reliability of wideband measurements using a research system and an ER-7C microphone
similar to that of the Mimosa HearID, at different time intervals through the use of absolute
differences. In their sample of 210 adults, they found a mean absolute difference in energy
reflectance of approximately 0.1 in the low frequency range increasing in the higher frequencies
to approximately 0.2 when measured approximately two weeks apart. These suggest that the
Mimosa HearID and the research prototype systems yields appropriate test-retest reliability in the
normal population.
Similar to the reports of reliability of the Mimosa HearID and prototype systems, the testretest reliability of the earlier prototype system from Interacoustics has been investigated. The
absolute differences and test-retest reliability of absorbance was investigated by Feeney et al.
(2017) in a group of 33 individuals using an Interacoustics Wideband Research System, a more
flexible prototype system than the commercially available Titan system. Results from Feeney et
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al. (2017) show that absorbance measurements obtained approximately 1 month apart had a
mean absolute difference of between 0.04 and 0.1 depending on frequency, suggesting the
research prototype system yields appropriate test-retest reliability in their population.

2.4.6

WAI and Middle Ear Pathologies
WAI has recently been used in an attempt to better identify and differentiate various

middle ear pathologies based on the physical characteristics of the middle ear system (Feeney et
al., 2003; Hunter et al., 2008; Keefe, Sanford, Ellison, Fitzpatrick, & Gorga, 2012; Merchant,
Merchant, Rosowski, & Nakajima, 2016; Nakajima et al., 2012; Hideko Heidi Nakajima et al.,
2013; Prieve et al., 2013; Sanford et al., 2012; Shahnaz, Bork, et al., 2009; Vander Werff et al.,
2007). These include otosclerosis (Allen, Jeng, & Levitt, 2005; Nakajima et al., 2013; Shahnaz,
Longridge, et al., 2009; Shahnaz, Bork, et al., 2009), ossicular disarticulation (Feeney et al.,
2003), third window disorders (Merchant et al., 2015), and otitis media with effusion (Keefe,
Sanford, Ellison, Fitzpatrick, & Gorga, 2012).
PA measurements in otosclerotic ears have consistently shown lower PA (higher
reflectance) below 1 kHz compared to normal ears (Feeney et al., 2003; Sanford et al., 2012;
Shahnaz, Bork, et al., 2009; Shahnaz, Longridge, et al., 2009). Reduced PA values in the low
frequencies may be explained by the increased stiffness of the middle-ear system caused by
abnormal otosclerotic bone growth with reduced mobility or fixation of the stapes in advanced
stages of the disease (Feeney et al., 2003; Nakajima et al., 2012; Nakajima et al., 2013; Shahnaz,
Bork, et al., 2009). Shahnaz et al. (2009) evaluated the number of otosclerotic ears with energy
reflectance above the 90th percentile at 0.5 kHz and found that 23/28 (82%) met this criterion.
The approximate value of their 90th percentile energy reflectance at 0.5 kHz is 0.8, which would
equate to PA of 0.2 at this frequency. A reduction in energy absorption by the middle ear system
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at these low frequencies is compatible with the characteristic low frequency conductive hearing
loss typically associated with otosclerosis. Nakajima et al. (2012) compared the sensitivity and
specificity of PA values in 14 ears with stapes fixation. When combined with average air-bone
gaps between 1-4 kHz, the absorbance level averaged over 0.6-1 kHz, these combined measures
had a sensitivity of 86% and specificity of 100%. PA combined with the audiometric conductive
component is a useful tool for identifying middle ear pathology in ears with otosclerosis.
Recently, Niemczyk, Lachowska, Tataj, Kurczak, & Niemczyk (2018) proposed that PA
differences exist across the frequency range, and identified five PA profiles in otosclerotic ears,
labelled types I-V. These profiles differ with respect to the number of absorbance peaks, the
frequency of the peaks as well as the depth of the peaks. Type I reflects PA profiles with two
moderate distinct peaks reaching moderate to high levels, Type II reflects PA profiles with a one
distinct peak at higher frequencies reaching a high value, type III reflects PA profiles with an
overall moderate PA value while demonstrating a reduction of PA below 1000 Hz, Type IV
reflects PA profiles with low PA values across the frequency bandwidth, and finally Type V
reflects PA profiles with lower PA limited to frequencies above 2000 Hz. Overall, these PA
profile types are categorized based on the subjective categorization of PA peak heights and
overall morphology. Therefore, while research has shown that in large otosclerotic populations
there is an overall lower PA in the low frequencies of otosclerotic ears, a variation in the profiles
across the frequency range should also be considered.

2.4.7

WAI and Advanced Phenotyping
In order for a measurement to be useful for phenotyping, it must be considered reliable

and should accurately portray known features of the phenotype of interest (Lanktree, Hassell,
Lahiry, & Hegele, 2010). In this thesis PA was compared across two new WAI instruments.
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WAI has been shown to be a reliable measurement (Feeney et al., 2014; Vander Werff et al.,
2007; Werner et al., 2010), while also capable of accurately identifying middle ear dysfunction
associated with various middle ear pathologies (Allen et al., 2005; Keefe et al., 2012; Merchant
et al., 2015; Nakajima et al., 2013; Shahnaz, Longridge, et al., 2009; Shahnaz, Bork, et al.,
2009).
In otosclerosis gene discovery research WAI holds promise as a new phenotyping tool to
aid in the segregation of affected family members from those unaffected by middle ear disease,
as well as confirm the etiology of the hearing loss. Due to the subjective nature of PA
classification by Niemczyk et al. (2018), and the lack of detailed information for the
classification of PA profiles in their five sub-types, the classification system reported in their
study was not used for phenotyping purposes in this thesis. Rather, the recommendations put
forth by Nakajima et al. (2013), Shahnaz et al. (2009) and Merchant et al. (2015) mentioned
above, served as a guideline for using WAI procedures to study middle ear pathology in families
with inherited hearing loss.

2.5
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Chapter 3
Advanced Phenotyping and FOXL1 Screening in an Ontario
Otosclerotic Population

3

3.1 Introduction
Recently, the first genetic mutation for otosclerosis was identified in a large
Newfoundland family, a 15 bp deletion in FOXL1 (Abdelfatah, 2014). It remains unclear
whether this mutation occurs in otosclerotic populations outside of the family, or founder’s
population where it was discovered.
The previous chapter describes the phenotyping methods currently used for genetic
studies of otosclerosis families, which include audiometry, acoustic reflexes, surgical
confirmation and rarely, high-resolution CT imaging (Bel Hadj Ali et al., 2008; Brownstein,
Goldfarb, Levi, Frydman, & Avraham, 2006; Chen et al., 2002; Pauw et al., 2006; Schrauwen et
al., 2011; Thys, Van Den Bogaert, et al., 2007; Tomek et al., 1998; Van Den Bogaert et al.,
2001). There have been reports of multifrequency tympanometry (Shahnaz & Polka, 1997;
Vanaja & Manjula, 2003), acoustic reflex thresholds (Hannley, 1993; Knud Terkildsen et al.,
1973), and occasionally otoacoustic emissions (Herzog, Shehata-Dieler, & Dieler, 2001; Keefe et
al., 2017; Singh, Gupta, & Verma, 2012) in clinical cohorts with otosclerosis. However, no
studies have investigated the advanced auditory phenotype of otosclerosis in addition to family
history in a clinical population data.

3.1.1 Aims of this Study
In this study, a cohort of patients with otosclerosis from the province of Ontario were
evaluated. There were 3 aims in this study:
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Specific Aim 1: To determine whether the newly discovered deletion in FOXL1 is
present outside the family from the province of Newfoundland and Labrador;
Specific Aim 2: To assess the family history and detailed phenotype in a cohort of
otosclerotic patients residing in southwestern Ontario and finally
Specific Aim 3: To create an in-depth clinical profile for both pre-operative and postoperative otosclerotic ears.

3.2 Methods
3.2.1

Subjects

Participants from Ontario, Canada were recruited from the H.A. Leeper Speech and
Hearing Clinic and the Department of Otolaryngology (London Health Sciences Centre –
University Hospital) at Western University. The was study approved by the Health Science
Research Ethics Board at The University of Western Ontario (HSREB #103679). Participants
qualified for the study if diagnosed with otosclerosis based on either surgical confirmation, or
clinical presentation, including the hallmark features of low-frequency conductive hearing loss
present either in isolation or as part of a mixed hearing loss, and absent acoustic reflex
thresholds. Ears that met the audiometric criteria for diagnosis of otosclerosis had air-conduction
thresholds greater than 25dB HL and an air-bone gap greater than 10dB at frequencies of 250,
500 and 1000 Hz. Exclusion criteria for the current study included a history of noise exposure,
exposure to ototoxic drugs potentially causing a sensorineural hearing loss (SNHL), or a history
of ear surgery besides corrective stapes surgery. Of the forty individuals recruited, 35
participants met the inclusion criteria. Of these, 33 subjects that had undergone either unilateral
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or bilateral stapes surgery, and two participants with a clinical diagnosis of otosclerosis but who
did not have corrective surgery were included in the final subject sample (Table 3).
Table 3. Summary of demographic information from 35 otosclerotic subjects including average
age (standard deviation), total number of males and females, and total number that had
undergone corrective surgery.
Ave Age (SD)
Females
Males
Total

3.2.2

53.76 (13.05)
54.85 (7.91)
54.11 (11.52)

Unilateral Surgery
Left
4
5
9

Bilateral
Surgery

No Surgery

Overall

6
3
9

2
0
2

24
11
35

Right
12
3
15

FOXL1 Screening
Saliva samples were collected using Oragene-DNA kits (DNA Genotek, Canada), and

genomic DNA extracted in the laboratory of Dr. Terry-Lynn Young at Memorial University of
Newfoundland (St. John’s, NL, Canada). DNA samples were screened at the Young Laboratory
at Memorial University by using Sanger sequencing for the newly found heterozygous deletion
c.976_990het_del within the FOXL1 gene. To do this, 4 primer sets were used to sequence the
entire FOXL1 gene (Table 4) and the Polymerase Chain Reaction (PCR) amplification protocol
was employed, where the amplified products were subsequently bidirectionally sequenced using
the Big Dye terminator Sanger sequencing, described in Abdelfatah (2014) and reported in
Appendix A.
Table 4. List of PCR sequencing primers spanning the deletion in FOXL1. Modified table from
PhD thesis of Nelly Abdelfatah 2014.
FOXL1 (NM_005250)

Exon
1a
1b
1c
1d

Primer ID

Sequence

NM_005250-Ex1aR
NM_005250-Ex1aR
NM_005250-Ex1bF
NM_005250-Ex1bR
NM_005250-Ex1cF
NM_005250-Ex1cR
NM_005250-Ex1dF
NM_005250-Ex1dR

GGAGGGAAAAGCTTGGAGTT
TGTCGTGGTAGAAGGGGAAG
GCCTCCCTACAGCTACATCG
GTCACCAGCGTCCTCGTT
GGAAGAGGAAGCCCAAG
GCAGGGGGAAATAAGAGAGG
AACGAGGACGCTGGTGAC
CCCAGGCAAAGATCATTTTA

Amplicon Size (bp)
579
514
585
585
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The pathogenicity of the 15bp deletion in FOXL1 was investigated by using the variant
interpretation process recommended by the American College of Medical Genetics and
Genomics reported by Richards et al. (2015) with the assistance of Dr. Darren O’Reilly, Director
of Molecular Genetics Lab at Memorial University and Dr. Terry-Lynn Young, Professor,
Discipline of Genetics at Memorial University and Co-Principal investigator. The process is
reported in Appendix B.

3.2.3

Family History Analysis
Participants were asked about hearing loss among their relatives through a structured

interview centered around family history (Appendix C). The questionnaire was designed to target
information pertaining to potential confounding effects on hearing loss including complications
at birth, history of hearing issues or vision issues in the participant and their family members. In
conjunction with the family history questionnaire, a family pedigree was created for each
participant to highlight whether any family member dating back three generations could be
identified as having hearing loss. As much detail as possible was obtained, including age of
onset, the potential etiology of the hearing loss, or a potential diagnosis of the hearing loss.

3.2.4

Phenotyping Procedures

Audiometry
Participants had air conduction (AC) and bone conduction (BC) thresholds tested using a
Grason Stadler (GSI 61) audiometer calibrated to American National Standards Institute
standards (re: S3.6.2010). Measurements were conducted in a sound-booth using ER3 insert
earphones for air conduction, and a bone oscillator for bone conduction thresholds. Air
conduction thresholds were measured at octaves between 0.25 – 8 kHz, while bone conduction
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thresholds were measured at octaves between 0.5-4 kHz, using a modified Hughson-Westlake
technique. Four frequency pure tone averages (PTA4) were calculated by averaging the
thresholds of 500, 1000, 2000 and 4000 Hz.
Acoustic Immittance
Acoustic immittance measurements including standard 226 Hz tympanometry,
multifrequency tympanometry and acoustic reflex thresholds were measured in both ears of each
participant. Acoustic immittance data was obtained for 67 of the 70 ears. One participant had a
sensitivity to the pressurized measurement and therefore immittance data could not be tested on
either ear, while the left ear of another participant could not be tested due to inability to acquire a
hermetic seal.
Conventional Immittance
Single component tympanometry, multifrequency tympanometry and acoustic reflexes
were measured in each ear using the GSI Tympstar v.2 tympanometer calibrated to ANSI
standard (re: S3.39.1989). For single component tympanometry, a probe tone of 226 Hz was
used, and tympanograms were classified for shape, ear volume, peak pressure and compliance.
Multifrequency Tympanometry
Utilizing the multifrequency tympanometry function of the Tympstar v.2, resonant
frequency was measured in each ear. Resonant frequency is calculated within the GSI Tympstar
v2 by calculating where the delta B crosses zero in a sweep frequency tympanogram. The
resonant frequency was calculated automatically within the Tympstar v.2 software and was
rounded to the nearest 50 Hz.
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Acoustic Reflex Threshold
Acoustic reflexes were calculated by presenting activation stimuli of 0.5, 1, 2, 4 kHz and
a broadband noise (BBN) in the presence of a 226 Hz probe tone. Thresholds were identified
when the compliance of the eardrum in the presence of the stimulus reached a minimum of 0.02
mL in two of three trials. If a reflex did not reach the criteria within three trials, the stimulus was
increased by 5 dB until an acoustic reflex threshold was obtained. No response was recorded if
there was no measurable acoustic reflex in two of three trials at the maximum stimulus level of
110 dB HL. Ipsilateral acoustic reflex thresholds represent the reflex obtained with the probe and
stimulus tone originating from the same ear, while contralateral acoustic reflex thresholds are
obtained with the stimulus tone and probe tone presented to different ears. The conventional
clinical nomenclature for acoustic reflexes is to name the ear specific reflex based on the
stimulus tone. However, since we are characterizing each ear separately, the reflex will be named
based on the location of the probe, while the terms ipsilateral and contralateral will be used to
describe the origin of the stimulus. Ipsilateral stimulation denotes a setup whereby the
stimulation tone and the probe are situated in the same ear, and contralateral stimulation denotes
a setup where the stimulation is occurring in the opposite ear to the probe.
Distortion Product Otoacoustic Emissions
Distortion product otoacoustic emissions (DPOAEs) were elicited using the Intelligent
Hearing Systems (IHS) DPOAE (v.4.54) system. Emissions were evoked using two tones, F1
and F2, where a F2/F1 ratio of 1.22 was used to elicit the DPOAE. The DPOAE was measured at
the frequency of 2F1-F2. F1 was presented at 65 dB SPL and f2 was presented at 55 dB SPL
(summary of frequencies in Table 5). A total of 17 DPOAEs were recorded spanning a 2F1-F2
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frequency range of 357-5649 Hz. At each DPOAE frequency, the noise-floor is measured, as
well as the distortion product level. The difference between the noise-floor and distortion product
is calculated and reported as the signal-to-noise ratio (SNR).
A screening protocol was used to determine whether a given ear had present or absent
DPOAEs across the broad frequency range. For an ear to pass DPOAE screening, there must be
at least 50% DPOAEs passed at all frequencies, 50% DPOAEs passed in every octave and 80%
passed between 1000 and 2000 Hz. A passed DPOAE was defined as a distortion product greater
than -10 dB SPL, and a signal-to-noise ratio (SNR) greater than 6 dB SPL between the noise
floor and the distortion product.
Table 5. Stimulus frequencies 1 and 2 (F1 and F2 respectively) along with their associated
distortion product frequency (2F1-F2) collected using the Intelligent Hearing Systems (IHS)
system. In total, 17 distortion products were elicited across an f2 frequency range of 553-8837
Hz.

F2 (Hz)
553
655
783
929
1105
1316
1560
1858
2211
2626
3125
3717
4416
5253
6250
7429
8837

F1 (Hz)
455
538
641
763
905
1076
1281
1521
1810
2152
2563
3047
3619
4309
5120
6089
7243

2F1-F2 (Hz)
357
421
499
597
704
836
1003
1184
1409
1677
2000
2377
2822
3365
3991
4749
5649
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Ear Status
Ears were separated into four groups; surgical ears, clinical otosclerotic ears, normal ears
and sensorineural hearing loss ears (SNHL). Any ear that had previously undergone corrective
surgery for otosclerosis was classified as “surgical ear”. Ears that met the audiometric criteria for
diagnosis of otosclerosis (air-conduction thresholds greater than 25dB HL and air-bone gap
greater than 10dB at frequencies of 250, 500 and 1000 Hz) were classified as “clinical
otosclerotic”. Any ears that had air-conduction thresholds greater than 25dB HL at three or more
octave frequencies but did not exhibit ABGs greater than 10dB at frequencies of 250, 500 and
1000 Hz were classified as SNHL. Finally, any ear with air-conduction thresholds below 25dB
HL were classified as “normal”.

3.3 Results
3.3.1

Ear Status
In the total sample, 70 ears were included in the analysis. Forty-two ears from 33

participants underwent corrective surgery for otosclerosis and were therefore categorized as
“surgical”. The remaining 28 ears were categorized based on audiometric results into either
“clinical otosclerosis” (n=14 ears), “SNHL” (n=3 ears), or “normal” (n=11 ears).

3.3.2

Phenotyping

Audiometry
Surgical ears (n=42) had a mean air conduction PTA4 value of 31.33 dB (SD = 18.17),
with mean thresholds of each tested octave ranging from 28.12 to 49.07 dB HL. The surgical
ears had a PTA4 air-bone gap of 12.76 dB (SD = 11.83), with mean thresholds from 8.60 to
25.38 dB HL. The surgical ears had an overall mean air conduction threshold with thresholds
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being best at the low-frequencies, and thresholds becoming more elevated in the higher
frequencies. This is represented by smaller air-bone gaps in the higher frequencies indicating an
overall average of a mixed hearing loss (Figure 5).
In the cases of clinical otosclerosis (n=14), mean air conduction PTA4 was 37.86 dB (SD
= 12.46). Octave specific mean thresholds ranged from 33.57 to 45.71 dB HL, with mean airconduction thresholds lowest at 2000 Hz, and highest at 8000Hz. PTA4 for air-bone gaps was
17.69 dB (SD = 7.87), with mean air-bone gaps at each octave frequency ranging from 9.64 to
33.85 dB. Air-bone gaps were largest in the lower frequencies, with the lowest mean ABG
measured at 2000 Hz. This profile is consistent with the classic audiometric profile of
otosclerosis of a low-frequency conductive hearing loss and the presence of a Carhartz notch at
2000 Hz.
Normal ears (n=11) had a PTA4 via air conduction of 9.66 dB HL (SD = 5.88) with mean
octave thresholds between 8.18- and 20-dB HL. Mean thresholds between 250-4000 Hz were all
under 15 dB HL, with the highest mean threshold measured at 8000 Hz measured at 20 dB HL.
Mean ABG measurements at octave frequencies ranged from 0 dB to 16 dB HL. The mean
PTA4 ABG was 5.11 (SD = 5.31).
The ears identified as SNHL (n=3) had a mean PTA4 via air conduction of 39.17 dB HL
(SD = 15.73). Mean thresholds at octave frequencies ranged from 36.67 dB HL and 45 dB HL.
The highest mean thresholds were measured at 8000 Hz. The mean PTA4 air-bone gap was 5.42
dB (SD = 6.05) with octave frequency means ranging between 1.67 to 8.33.

53

Figure 5. Mean audiometric thresholds separated based on ear status for 70 ears from 35
individuals diagnosed with otosclerosis. Ears separated into four groups: Surgical (n=42),
Normal (n=11), Clinical Otosclerosis (n=14) and SNHL (n=3). Circles represent mean air
conduction thresholds, and grey diamonds represent mean bone conduction thresholds. Error
bars represent  1 standard deviation.
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Acoustic Immittance
Mean ECV, TPP, Ytm (admittance) and RF (resonant frequency) were calculated based
on ear status (Table 6). Multivariate analysis of variance (MANOVA) was conducted to
determine whether there was a significant effect of ear status, gender and ear on measurements of
ear canal volume, mean admittance, tympanometric peak pressure and resonant frequency (Table
7). Due to the small sample size of SNHL ears, these ears were removed from analysis.
Significant multivariate effects were identified for ear status, F (8, 100) = 2.179, p = 0.035,
Wilk’s  = 0.725, partial 2 = 0.148, and gender, F (4, 50) = 5.945, p = 0.001, Wilk’s  = 0.678,
partial 2 = 0.322. Post-hoc analysis using a Bonferroni correction revealed a significant
difference in RF between surgical and clinical otosclerosis ears, as well as surgical and normal
ears. There was no significant difference in RF between clinical otosclerosis and normal ears. A
test of between subject effects revealed that RF was significantly higher among female ears
compared to males F (1, 53) = 22.479, p < 0.001, partial 2 = 0.298.
Table 6. Mean (M) and standard deviation (SD) values for ear canal volume (ECV),
Tympanometric peak pressure (TPP), admittance (Ytm), and resonant frequency (RF) for
surgical ears (n=40), clinical otosclerotic ears (n=14), normal ears (n=11) and SNHL ears (n=2).
Surgical
Clinical
Normal
SNHL
Otosclerosis
(n=40)
(n=14)
(n=11)
(n=3)
Variable
M
SD
M
SD
M
SD
M
SD
ECV
1.27
0.49
1.33
0.55
1.28
0.33
1.85
1.34
TPP
-13.63
56.15
-7.14
43.27
12.73
8.17
-32.50
81.32
Ytm
1.10
0.56
0.72
0.37
0.87
0.53
1.20
0.85
RF
676.92 134.19 921.43 306.16 840.00 225.83 950.00
N/A
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Table 7. Summary of MANOVA for four dependent variables of Ytm, ECV, TPP and RF
between three different ear statuses (normal, clinical otosclerosis, and surgical). Statistically
significant results are bolded.
Variable
Ear

Wilks 
.992

F
.104

df
4

Error df
50

Sig.
.981

Ear Status

.725

2.179

8

100

.035

Gender

.678

5.945

4

50

.001

Ear Status * Ear

.893

.728

8

100

.667

Ear Status * Gender

.791

1.554

8

100

.148

Ear * Gender

.971

.378

4

50

.823

Ear Status * Ear * Gender

.906

.629

8

100

.752

Distortion Product Otoacoustic Emissions
Mean DPOAE amplitudes and noise floor based on ear status are plotted in Figure 6. To
determine any significant difference in distortion product amplitude, a mixed model ANOVA
was conducted with gender and ear status (surgical, clinical otosclerosis and normal) as between
subject factors and frequency (17 frequencies) as a within-subject factor. Given the low number
of SNHL ears (n=3), they were removed from analysis. Following a Greenhouse-Geisser
correction to account for a violation of Mauchly’s test of sphericity (Greenhouse & Geisser,
1959), there was a significant interaction between ear status and frequency [F (20.824, 614.304)
= 2.3.278, p < 0.001]. Post-hoc analysis was conducted using a Bonferroni correction to examine
the nature of this interaction. Results suggest that ears classified as normal demonstrated a higher
distortion product amplitude compared to surgical ears at frequencies of 0.5-4 kHz, while normal
ears had a higher distortion product amplitude compared to clinical otosclerosis ears at
frequencies of 0.6-4 kHz (p < 0.05). There was no significant difference in distortion product
amplitude between surgical and clinical otosclerosis ears at any frequency.
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Figure 6. Mean distortion product (DP) otoacoustic emission amplitudes and noise floor
amplitudes in dB SPL for ears classified as Surgical (n=41), Normal (n=11), Clinical
Otosclerosis (n=14) and SNHL (n=3).
Results of the DPOAE screening procedure indicated that no post-surgical ears (n=41)
passed the DPOAE screen. Similarly, no ears with clinical otosclerosis (n=14) passed the
DPOAE screening. All of the ears categorized as normal (n=11) based on their audiometric
thresholds passed the DPOAE screening criteria.
Acoustic Reflex Thresholds
Acoustic reflex thresholds were evaluated for 67 ears of the 34 otosclerotic participants.
One participant (2 ears) could not be tested due to sensitivity of the pressurization and loud
stimuli, while one ear of another participant could not be tested due to the inability to obtain a
hermetic seal. There were no measurable acoustic reflex thresholds at any frequency tested in
ears classified as clinical otosclerotic (n=13). In the cases classified as normal, 100% of the ears
(11/11) had measurable ipsilateral acoustic reflex thresholds at frequencies of 500, 1000 and
2000 Hz with mean acoustic reflex thresholds of 86.8, 85.9 and 88.2dB SPL, respectively. In
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general, mean acoustic reflex thresholds were higher for contralateral presentation with mean
reflex thresholds ranging from 75-90dB SPL for ipsilateral presentation and 86.7-103.1dB SPL
for contralateral presentation. A summary of percent present and mean acoustic reflex thresholds
for the normal ears are reported in Table 8.
Table 8. Percent present and mean (SD) acoustic reflex thresholds for normal ears (n=11).
Normal
500 Hz
1000 Hz
2000 Hz
4000 Hz
BBN
Ears
Ipsi
Contra
Ipsi
Contra
Ipsi
Contra
Ipsi
Contra
Ipsi
Contra
(n=11)
% Present 100
72.7
100
81.8
100
90.9
100
63.6
90
90
Mean
86.8 103.1 85.9
98.3
88.2
98
90
100.8
75
86.7
(SD)
(5.6) (8.4) (5.8) (9.0) (6.4) (9.2) (7.1) (7.4) (6.1) (9.0)

3.3.3

FOXL1 Screening
Of the 35 participants, only 1 participant was identified with a single copy (heterozygous)

of the FOXL1 (c.976_990het_del) deletion identified in the NL family segregating with
autosomal dominant otosclerosis.
Based on the guidelines for interpretation of variants recommended by the American
College of Medical Genetics (ACMG) (Richards et al., 2015), the 15bp deletion in FOXL1 is
determined to be classified as “pathogenic” (Appendix B). Pathogenicity of the deletion is based
on the deletion meeting four criteria for pathogenicity recommended by the ACMG guidelines:
Supporting computational and predictive data (PP3), moderate computational and predictive data
(PM4), strong functional evidence (PS3) and strong segregation evidence (PPI-S). There is
computational evidence for the deleterious effect of the deletion meeting criteria for ACMG
guideline PP3 (see Abdelfatah 2014). The 15bp deletion results in a change in protein length of 5
amino acids meeting criteria for ACMG guideline PM4. To meet criteria of PS3, there is
reported strong functional evidence that the 15bp deletion has a damaging effect on gene
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expression (see Abdelfatah 2014). Finally, the criteria of PPI-S is met due the cosegregaton of
otosclerosis in family members with the FOXL1 deletion (see Abdelfatah 2014).

3.3.4

Family History
Family history questionnaires were conducted for the 35 participants across 33 families

(included two sets of sisters). Of the 33 family histories, 22 families had at least two relatives
with a hearing loss that developed between the ages of 20 and 60 years (Figure 7). Of these 22
families, 9 reported that an otosclerosis diagnosis was confirmed by an otolaryngologist.

Figure 7. Number of affected family members in each of the 22 families with a family history of
adult onset hearing loss. Cases were reported by the proband and identified as either otosclerosis
specifically (grey line) or unknown etiology (black line).

3.3.5

FOXL1 Phenotype Case Study
One participant out of 35 was heterozygous (carrier) for the FOXL1 (c.976_990het_del)

mutation. This section will serve as an individual case study outlining the auditory phenotype of
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this subject. Two retrospective pre-surgical audiological records were obtained for the proband,
as well as two post-surgical audiological tests.
Audiometric Thresholds
Audiometric thresholds were obtained retrospectively (3 audiograms) and prospectively (1
audiograms) for the FOXL1 carrier. Audiograms were obtained using ER3 insert earphones and
were reported to have good reliability. A summary of the audiometric thresholds is presented in
Figure 8. Two pre-surgical thresholds obtained at 61 years of age (5 months apart) reveal a
severe to profound mixed hearing loss in the right ear and a moderate rising to mild sensorineural
hearing loss in the left ear. Following stapedotomy surgery on the patient’s right ear (London
Health Sciences) air conduction thresholds improved to a moderate rising to mild sensorineural
hearing loss in the right ear. Similar results were obtained approximately 5 years later when the
subject was recruited into this study. Improvement of the air-conduction thresholds in her right
ear following successful stapedotomy surgery were consistent with otosclerosis. The presence of
stapes fixation and the diagnosis were confirmed by the surgeon at the time of surgery.
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Figure 8. Pre and post-surgery audiometric thresholds for the FOXL1 gene carrier. Left ear air
conduction thresholds denoted by blue X while left bone conduction thresholds denoted by blue
>. Right masked air conduction thresholds denoted by red triangles, while right masked bone
conduction thresholds denoted by red [.
Due to patient discomfort to pressurization, standard tympanometry, multifrequency
tympanometry and acoustic reflex thresholds could not be performed at the time of testing.
DPOAE testing was conducted without any discomfort to the subject. DPOAEs were considered
absent bilaterally based on the criteria provided in the Methods section, DPOES for both ears are
presented in Figure 9. However, present DPOAEs using the criteria of DP > -10dB SPL and
SNR > 6dB were present at 0.5 and 0.6 kHz in the right ear, and 0.4, 0.7 and 1.4 kHz in the left
ear.
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Figure 9. Distortion product (DP) otoacoustic emission amplitudes and noise floor amplitudes in
dB SPL for the proband heterozygous for FOXL1 deletion. Present DPOAEs represented by
asterisks (*). Right ear classified as Surgical ear, while left ear represents Non-surgical ear
classified as SNHL.
From the family history questionnaire, a pedigree was drawn (Figure 10). The family of
the proband were unavailable for study recruitment due to limitations of the research ethics. The
proband, individual IV-3, described a positive family history for late onset hearing loss.
Although there was no hearing loss reported on her mother’s side, she reported that her sister,
father, two paternal uncles and her paternal aunt had hearing loss. This pattern of transmission
(Figure 10) from one generation to the next, affecting both males and females, suggests a
positive family history consistent with an autosomal dominant trait. An analysis of the pedigree
was conducted to confirm an autosomal dominant inheritance pattern. The analysis for
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inheritance pattern was guided by recommendations reported by Shearer et al. (2017). The
proband was heterozygous for the FOXL1 deletion, suggesting a dominant transmission pattern
where only one copy of the affected allele is required to exhibit the phenotype. In cases of
recessive transmission patterns, two copies of the alleles must be inherited for the individual to
inherit the trait. Secondly, the family exhibits a later onset hearing loss restricted to the
proband’s paternal side of the pedigree. This suggests that the genetic trait for hearing loss is
being inherited from the paternal lineage. Finally, to rule out a situation of sex-linked dominant
inheritance pattern, individual IV-4 does not exhibit any signs of hearing loss. It would be
expected that in the case of sex-linked dominant transmission through the paternal lineage that
individual IV-4 would be an obligatory carrier of the allele because she would inherit the
affected allele from her father (III-4). This would be the case, because III-4 would carry the
affected allele on the X chromosome and would pass the affected X chromosome to all of his
daughters. Therefore, in the proband’s family, an autosomal dominant inheritance pattern is most
likely.
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Figure 10. Pedigree of Ontario proband identified as carrying FOXL1 c.976_990het_del deletion (Individual IV-3). Proband identified
by arrow in upper left. * represents hearing status unknown but reported as being suspected early onset hearing loss.
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3.4 Discussion
3.4.1

Phenotype
With respect to the ear asymmetry of otosclerosis and hearing loss, the phenotype of the

presented Ontario otosclerotic cohort appears to be quite variable. Of the thirty-five otosclerotic
subjects, eleven (31.4%) presented with true unilateral hearing loss, where their unaffected ear
had audiometric thresholds within normal clinical limits. These findings are consistent with
previous reports of approximately 53% of otosclerosis cases having true unilateral hearing loss in
an Iranian otosclerotic population (Khorsandi et al., 2018) and unilateral otosclerosis in
approximately 21% of cases in a Hungarian population (Karosi et al., 2012).
Fourteen of the seventy ears were classified as clinical otosclerosis when they presented
with a significant air-bone gap, greater than 10 dB at three frequencies while also presenting with
absent acoustic reflexes in the probe ear. In these ears the mean bone conduction thresholds at
octave frequencies between 250 to 4000 Hz ranged between 21.74 to 24.53 dB HL which fall
within the clinical criteria for “normal hearing” of 25 dB HL. Therefore, we would consider at
the population level that the clinical otosclerotic ears present with the conductive hearing loss. It
is possible that the clinical otosclerosis ears have a high-frequency sensorineural hearing loss
component to their hearing loss, as air-conduction thresholds at 8 kHz have a mean threshold of
approximately 50 dB HL. However, due to limitations of audiometry, air-bone gaps can only be
measured up to 4 kHz.
In total there were three ears from three different subjects with sensorineural hearing loss
in their non-surgical ear, representing 8.6% of ears in the study sample. These three ears would
be classified as cochlear otosclerosis cases. This is consistent with previous reports of
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otosclerosis that suggest that over the course of this disorder, hearing loss can progress to
become sensorineural or mixed in nature (Schuknecht & Barber, 1985).
The status of the middle ear is determined clinically by an otoscopic exam and acoustic
immittance tests; a well aerated ear shows no otoscopic evidence of middle ear pathology (for
example middle ear fluid), with a normal tympanogram and normal static compliance results
which suggest that the middle ear system is mobile and that sound conductance through the
middle ear system is possible. However, it has been reported that the use of traditional
tympanometric measures of static compliance may not be adequate in the differential diagnosis
of otosclerosis (Shahnaz, Bork, et al., 2009). This is due to the variability of static compliance in
the normal population, whereby a reduction in static compliance due to otosclerosis may not be
great enough to overcome the population variability.
An abnormal air-bone gap (i.e. conductive hearing loss component) combined with
absent acoustic reflexes and an otherwise aerated middle ear are therefore considered hallmark
features of otosclerosis. The results of this study were consistent with these findings. There was
no significant difference for Ytm with regards to gender, ear or ear status. However, there was a
significant difference in RF between ears with clinical otosclerosis and those which had
undergone stapes surgery. Post-surgical ears had an overall lower RF than ears with clinical
otosclerosis. Previous reports investigating tympanometric measurements in cases of otosclerosis
have suggested that otosclerotic ears have a significantly higher RF compared to normal ears
(Ogut, Serbetcioglu, Kirazli, Kirkim, & Gode, 2008; Shahnaz & Polka, 1997). The results of this
study indicate no significant difference in Ytm and RF between the ears categorized as normal
and those with clinical otosclerosis. These results suggest that ears with otosclerosis can

66

demonstrate values within normal limits for ECV, Ytm, TPP and RF and that multifrequency
tympanometry alone is not sensitive enough to distinguish otosclerotic ears from normal ears.
In summary, normal sensorineural hearing thresholds, indicated by normal bone
conduction thresholds, in the presence of a conductive hearing loss component are the hallmark
features of otosclerosis. Likewise, abnormal acoustic reflexes in a well-aerated ear are also
considered to be a clinical indication of otosclerosis. In this study, when stimulated ipsilaterally
or contralaterally, there were no measurable ipsilateral or contralateral acoustic reflex thresholds
in the probe ear for ears classified as surgical, which is expected since the stapedius muscle is cut
during stapedotomy surgery. ARTs were also absent in all clinical otosclerotic ears. This
supports the clinical concept of using absent ARTs as a method of differentially diagnosing
otosclerosis clinically. Absent acoustic reflex thresholds for detecting otosclerosis in individuals
with aerated middle ears, who also exhibit a significant conductive component (i.e. conductive or
mixed hearing loss), are clinical criteria used for the differential diagnosis of otosclerosis from
other middle ear disorders. In family studies, some members may not have surgically confirmed
otosclerosis, and this criterion is a valuable addition for phenotyping purposes.
This current study also utilized DPOAEs as a phenotyping tool for otosclerosis. Previous
research has been mixed in terms of the presence of OAEs either prior to or following stapes
surgery for otosclerosis (Riad, El-Rahman, Abdel Latif, Fawzy, & El-Anwar, 2017; Singh et al.,
2012). The results of this study provide evidence that in 42 ears that have undergone corrective
surgery for otosclerosis, none passed the DPOAE screening criteria. Sample mean data for all 17
frequencies also showed that the mean amplitude of DPOAEs for post-surgical otosclerosis was
significantly lower than amplitudes in the normal ears. Although the current study does not
provide any patient specific pre-surgical DPOAE measurements, 100% of ears suspected of
67

having otosclerosis (n=14) did not pass DPOAE screening and had mean DP amplitudes
significantly lower than normal ears. The results of this study suggest that DPOAEs will also be
helpful for phenotyping otosclerosis.
Superior semicircular canal dehiscence (SSCD) can mimic several of the hallmark
features of otosclerosis – specifically a conductive or mixed hearing loss combined with a
normal tympanogram, static compliance and otoscopic exam indicating a normally aerated
middle ear (Merchant, Rosowski, & McKenna, 2007; Keefe et al. (2017). In this regard, the use
of middle ear reflex and DPOAE testing may be particularly useful in genetic research. A
conductive hearing loss caused by SSCD can present with acoustic reflexes (Merchant &
Rosowski, 2008). Since we were unable to obtain any acoustic reflex thresholds in the probe ear
of the clinical otosclerotic ears, the use of acoustic reflex thresholds in normally aerated ears
should be used to better distinguish between conductive hearing losses due to stapes fixation
versus those with dehiscence of the semicircular canals. Furthermore, OAEs can be present in
ears with a conductive hearing loss and superior canal dehiscence (Merchant & Rosowski, 2008;
Thabet, 2011). In conclusion, both acoustic reflexes and OAEs are valuable physiological
procedures for detecting otosclerosis, and differentiating this disease from SSCD which can
mimic otosclerosis in many respects, particularly in those with an audiometric threshold profile
of low-frequency conductive hearing loss (Merchant, Rosowski, & McKenna, 2007).
The combination of audiometry, single or multifrequency tympanometry, acoustic
reflexes, wideband acoustic immittance and otoacoustic emissions may be particularly useful for
the advanced phenotyping of families with conductive and mixed hearing loss. Utilizing
advanced clinical phenotyping tools for the purpose of genetic studies can aid in the differential
diagnosis of various hearing disorders like SSCD. Another value of using DPOAEs and ARTs in
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genetic studies would be the identification and longitudinal investigation of non-penetrant cases.
Non-penetrant cases are individuals carrying the genetic mutation for a particular disorder, but
who do not exhibit any clinical features of the disorder. However, these non-penetrant cases may
be in the early stages of the disorder progression, and while they do not exhibit overt symptoms,
they may have sub-clinical features when sensitive methods are used to assess auditory function.
In the case of otosclerosis, using DPOAEs and ARTs may be useful physiological phenotyping
measures for this purpose. For example, in the case of pre-clinical otosclerosis, it is possible to
have poor or absent DPOAEs due to an abnormal middle ear system that is in the beginning
stages of developing stapes fixation. Likewise, a middle ear system that is disrupted due to early
otosclerosis may exhibit elevated or absent ARTs as the acoustic reflex is not strong enough to
overcome the increased stiffness of the early-otosclerotic middle ear. Additionally, newer
techniques of measuring the transmission of acoustic stimuli through the middle ear, such as
wideband acoustic immittance (WAI), may also aid in future genetic research studies.
Subsequent chapters of this thesis will focus on the use of these techniques, including WAI, as
advanced phenotyping tools following gene discovery, for the purpose of gene discovery.

3.4.2

Family History
Otosclerosis is known to be a highly heritable hearing disorder typically developing later

in life, around the 3rd decade and beyond. Results from the family history questionnaire
identified 22 families which were positive for a family history of non-congenital hearing loss.
Out of these 22 families, 9 were positive for multiple family members diagnosed with
otosclerosis, representing 27.3% of the families. These results are consistent with findings from
Shin et al. (2001) who reported 24.2% of their French otosclerotic population were positive for a
family history of otosclerosis. However, the high proportion of families with multiple cases of
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hearing loss in this study should be interpreted with caution. The recruitment letter clearly stated
that this was a study into the genetic causes of otosclerosis. Therefore, it is feasible that patients
with a family member diagnosed with a hearing loss were more likely to respond to the
recruitment letter than patients without any family history of hearing loss; this is a recognised
form of ascertainment bias.

3.4.3

FOXL1 Screening
Through genetic screening for the mutation in the FOXL1 gene, one participant in the

Ontario cohort carried the deletion (c.976_990het_del). The discovery of the Ontario participant
with the FOXL1 c.976_990het_del genetic confirms that this causative mutation is present in
other populations outside of Newfoundland. The onset of hearing loss, along with a positive
family history of autosomal dominant otosclerosis in this Ontario proband, is consistent with
findings from the Newfoundland FOXL1 families. The Ontario proband reports no known
familial connection to the island of Newfoundland.
The 15 bp deletion in FOXL1 is predicted to result in a loss of five amino acids within the
protein product and cosegregates with otosclerosis within a large Newfoundland family.
Functional microarray analysis of expression of the mutated FOXL1 gene confirmed that the
mutation results in a change in the transcription levels of many genes involved in inflammation
or bone remodelling, such as IL29 and CCXL10 (Abdelfatah, 2014). The FOXL1 deletion is
therefore considered pathogenic based on guidelines from the American College of Medical
Genetics (Richards et al., 2015).
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3.4.4

FOXL1 Proband Phenotyping
The Ontario gene carrier has unilateral stapes fixation caused by otosclerosis as well as a

positive family history, with vertical transmission, affecting both males and females, which is
suggestive of an autosomal dominant inheritance. An autosomal dominant inheritance with an
adult-onset hearing loss is consistent with previous reports of monogenic forms of otosclerosis
(Ealy & Smith, 2010). Additional phenotype and genetic information should be collected in both
affected and non-affected individuals of this family. This would allow for more comprehensive
phenotyping of FOXL1-related otosclerosis in the Ontario population.
Based on retrospective and prospective assessments, the proband presents with a severe
to profound mixed hearing loss in her right ear, and a moderate rising to mild sensorineural
hearing loss in her left ear, consistent with a clinical diagnosis of otosclerosis. Retrospective data
revealed absent ipsilateral and contralateral reflexes at all previous test dates and tympanometric
immittance within the normal range of 0.3 to 2.1 mL. However, due to the proband’s sensitivity
to the pressurized testing required for acoustic immittance measures, we were unable to obtain
acoustic reflex, tympanometry and resonant frequency measurements prospectively. Having the
proband undergo successful surgery, as well as receiving a surgical diagnosis of otosclerosis,
was an important step in confirming the presence of otosclerosis. As reviewed above, other
hearing disorders, such as superior canal dehiscence or enlarged vestibular aqueduct syndrome,
can mimic otosclerosis (Merchant et al., 2007; Wieczorek, Anderson, Harris, & Mikulec, 2013).
In addition to showing improved air conductive thresholds post-operatively, the proband’s boneconduction hearing thresholds at 4 kHz in her right ear also improved following her surgery. It is
expected that her air-conduction thresholds would improve following surgery, however on two
separate pre-surgery audiometric thresholds, her bone conduction thresholds at 4 kHz showed a
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moderate sensorineural loss, while two post-surgery audiometric thresholds confirmed a 40-45
dB improvement to a mild sensorineural hearing loss component at this frequency. There are
reports of an improvement in bone conduction thresholds following stapes surgery (Manuele &
Francesco, 2015; Quaranta, Besozzi, Fallacara, & Quaranta, 2005; Sperling, Sury, Gordon, &
Cox, 2013; Vijayendra & Parikh, 2011). The mean improvement of bone conduction thresholds
at 4 kHz reported by Sperling et al. (2013) was 6.3 dB in their cohort of 81 cases and the
maximum improvement of bone conduction thresholds at 4 kHz of 55 dB, however they did not
report how many individuals experienced such a drastic improvement. Bone conduction hearing
is thought to require three different pathways; the osseotympanic route, the displacement of
cochlear fluid, and the ossicular and cochlear fluid inertia (Tonndorf, 1966). Stiffening the stapes
has been shown to increase the resonant frequency of the middle ear system, result in a change in
the ossicular inertia, as well as change the physical characteristics of the oval window. This can
contribute to changes to the cochlear fluid flow by removing the stapes footplate’s contribution
to cochlear fluid inertia (Stenfelt, Hato, & Goode, 2002). The subsequent post-operative
improvement in bone conduction at 4 kHz may be due to changes to the inertia of the ossicles
and cochlear fluid and may be contributing factors to the reduced bone conduction thresholds
prior to stapes surgery.

3.4.5

Limitations and Future Directions
The identification of an otosclerotic proband outside of Newfoundland carrying the

FOXL1 deletion provides supporting evidence that the FOXL1 gene discovered by Abdelfatah
(2014) is truly causative. Further research in larger cohorts of otosclerosis patients will help
clarify the proportion of otosclerosis caused by this or other pathogenic variants in FOXL1.

72

In terms of phenotyping of otosclerosis, the utilization of resonant frequency to
distinguish otosclerotic from normal ears may have been limited by the frequency resolution of
the GSI Tympstar v2 which sweeps across frequencies of 250-2000 Hz in 50 Hz intervals
(Vanaja & Manjula, 2003). This low frequency resolution could explain why no significant
interaction between RF and ear status was discovered in the current study. A newer technique,
wideband acoustic immittance (WAI) is now available for physiological analysis of middle ear
function and may be valuable in the advanced phenotyping of otosclerosis (Shahnaz, Bork, et al.,
2009). The subsequent chapters of this dissertation will address the value of WAI for advanced
phenotyping of otosclerosis.
Another limitation of the current study was the investigation of only the 15bp deletion in
FOXL1. The aim was to identify whether this deletion was present in an outbred population,
outside of the Newfoundland founder population where it was identified. However, without
assessing the rest of the genome, the currents study cannot comment on concomitant genetiac
abnormalities. One Ontario proband was identified with this FOXL1 deletion, however there
were 22 additional families with later-onset hearing loss, of which 9 report having otosclerosis
specifically. Additional genotyping work on these Ontario families may identify other genetic
mutations responsible for monogenic forms of otosclerosis at unique or previously reported
genetic loci (Bel Hadj Ali et al., 2008; Brownstein, Goldfarb, Levi, Frydman, & Avraham, 2006;
Chen et al., 2002; Pauw et al., 2006; Schrauwen et al., 2011; Thys, Van Den Bogaert, et al.,
2007; Tomek et al., 1998; Van Den Bogaert et al., 2001). Future genetics work may include the
application of whole exome sequencing in order to identify new causative genes.
As more genes underlying the OTSC loci are identified, detailed phenotyping measures
could be used to delineate the clinical and sub-clinical course of this hearing loss, particularly the
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early development of otosclerosis. Early diagnosis of the disorder will become imperative as new
preventative or rescue treatments are developed. The natural history of otosclerosis may be best
studied in gene carriers before clinical symptoms are apparent. Advanced phenotyping should
include a combination of behavioural and physiological techniques (wideband energy
reflectance, OAEs, audiometry, acoustic reflex thresholds, and basic or multifrequency
tympanometry) to investigate auditory system function in genetically confirmed pre-clinical or
non-penetrant otosclerotic individuals.
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Chapter 4
Evaluation of Wideband Acoustic Immittance as an
Advanced Phenotyping Tool for Otosclerosis: Effect of Instrument,
Stimulus Level and Otosclerosis on Power Absorbance

4

4.1 Introduction
Wideband acoustic immittance (WAI) is an umbrella term referring to different methods
which use a wideband acoustic stimulus to assess the acoustic immittance of the middle ear
system. WAI is an emerging clinical method for detecting middle ear dysfunction and
differentiating between pathological conditions of the middle ear causing conductive hearing loss
(Merchant et al., 2015; Nakajima et al., 2012; Prieve, Feeney, Stenfelt, & Shahnaz, 2013;
Shahnaz, Bork, et al., 2009; Shahnaz, Longridge, & Bell, 2009).
One parameter of WAI, power absorbance (PA), is calculated between 0 and 1, where 0
represents no acoustic energy absorbed by the middle ear system, and 1 represents all the
acoustic energy absorbed by the middle ear system. There are reports of significant differences in
PA between ears with otosclerosis, semicircular canal dehiscence and normal ears (Merchant et
al., 2016, 2015; Nakajima et al., 2012; Prieve et al., 2013). Since PA has demonstrated the ability
to differentially diagnose middle ear pathologies, it has potential for improving auditory
phenotyping for genetic studies of otosclerosis.
WAI measurements are now available in 2 commercial systems: The Interacoustics Titan
and the Mimosa HearID. The Titan allows users to conduct three-dimensional tympanometry
measurements in a pressurized environment. A tight-fitting rubberized tip is required with the
Interacoustics Titan ear canal probe in order to maintain a hermetic seal while pressurized ear
canal measurements are acquired. This system uses a wideband chirp stimulus to acquire WAI
77

data across frequencies of 0.26-8kHz, and across pressures from +200 to -300 daPa, including
ambient or tympanometric peak pressure. The Mimosa HearID system is a non-pressurized
system capable of measuring PA across the frequency spectrum but at ambient pressure only.
The non-pressurized Mimosa HearID system uses an ER-10C foam tip connected to the ear canal
probe in order to deliver chirp or tone stimuli and record responses. Research focusing on the
diagnostic value of WAI has used different WAI systems and protocols (Feeney et al., 2003;
Keefe & Simmons, 2003; Merchant et al., 2016; Prieve et al., 2013; Robinson, Thompson, &
Allen, 2016; Shaver & Sun, 2013). Although PA has been measured for the Mimosa HearID and
Interacoustics Titan, or their prototype systems, (Feeney et al., 2017; Jaffer, 2016; Vander Werff,
Prieve, & Georgantas, 2007), the PA results collected with these 2 instruments have not been
compared under the same experimental conditions in the same ear.
Both WAI systems also allow for the measurement of ear-canal volume (ECV). ECV is a
useful clinical tool, as it indicates the overall size of the ear-canal and can be sensitive to help
identify the presence of a perforation of the eardrum, or evaluate the patency of ventilation tubes
in children (MRC Multicentre Otitis Media Study Group, 2008; Shanks, Stelmachowicz,
Beauchaine, & Schulte, 1992). ECV also has implications for the measurement of PA. Stepp &
Voss (2005) suggest that variability in ECV in the normal population may contribute to
variations in absorbance measurements. The effect of middle ear cavity volume on absorbance
was further investigated by Voss et al. (2008) who report an increase in absorbance with an
increase in middle-ear cavity volume. As highlighted in Chapter 2, the two systems use different
methods to calculate ear-canal area, which is an important component for the Thevénin
calibration process. Therefore, it is important to compare instrument effects on ECV for two
reasons. The first, is to determine whether ECV from one system can be directly compared to
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another for clinical purposes, and the second is to determine whether differences in ECV may be
contributing to instrument differences in PA.
The value of PA for detecting and differentiating middle ear pathology also depends, in
part, on within and between subject variability. Factors that can contribute to test-retest
reliability in normal ears include placement and reinsertion of the measurement probe (Abur,
Horton, & Voss, 2014), time delay between recordings (Mahoney, McFarland, Carpenter, Rizvi,
& Cacace, 2013; Vander Werff et al., 2007; Werner et al., 2010), and changes in middle ear
pressure with repeated measurement (Burdiek & Sun, 2014). The test-retest reliability of WAI
measurements has been investigated for different test instruments and populations (Feeney et al.,
2017; Jaffer, 2016; Rosowski, Nakajima, & Hamade, 2012; Vander Werff et al., 2007). Findings
from previous studies of the test-retest reliability of PA suggest that PA exhibits good test-retest
reliability. However, no direct comparison of test-retest reliability has been conducted between
the two systems.

4.1.1

Aims of Study 1:
Although PA and its test-retest reliability has been measured for the Mimosa HearID and

Interacoustics Titan, or their prototype systems (Feeney et al., 2017; Jaffer, 2016; Vander Werff,
Prieve, & Georgantas, 2007), WAI measurement outcomes for these 2 instruments have not been
directly compared. Both the absolute PA and test-retest reliability of this measure will be
compared for the Mimosa HearID and Interacoustics Titan under the same experimental
conditions. The Mimosa HearID has the option to record PA using different wide band stimulus
levels between 60 – 80 dB SPL. Since the effect of stimulus level on PA has yet to be reported in
the literature, this study will also investigate the stimulus level effects on PA outcomes using the
Mimosa system. There were two specific aims for Study 1:
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Specific Aim 1. Conduct an inter-instrument comparison of two commercially available
instruments, the Interacoustics Titan and the Mimosa HearID. More specifically:
Specific aim 1a: Compare PA outcomes for the two systems using the same
stimulus level.
Specific aim 1b: Compare PA test-retest reliability between the two systems.
Specific aim 1c: Compare ECV outcomes for the two systems.
Specific aim 1d: Compare ECV test-retest reliability between the two systems.
Specific Aim 2. Compare PA measurements obtained at various stimulus levels using
the Mimosa HearID. More specifically:
Specific aim 2a: Compare PA measurements obtained at four stimulus levels
using the Mimosa HearID.
Specific aim 2b: Compare test-retest reliability of PA measurements obtained at
four stimulus levels using the Mimosa HearID.

4.2 Study 1 Methods
Normal hearing subjects were invited and consented to participate in the study. An initial
assessment of the ear and hearing thresholds was performed to determine that subjects met
additional inclusion criteria. Those that passed the initial assessment phase proceeded to the
experimental procedures evaluating the WAI and were asked to sit quietly in a sound-treated
booth for one session lasting approximately 1.5 hours.

4.2.1

Subjects
Subjects were invited to participate in the study if they were between the ages of 18-75

and had self-reported normal hearing. Individuals with a hearing impairment related to injury or
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disease or history of previous ear surgeries or conditions (i.e. chronic ear infections) were
excluded from participating in the study. In order to pass inclusion criteria for the study, subjects
were required to have a clear otoscopic examination, free of occluding cerumen and normal
tympanic membrane, normal hearing thresholds and normal middle ear status using conventional
acoustic immittance measures. Normal hearing levels in subjects were defined as air conduction
thresholds of 25 dB HL or below at octave frequencies between 0.25 – 8 kHz and no air-bone
gap greater than 10 dB at octave frequencies between 0.25 – 4 kHz. Subjects were also
considered for the study if they had normal tympanometric measures, which included 226 Hz
tympanometry, where compliance was within 0.2-2.1 mL and tympanometric peak pressure was
between +50 and -100 daPa.
A total of 52 subjects were recruited as study participants. However, 12 subjects did not
participate in the experimental procedures for the following reasons: failing audiometry inclusion
criteria (n=5), failing tympanometry inclusion criteria (n=1) or inability to complete testing due
to limitations in schedule and incomplete data (n=6). An additional 15 subjects underwent
experimental procedures but were removed from the study due to poor seal of the probe in the
ear canal (n=12) or a noisy measurement (n=3). In total the final sample included twenty-five
subjects (14 females, 11 males; 50 ears) with an average age of 38.8 (ranging from 22.5 to 68.2
years old) representing 50 ears.

4.2.2

Instrumentation
Pure tone audiometry was conducted using the Interacoustics AC40 audiometer calibrated

according to ANSI standards (re: S3.6.2010). Both air and bone conduction thresholds were
measured. Measurements were conducted in a sound booth using ER3 insert earphones for air
conduction, and a bone oscillator for bone conduction thresholds. Air conduction thresholds were
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measured between 0.25 – 8 kHz, while bone conduction thresholds were measured between 0.25
– 4 kHz. A standard bracketing method was used to conduct audiometry.
Standard 226 Hz tympanometry was conducted using the Interacoustics Titan system
(version 3.3.0) and pressures between +200 daPa to -300 daPa. Tympanometric peak pressure,
and compliance were collected. Tympanometric peak pressure and compliance served as
confirmation of normal tympanic membrane function and normal middle ear pressure. All ears in
the study had tympanometric peak pressures between -100 and +50 daPa, and compliance values
between 0.2 and 2.1cc.
Power absorbance and ECV were collected using the two systems; the Mimosa HearID
and Interacoustics Titan. PA and ECV was collected with the Mimosa HearID (version 5.1.7.1)
using the middle ear power analysis (MEPA3) protocol while PA and ECV were collected with
the Interacoustics Titan using the 3D Tympanometry protocol (version 3.3.0.).

4.2.3

Experimental Procedures
Power absorbance and ECV measurements were collected twice for each system

providing two trials per instrument and for the right and left ears of each subject. The ear order
was randomly selected. Trial 2 of each ear was measured only after the probe was reinserted. For
each instrument, the acquisition order of ears and trials went as follows: Ear 1-Trial 1, Ear 2Trial 1, Ear 1-Trial 2, Ear 2-Trial 2. To minimize any potential pressurization effects on the
middle ear measurements, data was first acquired using the Mimosa HearID followed by
measurements with the Interacoustics Titan.
Titan measurements using the 3D tympanometry protocol were conducted with a
wideband chirp stimulus spanning 0.2 kHz – 8 kHz at a stimulus level of 100 dB peak equivalent
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SPL, which is approximately 65 dB SPL. During stimulus presentation, pressure was swept
across +200daPa to -300 daPa.
HearID measurements were conducted using a wideband stimulus spanning 0.2 kHz to 6
kHz at stimulus levels of 60, 65, 70, and 80 dB SPL. PA and ECV measurements collected by
the Mimosa HearID and used for comparison to the Interacoustics Titan were achieved under the
65 dB SPL stimulus condition. This level was chosen to match the stimulus level of the
Interacoustics Titan since the Titan does not allow for the manipulation of stimulus level.

4.2.4

Data Analyses
For the inter-instrument comparison of absolute PA, measurement results were exported

from each instrument and processed as follows. PA measurements for the Titan were extracted
from the 3D tympanogram by exporting PA values obtained at atmospheric pressure. PA
measurements from trial 1 and trial 2 of each condition were averaged together across the full
frequency bandwidth of the measurement. PA measurements obtained at 4 stimulus levels were
exported from the Mimosa system and processed in a similar manner. At each stimulus level (60,
65, 70 and 80 dB SPL), PA measurements obtained over two trials were averaged together for
each participant. Following this calculation, the PA measurements were then divided into 1/3rd
octave bands. Once the mean PA was obtained, the full bandwidth measurement was divided into
fourteen 1/3rd octave bands. The upper limit of 1/3rd octave bands was chosen at 5 kHz. This
allowed for the full 1/3rd octave bandwidth to be included in the average for both systems.
In order to evaluate the test-retest reliability of PA measurements, and to compare the
test-retest reliability between systems, the absolute difference in PA was calculated between
trials. First, the PA of each trial was averaged into 1/3rd octave bands. The absolute difference
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between Trial 1 and 2 was then calculated for each octave band. The absolute difference between
trials was measured for the Titan at 65 dB SPL and for the Mimosa at 60, 65, 70 and 80 dB SPL.
For the inter-instrument comparison of ECV, measurement results were exported from
each instrument and processed as follows. PA measurements for the Titan were extracted from
the 3D tympanogram. ECV measurements from trial 1 and trial 2 of each condition were
averaged together. ECV measurements obtained at 65 dB SPL with the Mimosa were extracted.
ECV measurements obtained over two trials were averaged together for each participant.
For the analysis of the test-retest reliability of ECV measurements, and to compare the
test-retest reliability between systems, the absolute difference in ECV was calculated between
trials. The absolute difference between trials was measured for the Titan at 65 dB SPL and for
the Mimosa at 65 dB SPL.

4.2.5

Statistical Analysis
For the inter-instrument comparison of absolute PA, a mixed model ANOVA was

conducted with frequency (14 levels), instrument (2 levels) and ear (2 levels) as the withinsubject factor while sex (2 levels) served as a between-subject factor. When appropriate, posthoc analysis was conducted by completing a pairwise comparison following Bonferroni
correction to determine the frequencies where PA was significantly different between the two
systems. The inter-instrument difference in test-retest reliability of PA measurements was also
investigated using a mixed model ANOVA to test for mean absolute differences in PA with
instrument (2 levels), ear (2 levels) and frequency (14 levels) as within-subject factors and sex (2
levels) as a between-subject factor. Further analysis of the test-retest reliability of each system
was carried out by calculating the Pearson correlation coefficient between Trial 1 and Trial 2 for
each system.
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An inter-system comparison of ECV measures was conducted using a Bland-Altman
approach (Bland & Altman, 1999). The difference between ECVs obtained with each system was
plotted on the y-axis, while the mean ECV obtained with the two systems was plotted on the xaxis. A one-sample t-test was used to determine if there were significant differences between the
two systems. Further analysis of the instrument differences of ECV was conducted using a mixed
model ANOVA where instrument (2 levels), ear (2 levels) served as within-subject factors and
sex (2 levels) as a between-subject factor.
For the analysis of ECV test-retest reliability, a similar Bland-Altman approach was
conducted separately for each instrument. The difference between ECVs obtained at each trial
was plotted on the y-axis, while mean ECV obtained with the two trials was plotted on the xaxis. A one-sample t-test was used to determine if there were significant differences between the
two systems. A comparison of the test-retest reliability of ECV was conducted using a mixed
model ANOVA for absolute mean differences between Trial 1 and Trial 2, where instrument (2
levels), ear (2 levels) served as within-subject factors and sex (2 levels) as a between-subject
factor.
For the Mimosa Hear ID system, a mixed-model ANOVA was conducted to determine
whether stimulus presentation level had a significant effect on absolute PA measurement.
Stimulus level (4 levels), frequency (14 levels) and ear (2 levels) were used as within-subject
factors while sex served as a between-subject factor. When appropriate, post-hoc analysis was
conducted by completing a pairwise comparison following Bonferroni correction.
Stimulus level effects on test-retest reliability were also examined for the Mimosa
HearID. A mixed model ANOVA was completed for mean absolute difference of PA using
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frequency (14 levels), stimulus level (4 levels) and ear (2 levels) as within-subject factors and
sex (2 levels) as a between subject factor. When appropriate, post-hoc analysis was conducted by
completing a pairwise comparison following Bonferroni correction.

4.3 Study 1 Results
4.3.1

PA System Comparison

Power absorbance collected using the two systems was compared to determine whether there
were instrument effects on PA measurements. The results of the mixed model ANOVA
analyzing the inter-instrument differences in PA revealed a violation of sphericity using
Mauchly’s test of sphericity for frequency χ2(90) = 642, p < 0.001, and therefore a GreenhouseGeisser correction was used. It was then determined there was a significant main effect for
frequency [F (2.163, 51.903) = 97.803, p < 0.001] and instrument [F (1, 24) = 9.425, p = 0.005].
There was also a significant interaction between ear and frequency [F (2.461, 59.063) = 3.222, p
= 0.037] and instrument and frequency [F (2.569, 61.647) = 25.247, p < 0.001]. There was no
significant effect of sex on PA measurements (p >0.05). Post-hoc analysis suggests there is a
significant difference in PA measured from different instruments at all frequencies except 1587,
2000 and 5040 Hz (p < 0.05). Mean PA values for both systems are plotted in Figure 11 and
mean PA values along with their 95% confidence interval are reported in Appendix E. Post-hoc
analysis suggests there is a significant difference in PA between ears, where right ears had a
lower PA at frequencies of 1587 Hz and 2000 Hz, and a higher PA at frequencies of 2520, 3175
and 4000 Hz (p < 0.05).
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Figure 11. Mean power absorbance (PA) for Mimosa HearID and Interacoustics Titan (n=50
ears). Error bars represent standard deviations. Significant differences in PA between
instruments are denoted by asterisks (*).

4.3.2

PA System Comparison Test-retest Reliability
An inter-system comparison of test-retest reliability of PA measurements was carried out

by comparing the absolute difference in PA between the two trials of the two systems (Figure
12). This was conducted using a mixed model ANOVA approach. A violation of sphericity using
Mauchly’s test of sphericity was found for frequency χ2(90) = 329.574, p < 0.001, therefore a
Greenhouse-Geisser correction was used to determine significance which revealed a significant
effect of frequency on test-retest reliability (F (4.168, 95.868) = 3.701, p = 0.007) and a
significant interaction of instrument and frequency (F (4.80, 110.394) = 4.591, p = 0.001). A
paired samples t-test with a Bonferroni correction indicated that the Titan had a significantly
lower inter-trial difference in absorbance at 0.25 kHz compared to the Mimosa (p = 0.014), while
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the Mimosa had significantly lower inter-trial differences in absorbance between 3.2 - 4.0 kHz,
as shown in Figure 12 (p < 0.05).

Figure 12. Mean absolute difference between trial 1 and trial 2 of power absorbance (PA) using
the 65 dB SPL stimulus level of the Mimosa HearID and the PA measurement at ambient
pressure of the Interacoustics Titan 3D tympanometry measurement (n=50 ears). Error bars
represent standard deviations. Significant differences in absolute difference of PA between
instruments are denoted by asterisks (*).

The test-retest reliability of PA measurements was analyzed separately for both systems
using Pearson correlation coefficients of trial 1 versus trial 2 (Figures 13 and 14). The Pearson
correlation coefficients of PA measurements obtained using the Interacoustics Titan were
significant across all octave bands, while all Pearson correlation coefficients of PA
measurements obtained using the Mimosa HearID were significant across octave bands with the
exception of the 250 Hz 1/3rd octave band (r = .250, N = 50, p = .053).
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Figure 13. Test-retest reliability of power absorbance of the Interacoustics Titan measured by Pearson Correlation Coefficients (n =
50 ears). X-axis represents trial 1, and y-axis represents trial 2. Solid black line represents the trend line while diagonal dashed line
represents a 1:1 ratio. Pearson correlation coefficients (r) are also reported.
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Figure 14. Test-retest reliability of power absorbance (PA) of the Mimosa HearID measured by Pearson Correlation Coefficients (n =
50 ears). X-axis represents trial 1, and y-axis represents trial 2. Solid black line represents the trend line while diagonal dashed line
represents a 1:1 ratio. Pearson correlation coefficients (r) are also reported. * indicates a Pearson r value with a p > 0.001.
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4.3.3

ECV System Comparison
The Bland-Altman plot comparing ECV measurements obtained with the Titan and

Mimosa are presented in Figure 15. The mean difference was -0.046 with a limit of agreement of
-0.56 to 0.46. A one-sample T-test was carried out to test whether mean ECV difference was
significantly greater than zero. Results indicated that there was no significant difference in mean
ECV difference between the two systems [t (49) = -1.250, p = .217]. This suggests that the ECV
measurements conducted with the two systems are similar. To confirm these results, a linear
regression analysis to predict mean ECV on ECV difference was performed. Results suggest that
there is a significant regression between mean ECV and mean ECV difference with the two
systems [F(1,48) = 4.148, p = .047] with an R2 of .08, suggesting that ECV measurements
obtained with the two systems are significantly different. On careful observation of the data, it
was observed that three measurements fell outside of 2 standard deviations (clinically more
stringent) from the group mean difference (shown in filled black in Figure 15). These data points
were removed, and re-analysis was done where no significant regression between mean ECV and
mean ECV difference of the two systems was identified [F(1,48) = 2.573, p = .116] with an R2 of
.054.
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Figure 15. Bland-Altman plot for the comparison of ear canal volume (ECV) measurements
obtained with the Titan and the Mimosa. Solid black line represents the trend line, while dashed
grey lines indicate mean of the difference between the two systems and 1.96 SD around the
mean. Filled black data points represent data points falling outside of 2 SD from the group mean.
To compare the ECV between systems, a mixed model ANOVA was performed
comparing mean ECV obtained via the Interacoustics Titan (M = 1.47, SD = .30) to ECV values
obtained using the Mimosa (M = 1.51, SD = .37). Results indicate no significant difference in
mean ECV collected between the Titan and Mimosa [F (1,23) = 1.710, p = .204]. This suggests
that at a population level, there does not appear to be a significant difference in ECV obtained by
either system.

4.3.4

ECV Test-retest Reliability
The distribution of ECV measurements obtained from each system were assessed for

normality using the Shapiro-Wilks test, whereby it was determined that measurements obtained
with the Titan and Mimosa were normally distributed (p > 0.05). The Bland-Altman plot for
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ECV obtained with the Titan and Mimosa are reported in Figure 16. For the Titan, the mean
difference was 0.035 with a limit of agreement of -0.24 to 0.31. A one-sample T-test was carried
out to test whether mean ECV difference was significantly greater than zero. Results indicated
that there was no significant difference in ECV mean difference between trial 1 and trial 2 of the
Titan [t (49) = 1.769, p = 0.083]. This suggests that the measurements conducted at two different
time intervals were similar for the Titan. These results were confirmed with a linear regression
analysis to predict mean ECV on ECV difference. There was no significant regression between
mean ECV and ECV difference with the Titan [F(1,48) = 2.182, p = 0.146] with an R2 of .043. A
similar analysis was carried out for the Mimosa, where a one-sample T-test suggests that mean
ECV mean difference between the two trials was not significantly different from zero [t(49) =
1.359, p = .180]. This suggests that the two ECV measurements conducted with the Mimosa
were similar. These results were also confirmed with a linear regression analysis to predict mean
ECV on ECV difference, where there was no significant regression [F(1,48) = .031, p = .861]
with an R2 of .001.
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Figure 16. Bland-Altman plot for the test-retest reliability of ear canal volume (ECV)
measurements obtained with the Titan and the Mimosa. Dashed black lines represent the trend
lines, while solid grey lines indicate means of the difference between trial 1 and trial 2. Dashed
grey lines represent 1.96 SD around the mean.
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The results of the mixed model ANOVA indicate the absolute difeerence between
consecutive ECV measures was greater when using the Mimosa HearID than the Interacoustics
Titan (F(1,23) = 5.819, p = 0.024), suggesting the Titan had better test-retest reliability Figure
17).

Figure 17. Mean absolute difference in ear canal volume (ECV) collected in two trials using the
Interacoustics Titan and Mimosa HearID. Error bars represent 5th and 95th percentile values.

4.3.5

Stimulus Effects on PA
Mean PA within each 1/3rd octave band was calculated for each of the four stimulus

levels, as shown in Figure 18. The results of the mixed model ANOVA revealed a violation of
sphericity using Mauchly’s test of sphericity for frequency χ2(90) = 580.860, p < 0.001 and
stimulus level χ2(5) = 24.992, p < 0.001. A Greenhouse-Geisser correction was used to determine
significance. There was a significant main effect of stimulus level [F (1.699,39.07) = 5.110, p =
.014] and frequency [F (2.41,55.426) = 96.106, p < .001], and for the interaction between
stimulus level and frequency [F (6.683,153.718) = 2.339, p = .029]. Post hoc analysis with a
Bonferroni correction for multiple comparisons are also presented in Figure 18. The 60 dB SPL
stimulus level had significantly higher PA at 314 Hz compared to the 80 dB SPL condition (p =
.013). At 397 Hz, PA was significantly higher in the 60dB SPL condition compared to the 70 (p
95

= .030) and 80 dB SPL (p < .001) conditions. At 2000 Hz the 60 dB SPL condition had
significantly higher PA compared to the 65 dB SPL condition (p = .024) and the 80dB SPL
condition (p = .009), while the 65dB SPL condition had significantly lower PA compared to the
70dB SPL condition (p = .031). Also, at 2000Hz, the 70dB SPL condition had significantly
higher PA compared to the 80dB SPL condition (p = .034). At 3174Hz, the 60dB SPL condition
had significantly higher PA compared to the 80dB SPL condition (p = .024). Finally, at 5039 Hz,
the 60dB SPL condition had significantly lower PA compared to the 65dB SPL condition (p =
.023).

Figure 18. Mean power absorbance (PA) measured in 50 ears using 4 stimulus levels (60, 65, 70,
and 80 dB SPL) with the Mimosa HearID. Error bars represent standard deviations. Significant
differences in absolute difference of PA between instruments are denoted by asterisks (*).
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4.3.6

Stimulus Effects on test-retest reliability of PA
There were three events where significance was not reached with regards to Pearson

correlation coefficients (Table 9). The 60dB SPL measurement of PA using the Mimosa HearID
did not have a significant correlation coefficient at 1/3rd octave bands of 250 Hz (r = -.141, N =
50, p = .33) and 315 Hz (r = .011, N = 50, p = .941) while the 65dB SPL PA measurement did
not have significant Pearson correlation at the 250 Hz octave band (r = .275, N = 50, p = .053).

Table 9. Effect of stimulus level on test-retest reliability of power absorbance (PA) of the
Mimosa HearID measured by Pearson Correlation Coefficients (n = 50 ears) at four different
stimulus levels. Correlation coefficients with P values of >0.001 are bolded*.
Frequency (Hz)
250

315

397

500

630

794

1000

1260

1587

2000

2520

3175

4000

5040

-.141*
.275*
0.527
0.665

.011*
0.677
0.811
0.797

0.689
0.882
0.865
0.843

0.768
0.924
0.857
0.867

0.792
0.949
0.851
0.87

0.837
0.944
0.817
0.819

0.745
0.907
0.823
0.835

0.907
0.876
0.896
0.905

0.922
0.898
0.946
0.962

0.959
0.954
0.968
0.967

0.929
0.933
0.954
0.96

0.968
0.963
0.967
0.956

0.951
0.966
0.963
0.961

0.917
0.954
0.94
0.94

Stim Level
60dB SPL
65dB SPL
70dB SPL
80dB SPL

The stimulus effects on test-retest reliability of PA revealed a violation of sphericity
using Mauchly’s test of sphericity for frequency χ2(90) = 480.757, p < 0.001, and stimulus level
χ2(5) = 37.025, p < 0.001, therefore a Greenhouse-Geisser correction was used to determine
significance. There was a significant main effect of frequency [F (2.964,68.163) = 4.161, p =
.009] and stimulus level [F (11.743, 40.098) = 13.966, p < .001] and a significant interaction of
frequency and stimulus level on the inter-trial difference of absorbance [F (4.435,102.007) =
11.418, p < .001]. Post-hoc analysis with a Bonferroni correction for multiple comparisons
revealed the 60 dB SPL stimulus level had significantly higher absolute differences in
absorbance compared to the other three stimulus level conditions at 0.25 kHz and 0.314 kHz (p <
0.001) and for the 65 dB SPL condition at 0.63 kHz (p = .044). It was also discovered that the 80
dB SPL condition had a significantly smaller absolute difference in absorbance at 0.25 kHz
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compared to the 70 dB SPL condition (p = 0.022). Between trial differences in absorbance for
the 1/3rd octave bands are plotted in Figure 19 and statistically significant differences are
indicated.

Figure 19. Mean absolute difference between trial 1 and trial 2 of power absorbance (PA) using
various stimulus levels (60, 65, 70- and 80-dB SPL) with the Mimosa Hear ID (n = 50 ears).
Error bars represent standard deviations. Significant differences in absolute difference of power
absorbance between instruments are denoted by asterisks (*).

4.4 Study 1 Discussion
WAI has the potential to be a powerful tool for the identification and differential
diagnosis of middle ear pathologies. Commercial systems, Interacoustics Titan and Mimosa Hear
ID have been designed for clinical use, but the data produced by these 2 systems may not be
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comparable. Standards for these instruments do not exist, and research focusing on WAI has
used different instruments and protocols.
In this study, absolute PA and test-retest reliability were directly compared for the two
commercial systems, the Mimosa HearID and the Interacoustics Titan systems under the same
experimental conditions. Frequency-specific differences were found, with PA measurements
using the Mimosa HearID significantly lower between 250-1260 Hz and significantly higher
between 2520-4000 Hz compared to the Interacoustics Titan. This inter-instrument difference in
PA is greater than that reported by Shahnaz et al. (2013), who found a significant difference only
at 5000 Hz, with the commercial Mimosa Hear ID having lower PA at this frequency compared
to the prototype WAIT (wideband acoustic immittance tympanometry) a non-commercial
Interacoustics research system. Shahnaz et al. (2013) suggests that instrumental differences were
minor, and that differences in pathology would be large enough to overcome these instrument
effects. Differences in PA between the two systems may be in part due to calibration technique,
the method to calculate ear canal area or the type of probe tip used (Shanaz et al, 2013). Results
of the inter-instrument effects on ECV volumes suggest that there was no significant difference
in ECV between the two instruments, providing evidence that instrument differences in PA are
not likely due to differences in ECV calculations between the two systems. Additional work
should be conducted to investigate these instrument effects on PA.
These results have implications for the clinical application of PA research in disordered
populations. Recent studies report significantly different PA profiles in conductive hearing losses
compared to normal ears (Merchant, Merchant, Rosowski, & Nakajima, 2016; Nakajima et al.,
2012; Nakajima et al., 2013; Niemczyk, Lachowska, Tataj, Kurczak, & Niemczyk, 2018;
Sanford, Schooling, & Frymark, 2012; Shahnaz et al., 2009). Clinical diagnostic criteria for an
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abnormal PA result, and algorithms for the differential diagnosis of specific pathologies,
including otosclerosis and superior canal dehiscence (Merchant et al., 2015; Nakajima et al.,
2012; Sanford et al., 2012) have been developed. Since there are instrument-specific effects on
PA, the use of WAI for evaluating middle ear pathology must be interpreted accordingly using
instrument specific normative data. Additional work should continue to investigate the interinstrument differences in PA, as well as work toward developing a standard in PA
measurements.
The inter-instrument comparison of test-retest reliability under the same experimental
conditions also revealed a difference between the two systems. The Interacoustics Titan
demonstrated significantly better test-retest reliability in the lowest 1/3rd octave band (250 Hz)
and worse test-retest reliability in higher frequency octave bands of 2520, 3175 and 4000 Hz
compared to the Mimosa HearID,
Results of this study are consistent with previous investigations of test-retest reliability
using either current or research prototype versions of the Interacoustics system (Feeney et al.,
2017) and the Mimosa system (Feeney et al., 2014; Vander Werff et al., 2007). The test-retest
reliability of 0.025-0.072 found here for the Interacoustics Titan are consistent with Feeney et al.
(2017), with mean between-trial differences of 0.04-0.1 identified for a research prototype of the
Interacoustics system. Furthermore, the mean between-trial differences from 0.026 - 0.056 for
the Mimosa HearID found in this study are similar to the test-retest differences < 0.1 reported for
a research prototype system of the Mimosa, with PA recorded during the same session (Vander
Werff et al., 2007). Werner et al. (2010) report that when measurements were obtained
approximately 2 weeks apart, wideband measurements had a mean absolute difference between
0.1- 0.2, also using a research prototype similar to the Mimosa system. These findings indicate
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that more variability in PA measurements occur when separated by a longer period of time
between recording sessions. Longitudinal variability of PA measurements obtained with the
Interacoustics Titan and Mimosa Hear ID systems over significantly longer timescales are
required before WAI can be used to track the natural course of middle ear diseases.
For both systems, the variability of repeated measurements in this study was lower than
the variability in the normative population, and similar to the findings of Rosowski et al. (2012).
However, frequency-specific differences in inter-trial reliability were also identified in this
study. Specifically, the Interacoustics Titan exhibits slightly better test-retest reliability at the
very lowest frequency band (250 Hz) compared to the Mimosa HearID, while the Mimosa
exhibits slightly better test-retest reliability in the mid-frequency bands (2520 - 4000 Hz).
Users of the Mimosa system have the flexibility to record PA measurements at 4 stimulus
levels between 60- 80 dB SPL. A stimulus effect on PA below 2000Hz, and also in higher
frequency bands (3175 and 5040 Hz) was identified in Study 1. A low frequency reduction in PA
below 2000 was found at 80 dB SPL only, and may be explained by induction of the acoustic
stapedius-muscle reflex at this high presentation level. Using a research prototype WAI system
similar to the Mimosa HearID, Feeney & Sanford (2005) identified decrease reduction in PA
below 1000 Hz following contralateral activation of the acoustic reflex, which decreased as a
function of increasing stimulus level. A similar increase in middle ear stiffness with activation of
the ipsilateral acoustic reflex could also explain the PA findings of study 1.
Test-retest reliability below 315 Hz was significantly worse at 60 dB SPL and
significantly better at 80 dB SPL compared to the other stimulus levels. In the 60 dB SPL
condition PA may be contaminated by low frequency noise generated by the body (Buss, Porter,
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Leibold, Grose, & Hall, 2016) resulting in a poor signal-to-noise ratio (Liu et al., 2008). Using
stimulus level between 65 dB SPL – 80 dB SPL should improve SNR and provide a more
reliable PA measurement, however changes introduced by activation of the acoustic reflex may
be introduced as the stimulus intensity increases.

4.5 Study 2: Evaluation of PA Variability and Effects of
Otosclerosis on PA
Differences in absolute PA have been reported for ears with otosclerosis compared to
normal ears. Otosclerotic ears have a lower absorbance in frequencies below 1000 Hz (Feeney et
al., 2003; Merchant et al., 2016; Nakajima et al., 2012; Sanford et al., 2012; Shahnaz, Bork, et
al., 2009). Several methods have been used to investigate the differences in PA between normal
and otosclerotic ears, or otosclerotic ears and other middle ear pathologies. Shahnaz, Bork, et al.
(2009) compared energy reflectance (inverse of PA) between normal and otosclerotic ears using
group differences. The effect of otosclerosis on PA has also been investigated using cadaveric
ears and controlling for the middle ear pathology (Merchant et al., 2016). Results of this
controlled study suggest that inducing stapes fixation results in a decrease in PA of greater than
0.2 below frequencies of 1000 Hz. Results by Nakajima et al. (2012) report the PA profile of
various middle ear disorders, where the PA profile of four otosclerotic ears were reported and no
statistical analysis was conducted. Three of the four ears demonstrated the characteristic lowfrequency low-absorbance compared to normal ears, however one ear demonstrated a PA peak,
around 800 Hz. This variability of PA of otosclerotic ears was recently investigated in a large
otosclerotic population of 77 ears (Niemczyk et al., 2018). By visually examining each PA plot,
they propose that otosclerotic ears can be categorized into five subgroups based on their PA plot
characteristics. These characteristics include the number of peaks in the plot, the frequency of the
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peaks and the height of the peaks. Their preliminary findings suggest that PA plots of
otosclerotic ears are quite variable and that the variability of these PA plots should be
investigated further. Overall, on a population level, otosclerotic ears have low PA below 1000
Hz, yet there is some evidence to suggest that there is individual variability with a more complex
PA profile across otosclerotic ears.

4.5.1

Aim of Study 2:

The aim of Study 2 was to compare PA measurements between normal ears and otosclerotic ears.
Specific aim 2: Compare PA measurements obtained in the normal hearing control group
to a cohort of otosclerotic ears.

4.6 Study 2 Methods
4.6.1

Subjects
The normal hearing control group for Study 2 were the same subjects presented in Study

1 of this chapter. The normal hearing control group consisted of 25 subjects (50 ears). The
otosclerotic cohort was recruited from two sources. All otosclerosis subjects had surgically
confirmed otosclerosis in at least one ear, and all ears met the criteria for clinical otosclerosis
with a significant air-bone gap and absent acoustic reflexes (same criteria as outlined in Chapter
3). The first source were pre-surgical cases from University Hospital in London, Ontario, later
confirmed otosclerotic subjects following successful stapes surgery. Five subjects, with eight
otosclerotic ears, were included from this group. Five other otosclerotic subjects were recruited
to the study in the province of Newfoundland. These five subjects had previously undergone
successful stapes surgery, confirming otosclerosis, and presented with clinical otosclerosis in
their non-surgical ear. These non-surgical ears presenting with a conductive hearing loss were
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considered as clinical otosclerotic ears and included in the study. In total, 13 otosclerotic ears
from nine patients were included for analysis.

4.6.2

Instrumentation
PA was obtained in both the control group and the otosclerotic cohort using the Mimosa

HearID at a stimulus level of 80 dB SPL. This instrument and stimulus level were selected based
on the results of study 1 which reports a significantly better test-retest reliability of the Mimosa
HearID at 80 dB SPL stimulus level. Additional information about the instrumentation is
reported in Study 1.

4.6.3

Data Analyses
PA data was analysed in the same manner as reported in Study 1.

4.6.4

Statistical Analyses
The effects of otosclerosis on PA were examined using 1/3rd octave band PA

measurements from the normative group and the otosclerotic cohort. A mixed model ANOVA
was completed for mean PA using frequency (14 levels) as within-subject factor and sex (2
levels) and ear status (2 levels) as a between-subject factor. When appropriate, post-hoc analysis
was conducted by completing a pairwise comparison following Bonferroni correction.

4.7 Study 2 Results
Mean PA values for normal ears and otosclerotic ears are plotted in Figure 20. The effect
of otosclerosis on PA revealed a violation of sphericity using Mauchly’s test of sphericity for
frequency χ2(90) = 1509.777, p < 0.001, therefore a Greenhouse-Geisser correction was used to
determine significance. There was a significant main effect of frequency [F (3.114,183.728) =
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161.475, p < .001]. The main effect of ear status approached by did not reach statistical
significance of p < 0.05 [F (1,59) = 3.447, p = .068].
Overall, seven of thirteen otosclerotic ears demonstrate PA values below 1 SD of the
normative mean at frequencies below 1000 Hz (Figure 20), while 6 of 13 demonstrate PA values
above the normative mean at these low frequencies, with four of these ears demonstrating the
unusual peak pattern. In total, 10/13 otosclerotic ears demonstrate PA profiles of either lowabsorbance (n=6) in the low-frequencies or the unusual peak between 800-1000 Hz (n=4). A
review of PA profile plots of the normative ears revealed the 800 -1100 Hz PA peak to be
present in 4/50 ears, with two of those ears having elevated compliance values greater than 1.7
mL based on standard 226 Hz acoustic admittance.
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Figure 20. A) Mean (1 SD) power absorbance (PA) measured in normal ears (n=50) represented by black line, and otosclerotic ears
(n=13), represented by red line using 80 dB SPL stimulus level with the Mimosa HearID. Grey lines represent individual otosclerotic
ear PA measurements. B) Mean power absorbance (PA) averaged into 1/3rd octave bands, measured in normal ears (n=50), and
otosclerotic ears (n=13). Error bars represent standard deviations.
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4.8 Study 2 Discussion
In Study 2 of this chapter, there were no statistically significant differences in power
absorbance between otosclerotic and normal ears, however results were approaching
significance. A lack of statistical significance was likely due to the low number of otosclerotic
ears available to the study. Previous studies comparing otosclerotic ears to normal ears, where a
significant decrease in PA (increase in energy reflectance) in low frequencies are reported, which
is explained by increased stiffness of the middle ear. Sclerotic bone growth around the stapes
results in a less efficient middle ear system, particularly for low-frequency stimuli which results
in less acoustic energy absorption by the middle ear (Feeney et al., 2003; Merchant et al., 2016;
Nakajima et al., 2012; Sanford et al., 2012; Shahnaz, Longridge, et al., 2009).

An interesting finding of our otosclerotic cohort revealed 4/13 demonstrating a second
PA profile, presenting with a PA peak around 800-1100 Hz. This peak profile is similar to the
reported subgroup IV reported by Niemczyk, Lachowska, Tataj, Kurczak, & Niemczyk (2018).
A low frequency PA peak was also reported in one otosclerotic ear by Nakajima et al. (2012)
while a similar PA profile can also be seen in the results from Shahnaz, Bork, et al. (2009), who
provide individual PA plots for an otosclerotic population of 28 ears. Two otosclerotic ears in
their cohort also exhibit this characteristic PA peak occurring around 800 Hz. The same profile
has been reported in ears with normal hearing thresholds, but who demonstrate elevated
compliance values of greater than 1.7 mL (Feeney et al., 2014). A review of PA profile plots of
the normative ears presented in Study 1 revealed the 800 -1100 Hz PA peak to be present in 4/50
ears, with two of those ears having elevated compliance values greater than 1.7 mL. Therefore,
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when interpreting the presence of the abnormal PA peak, standard tympanometry will be
considered, as ears with elevated compliance values may exhibit the same PA profile.
Differences in the PA profile of otosclerotic ears may reflect changes associated with
disease progression and/or location of sclerotic bone growth. Early work from Schuknecht &
Barber (1985) based on temporal bone histology reveal variability in location as well as size of
sclerotic bone growth. Future work should focus on investigating whether there are any
correlations between PA sub-types or profiles and the location of the sclerotic bone growth or the
disease progression using advanced imaging methods, such as high-resolution CT (Maraghy et
al., 2015; Quesnel et al., 2013), or by measuring PA pre-surgically and correlating the PA
profiles to the size and location of sclerotic bone growth at the time of corrective surgery. During
the natural course of otosclerosis, abnormal bone growth may induce changes in middle ear mass
and/or stiffness which in turn differentially affect the PA. Since otosclerosis begins with the
formation of spongy vascularized bone growth (otospongiosis) before transitioning to harder
sclerotic bone growth (Parahy & Linthicum, 1984), it is possible that PA may be sensitive
enough to detect differences in the various stages of disease progression. PA has shown to be
sensitive to middle ear disorders with altered mass and stiffness characteristics. In a controlled
study using cadaveric ears to measure PA in mass-dominated and stiffness dominated middle ear
conditions, the PA profile in a more mass-dominated middle ear system (ie. ossicular
discontinuity), has a PA profiles where a peak in PA is present in the low-frequencies around
800-1000 Hz, while stiffening the middle ear by fixating the stapes (ie. otosclerosis) resulted in a
lower absorbance in the low frequencies similar to our mean PA in the entire otosclerotic cohort
(Merchant et al., 2016).
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Previous work has attempted to determine criteria for the determination of presence or
absence of otosclerosis using wideband acoustic immittance (Shahnaz, Bork, et al., 2009),
however recent work by Keefe et al. (2017) suggests that WAI be included as part of an overall
test battery including acoustic reflexes and otoacoustic emissions in order to improve the overall
diagnostic accuracy of otosclerosis compared to normal ears. Since there is currently no standard
for determining normal versus abnormal PA profiles, it is recommended that an abnormal PA
profile be considered when PA is 1 SD below the normative mean at frequencies below 1000 Hz,
or if the PA plot demonstrates a peak falling outside of 1 SD at frequencies between 800-1100
Hz. Both of these characteristic PA plots have been reported in otosclerotic ears (Nakajima et al.,
2012; Niemczyk et al., 2018; Shahnaz, Bork, et al., 2009). It is also recommended that an
abnormal PA profile only be considered as part of a greater test battery, where an altered PA
profile plot will only be considered as evidence of otosclerosis or potential early onset
otosclerosis if it is companioned with another clinical indicator, such as hearing loss (conductive,
mixed or SNHL), absent reflexes or absent otoacoustic emissions (Chapter 3, Keefe et al., 2017).

4.8.1

Overall Conclusions
In conclusion, Study 1 identified an inter-instrument difference in PA and test-retest

reliability between the two commercially available systems. Since there is no current standard for
the measurement of PA, clinicians and researchers should use of the same equipment and
measurement protocols when collecting data and interpreting results. Study 2 reports that within
individual ear data, a PA profile with a characteristic peak in the low frequencies was identified
in 31% of otosclerotic ear and 8% of normal control ears. These results support previous reports
of an otosclerotic PA peak (Nakajima et al., 2012; Niemczyk et al., 2018; Shahnaz, Bork, et al.,
2009), possibly due to a change in mass (Merchant et al., 2016) and should also be considered
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when classifying PA profiles. Otosclerosis is typically associated with low compliance due to the
increased middle ear stiffness (Hannley, 1993; Ogut et al., 2008; Zhao et al., 2002). However,
the presence of high compliance (greater than 1.75 mL) should be considered when interpreting
this PA peak profile (Feeney et al., 2014), as a highly compliant middle ear, as measured by
standard tympanometry, has demonstrated the same PA peak profile described in the present
otosclerotic sub-group. Limitations of Study 2 include the low number of otosclerotic ears
available for recruitment, a likely contributor to the lack of statistical significance of PA between
normal and otosclerotic ears. Recruitment numbers for pre-operative research on otosclerotic
ears was low due to the limited recruitment window between when an individual is seen by the
otolaryngologist to determine surgical candidacy and when they are scheduled for corrective
stapes surgery. Future work should focus on the recruitment of additional pre-surgical ears to
determine further PA differences between normal ears and otosclerotic ears, as well as to
investigate the variability of PA among pre-surgical otosclerotic ears.
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Chapter 5
Advanced Phenotyping of a Large Otosclerotic FOXL1
Newfoundland Family

5

5.1 Introduction
The purpose of this study is to investigate the auditory phenotype of otosclerosis in
FOXL1 gene carriers in a large Newfoundland otosclerotic family. Family design methodologies
are beneficial over population studies because they help reduce the effects of population
stratification and heterogeneity (Laird & Lange, 2006). Earlier in this thesis, the auditory
phenotype of an Ontario otosclerotic population was reported, suggesting a broad mix of
auditory phenotypes in that heterogenous population. Analysis of the auditory phenotype in a
more homogenous population, a family with the FOXL1 mutation, allows for an improved
understanding of the phenotype and phenotypic variation due to changes in the same gene.
For the family design methodology, a cross-sectional analysis of Family 2081 was carried
out. Investigation of audiometry, ARTs, DPOAEs, and WAI improve our understanding of
variability within a family context. Audiometric thresholds were used to develop a predictive
model for the FOXL1-associated hearing loss, which will lead to the better understanding of the
natural course of FOXL1-specific otosclerosis.

5.1.1

Aims of this Study
The aims of this study are to conduct a phenotypic analysis on gene carriers of the

FOXL1 deletion using clinically available tools. More specifically, the aims are:
Specific aim 1: Develop a predictive model for FOXL1-associated hearing loss.
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Specific aim 2: Compare audiometric and non-audiometric phenotypes of ARTs,
DPOAEs and WAI of carriers with non-surgical family members with the FOXL1
deletion.
Specific aim 3: Summarize the phenotypes of all FOXL1 gene carriers.

5.2 Methods
The test battery for participants in the research study consisted of audiometry,
tympanometry, DPOAEs, ART testing and WAI measurements. Conventional immittance testing
as well as ARTs were obtained using the Interacoustics Titan, whereas wideband acoustic
immittance measurements were conducted using the Mimosa HearID. The testing protocol for
this study is an abbreviated test battery of the protocol presented in Chapter 4. The test battery
for this phenotyping study was selected based on test-retest reliability, phenotypic relevance, as
well as limiting the protocol to an acceptable length of time.

5.2.1

Family 2081
Family 2081 has thirteen family members carrying the 15bp deletion in the FOXL1 gene.

A pedigree of the family was constructed (Figure 21). Only family members heterozygous for
the deletion were recruited for this study in collaboration with Memorial University (MUN
Ethics #01.186).
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Figure 21. Pedigree for Family 2081, a large Newfoundland otosclerotic family with FOXL1 deletion co-segregating with
otosclerosis.
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5.2.2

Retrospective Data
Retrospective audiometric data (per-surgery) was collected from affected family

members carrying the FOXL1 deletion (N=8) who consented to the study. Patient histories were
also retrospectively collected to obtain age of onset data. Audiograms were analysed for air
conduction hearing threshold levels at 0.25, 0.5, 1, 2, 4 and 8 kHz, while bone conduction
thresholds were analyzed for frequencies of 0.5, 1, 2, and 4 kHz. Air-bone gaps were calculated
by subtracting bone conduction thresholds from air conduction thresholds at their given
frequencies.

5.2.3

Prospective Data
Prospective data was collected on two of nine FOXL1 deletion carriers, representing the

two family members who had not undergone corrective surgery for otosclerosis. Corrective
stapes surgery alters the physical properties of the middle ear by replacing the stapes with a
prosthetic piston. This physical change to the middle ear will significantly change the nonaudiometric data such as tympanometry and WAI. As reviewed in Chapter 3, otosclerotic ears
that have undergone surgery do not have measurable ARTs or present DPOAEs.

5.2.3.1

Audiometry

Pure tone audiometry was conducted using the Interacoustics AC40 audiometer calibrated
according to ANSI standards (re: S3.6.2010). Both air and bone conduction thresholds were
measured. Measurements were conducted in a sound-booth using ER3 insert earphones for air
conduction, and a bone oscillator for bone conduction thresholds. Air conduction thresholds were
measured between 0.25 – 8 kHz, while bone conduction thresholds were measured between 0.5-4
kHz. A standard bracketing method was used to conduct audiometry.
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To measure the rate of progression of the hearing loss within Family 2081, retrospective
and prospective audiometric thresholds (air conduction and bone conduction), along with airbone gaps were plotted with respect to age. All available pre-surgical retrospective hearing
thresholds were included in the analysis. Prior to analysis, ears were separated into two
categories: worse ear and better ear. Ears were classified into these two groups based on puretone averages of 500, 1000 and 2000 Hz (PTA3). Linear regression was then conducted between
age and threshold for air-conduction thresholds, bone-conduction thresholds and air-bone gaps
for the categories of worse and better ear. A model was calculated to determine the frequencyspecific progression reported in dB per decade. Linear regression was also used to generate a
predicted audiogram for FOXL1 deletion carriers. The predicted audiogram was generated by
using linear regression from air conduction and bone conduction thresholds of the worse ears for
eight family members heterozygous for the FOXL1 deletion. The worse ear was used to generate
the hearing loss model since otosclerosis can appear as a unilateral hearing loss or develop
asymmetrically.

5.2.4

Acoustic Immittance

5.2.4.1

Tympanometry (conventional)

Standard 226 Hz tympanometry was conducted using the Interacoustics Titan hardware
version 1.0 and Titan Suite version 3.2.2.5 software. Tympanometry was conducted using a 226
Hz probe tone between pressures of +200 daPa to -300 daPa. Tympanometric peak pressure,
compliance, and ear canal volume were all collected.

5.2.4.2

Acoustic Reflex Thresholds

Acoustic reflex thresholds were measured using the Interacoustics Titan system. ARTs
were measured both ipsilaterally and contralaterally at generator tone frequencies of 0.5, 1, 2, 3,
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4 kHz, along with a wideband noise (WBN). A probe tone of 226 Hz was used at all frequencies.
To pass the criteria for the ART to be considered present, an amplitude of 0.02 mL or greater
must be measured in two out of three presentations. Failure to meet criteria at the given stimulus
level would result in an increase in stimulus by 5 dB. An initial stimulus level of 80 dB HL was
used for all measurements, with a maximum stimulus presentation level of 100 dB HL. Failure to
meet the amplitude criteria at all stimulus levels up to and including 100 dB HL resulted in the
classification of “absent” acoustic reflex. The same nomenclature for ARTs in Chapter 3 was
used in this chapter. The designation of the ear represents the probe ear and not the stimulus ear
as is conventional in audiology clinics. For example, in cases of right contralateral reflexes, the
stimulating tone is generated from the left ear, and the reflex is measured in the right.

5.2.4.3

Wideband Acoustic Immittance

Power absorbance was measured using the Mimosa HearID system at a stimulus level of
80 dB SPL. This level was chosen based on results from the previous chapter of this dissertation.
80 dB SPL generated the best test-retest reliability in the low frequency octave band (0.25 kHz).
Methods for PA acquisition are described in Chapter 4. PA measurements were compared to the
normative data set reported in Chapter 4 for all 50 ears. The normative mean was subtracted
from PA measurements of each individual to calculate the PA difference from the mean.
PA measurement for an individual family member was considered abnormal if their PA
measurement below 1000 Hz was outside 1 SD of the normative mean as previously reported in
the literature and in Chapter 4 (Feeney et al., 2003; Shahnaz, Bork, et al., 2009; Shahnaz,
Longridge, et al., 2009). PA profiles were interpreted for the presence of the classical PA profile
associated with otosclerosis, where PA is expected to be lower than the normative mean in the
low frequencies (below 1000 Hz). PA profiles were also considered abnormal if they
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demonstrated a peak between 800-1100 Hz which has also been associated with otosclerosis
(Chapter 4, Nakajima et al., 2012; Niemczyk et al., 2018; Shahnaz, Bork, et al., 2009).

5.2.5

Distortion Product Otoacoustic Emissions (DPOAEs)
Distortion product otoacoustic emissions were elicited using the Mimosa HearID system.

The F2 primary tone was presented at 65 dB SPL, while the F1 tone was presented at 55 dB SPL.
The frequency ratio of F2/F1=1.22 was used to elicit the distortion product. The DP was
measured as the amplitude of the response at 2F2-F1. The normative data set from Gorga et al.
(1997) was used, whereby minimum DPOAE levels were chosen based on the 10th percentile of
their normative ears. A list of F1, F2 and the associated 2F2-F1 distortion product, along with the
10th percentile of their normal population from the normative data set were used as criteria for
the presence/absence of a distortion product at each F2 frequency (Table 10). For a DPOAE to
be considered present, it must have a minimum signal-to-noise ratio of 6 dB and meet the
frequency specific minimum DP level.
Table 10. F2, F1, 2F1-F2 and minimum distortion product level values for measured DPOAEs
collected using the Mimosa HearID system. In total, 12 distortion products were elicited across
an F2 frequency range of 984-8016 Hz.
F2 (Hz)

F1 (Hz)

2F1-F2 (Hz)

Min DP level (dB)

984
1500
2016
2484
3000
3516
3984
5016
5484
6000
6984
8016

844
1266
1688
2062
2484
2906
3328
4172
4594
5016
5812
6556

703
1031
1359
1641
1969
2297
2672
3328
3703
4031
4641
5297

-8
-7
-10
-11
-12
-9
-6
-7
-7
-8
-15
-22
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5.3 Results
Overall, nine family members of 2081 have been identified as heterozygous for the
FOXL1 deletion causing otosclerosis. Of these nine individuals, seven have been identified as
being affected by otosclerosis by an otolaryngologist on the basis of surgical confirmation. Since
these individuals have undergone middle ear surgery to correct for their stapes fixation due to
otosclerosis, and thus altering the physical characteristics of their middle ear, they were removed
from any prospective data analysis. Individuals 0002, 0016 and A001 (Figure 21) were
unavailable to participate in the prospective data collection. These individuals represent cases of
unilateral surgical intervention, and had they been available to participate, their non-surgical ear
would have been included in the analysis.

5.3.1

FOXL1 deletion carriers
Audiometric thresholds were available for eight family members of Family 2081

heterozygous for the FOXL1 deletion. Three family members presented with bilateral conductive
hearing loss prior to stapes surgery (individuals 0000, 0004 and A001). Only one family member
presented with a bilateral mixed hearing loss (0005). Two family members presented with a
unilateral mixed hearing loss, accompanied with a sensorineural hearing loss on the non-surgical
ear (0002, 0016). Finally, two carriers of the deletion exhibited normal, or essentially normal
hearing thresholds and were classified as non-penetrant carriers (A005, A006). All affected
members of the family reported an onset of hearing loss within the second or third decade of life.
To investigate the rate of progression of the hearing loss in this family, air-conduction
and bone-conduction thresholds along with air-bone gaps were plotted based on age for each
participants’ worse ear (Figure 22) and for their better ear (Figure 23). A linear model was
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created based on available retrospective audiometric data to determine the approximate rate of
progression of the hearing loss. Results of the linear regression are reported for the worse ear
(Table 11) and for the better ears (Table 12). R2 values of the worse ears were calculated between
.194 and .508 for air-conduction and bone-conduction thresholds and age, while the better ears
had R2 value between .068 and .619. All linear regression models were statistically significant
with the exception of BC thresholds versus age at frequencies of 500 and 1000 Hz in the better
ears.
The overall progression of otosclerosis in this family is quite variable (Figures 22 and
23). In general, AC and BC thresholds and measured ABGs increase over the lifespan at all
frequencies. There is a difference in the rate of progression between the conductive component
and sensorineural component of the hearing loss, with the conductive component progressing
more rapidly at frequencies of 500, 1000 and 2000 Hz and the sensorineural component to the
hearing loss progressing more rapidly at 4000 Hz.
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Figure 22. Audiometric thresholds of participants’ worse ear as a function of age for eight family members of Family 2081 identified
as heterozygous for FOXL1 deletion. Each colour represents data from a different family member. Data points connected with a line
represent longitudinal data from the same individual ear. Audiometric thresholds broken down into air conduction (total hearing loss),
bone conduction (sensorineural hearing loss component) and air-bone gap (conductive hearing loss component).
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Figure 23. Audiometric thresholds of participants’ better ear as a function of age for eight family members of Family 2081 identified
as heterozygous for FOXL1 deletion. Each colour represents data from a different family member. Data points connected with a line
represent longitudinal data from the same individual ear. Audiometric thresholds broken down into air conduction (total hearing loss),
bone conduction (sensorineural hearing loss component) and air-bone gap (conductive hearing loss component).
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Table 11. Linear regression analysis for relationship between age and worse ear hearing
thresholds for eight family members heterozygous for the FOXL1 deletion.
Source
Air Conduction
250 Hz
(Constant)

B

Worse Ear
SE B
β

t

p

R2

.959
-.652

.357
15.409

.440

2.686
-.042

.012
.967

.194

500 Hz
(Constant)

1.200
-6.886

.429
18.534

.454

2.794
-.371

.009
.713

.206

1000 Hz
(Constant)

1.271
-10.09

.425
18.362

.479

2.988
-.549

.006
.587

.229

2000 Hz
(Constant)

1.517
-21.84

.341
14.709

.631

4.452
-1.485

.000
.148

.398

4000 Hz
(Constant)

1.361
-6.413

.265
11.422

.685

5.143
-.562

.000
.579

.469

8000 Hz
(Constant)

1.204
-10.01

.404
17.425

.478

2.982
-.575

.006
.570

.229

.743
-12.08

.214
10.214

.656

3.477
-1.182

.003
.254

.430

1000 Hz
(Constant)

.502
-.770

.217
10.390

.500

2.311
-.074

.035
.942

.250

2000 Hz
(Constant)

.927
-11.04

.204
9.259

.712

4.541
-1.193

.000
.247

.508

4000 Hz
(Constant)

.694
-5.43

.228
10.910

.605

3.039
-.497

.008
.626

.366

Bone Conduction
500 Hz
(Constant)
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Table 12. Linear regression analysis for relationship between age and better ear hearing
thresholds for eight family members heterozygous for the FOXL1 deletion.
Source
Air Conduction
250 Hz
(Constant)

B

Better Ear
SE B
β

t

p

R2

.980
-11.21

.263
11.348

.563

3.730
-.988

.001
.331

.317

500 Hz
(Constant)

1.031
-11.10

.312
13.464

.517

3.307
-.825

.002
.416

.267

1000 Hz
(Constant)

1.214
-17.61

.301
13.015

.592

4.027
-1.353

.000
.186

.351

2000 Hz
(Constant)

1.379
-29.35

.339
14.627

.596

4.070
-2.006

.000
.054

.356

4000 Hz
(Constant)

1.855
-42.36

.317
13.688

.730

5.852
-3.095

.000
.004

.533

8000 Hz
(Constant)

1.415
-26.47

.408
17.617

.540

3.459
-1.502

.002
.144

.292

.217
5.937

.208
10.134

.261

1.046
.586

.312
.567

.068

1000 Hz
(Constant)

.389
1.009

.226
11.003

.407

1.726
.092

.105
.928

.166

2000 Hz
(Constant)

.739
-11.78

.217
10.569

.661

3.412
-1.115

.004
.283

.437

4000 Hz
(Constant)

.971
-19.27

.203
9.924

.787

4.774
-1.942

.000
.073

.619

Bone Conduction
500 Hz
(Constant)

A summary of the rate of progression in dB/decade is reported in Table 13 for AC and
BC thresholds in the worse and better ear. In the worse ears, progression of hearing loss occurs
most rapidly in 2000 Hz AC thresholds, while the better ears have a most rapid progression in
4000 Hz AC thresholds. In both the worse and better ears, BC thresholds had an increase in the
rate of progression with increasing frequency, indicative of a progressive SNHL component to
the hearing loss. In the worse ear, air-conduction thresholds were estimated to deteriorate at a
rate between 9.6-15.2 dB/dec, while bone-conduction thresholds were estimated to deteriorate at
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a rate between 5.0-18.6 dB/dec depending on frequency. Similar rates of progression were
identified in the better ears, however linear regression analysis was not significant for boneconduction thresholds at 500 and 1000 Hz.
Table 13. Rate of progression of air-conduction (AC) and bone-conduction (BC) thresholds
reported in dB per decade (dB/dec) for eight family members of Family 2081 identified as
heterozygous for FOXL1 deletion. Numbers bolded with * represent non-significant linear
regression analysis.
Frequency (Hz)
250
500
1000
2000
4000
8000
Worse AC
9.6
12.0
12.7
15.2
13.6
12.0
Ear
BC
7.4
5.0
9.3
18.6
Better AC
9.8
10.3
12.1
13.8
18.6
14.2
Ear
BC
2.2*
3.9*
7.4
9.7

5.3.1.1

Predicted Audiogram

A separate linear regression analysis was carried out following removal of the nonpenetrant cases for the worse ears of FOXL1 gene carriers (Table 14). Analysis from the linear
regression of the worse ear was used to generate a predicted audiogram based on three ages of
20, 40 and 60 years (Figure 24). Based on the linear regression predictive model, it is estimated
that FOXL1 deletion carriers will exhibit a moderate conductive hearing loss around the age of
20. This is consistent with phenotypic results of family members carrying the mutation who
report their hearing loss being identified in their 20s (Table 15). Predictive modeling at the age
of 40 reveals a moderately-severe mixed hearing loss, with predicted bone conduction thresholds
demonstrating the beginning of the associated sensorineural component to the FOXL1 hearing
loss. By the age of 60, the predicted audiogram suggests a profound mixed hearing loss. This is
consistent with participant 0002 who underwent surgery for a cochlear implant. All other family
members with such severe hearing loss had undergone corrective stapes surgery to resolve the
conductive component to their hearing loss.
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Table 14. Linear regression analysis for relationship between age and worse ear hearing
thresholds for six family members heterozygous for the FOXL1 deletion who exhibit clinical
signs of otosclerosis. The two non-penetrant cases of Family 2081 were removed from analysis.
Source
Air Conduction
250 Hz
(Constant)

B

Worse Ear
SE B
β

t

p

R2

.828
29.273

.155
7.155

.809

5.338
4.091

.000
.001

.655

500 Hz
(Constant)

1.003
31.174

.178
8.198

.825

5.647
3.803

.000
.002

.680

1000 Hz
(Constant)

1.100
25.555

.241
11.133

.762

4.559
.295

.000
.037

.581

2000 Hz
(Constant)

1.273
9.591

.273
12.590

.770

4.668
.762

.000
.458

.592

4000 Hz
(Constant)

1.248
13.611

.212
9.772

.836

5.896
1.393

.000
.184

.699

8000 Hz
(Constant)

1.160
17.683

.252
11.645

.765

4.598
1.519

.000
.150

.585

.724
-5.813

.214
10.513

.713

3.377
-.553

.006
.591

.509

1000 Hz
(Constant)

.485
6.526

.193
9.453

.604

2.517
.690

.029
.504

.365

2000 Hz
(Constant)

1.044
-14.123

.203
9.941

.841

5.150
-1.421

.000
.183

.707

4000 Hz
(Constant)

.583
.181

.269
13.183

.547

2.169
.014

.053
.989

.299

Bone Conduction
500 Hz
(Constant)
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Figure 24. Predicted audiogram generated from linear regression results for the worse ear of FOXL1 deletion carriers for three ages:
20, 40 and 60 years old.

129

5.3.2

Non-Surgical Case Studies
Within Family 2081, there have currently been two FOXL1 mutation carriers (individual

A005, A006) recruited with no evidence of the clinical features of otosclerosis. These clinical
features would include evidence of a conductive hearing loss, or evidence of cochlear
otosclerosis. The only exceptions to this would be the absence of acoustic reflexes using a high
frequency probe tone in both cases, the presence of a high-frequency SNHL in individual A005,
and the abnormal PA measurement in individual A006. A summary of the advanced phenotyping
in these two non-surgical cases is reported.
Individual A005
Audiometric thresholds for A005 reveal a mild high-frequency sensorineural hearing loss
at 3 and 4 kHz at the age of 26.7 years in his left ear (Figure 25). Over the next two and a half
decades, the hearing loss in the high frequencies increases gradually, progressing to a moderate
high-frequency sensorineural hearing loss between 2000 - 4000 Hz, rising back to normal
hearing above 4000 Hz. Hearing thresholds in A005’s right ear also demonstrates a sensorineural
hearing loss notch around 4 kHz which is present by the age of 52.3 years. The advanced
phenotypic procedure was conducted at the age of 52.8 years and is presented in Figures 26 and
27.
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Figure 25. Audiometric thresholds obtained for family member A005. Conventional audiometric
symbols are used where x = left air conduction, o=right air conduction, <=right unmasked bone
conduction, and >=left unmasked bone conduction.
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A005 had measurable reflexes in the left ear (Figure 26). An elevated reflex was
identified at 4000 Hz, with absent contralateral reflexes at 500 and 4000 Hz in the left ear.
However, in A005’s right ear, acoustic reflexes were elevated in the low frequencies, and absent
at 4000 Hz and using a wideband noise in the right (Figure 27). There were also no measurable
contralateral reflexes with the probe in the right ear. Distortion product otoacoustic emissions
were recorded at twelve frequencies spanning 2F1-F2 frequencies of 700 to 5300 Hz. In A005’s
left ear, all DPOAEs were considered absent with the exception of distortion products at
frequencies of 1031 and 4641 Hz (Figure 27). DPOAEs are mainly present in the right ear, with
the exception of 2F1-F2 frequencies of 703 and 5297 Hz (Figure 27). Power absorbance for
individual A005 falls within 1 standard deviation of the norm for frequencies up to
approximately 1800 Hz, where PA in both the left (Figure 26) and right (Figure 27) ear fall just
outside of 1 standard deviation of the normative range.
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Figure 26. Phenotypic results for left ear of individual A005. Results show most recent
audiogram, acoustic reflex thresholds (ARTs), standard tympanometry, distortion product
otoacoustic emissions (DPOAEs) and power absorbance (PA). DPOAEs meeting criteria to be
considered present are denoted by an asterisks (*).
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Figure 27. Phenotypic results for right ear of individual A005. Results show most recent
audiogram, acoustic reflex thresholds (ARTs), standard tympanometry, distortion product
otoacoustic emissions (DPOAEs) and power absorbance (PA). DPOAEs meeting criteria to be
considered present are denoted by an asterisks (*).
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Overall, the phenotype of A005 suggests a possible case of non-penetrance, given that he
was 53.8 years of age at the time of recruitment. The case of non-penetrance is difficult to
determine given there are some findings indicating possible onset of otosclerosis. Audiometric
thresholds, while consistent with industrial workplace noise exposure, could be a result of
cochlear otosclerosis. Distortion product otoacoustic emissions were mostly absent in the left ear.
Acoustic reflexes were absent in or elevated in the better right ear, and present in the worse ear.
Finally, PA in both ears would be classified as normal since the PA profile does replicate those
presented in Chapter 4.
Individual A006
Audiometric thresholds for A006 were retrospectively collected from a previous hearing
test conducted at age 27.9 years, along with two audiometric tests collected as part of the hearing
research study; ages 30.5 and 34.1 years of age (Figure 28). All three tests reveal AC thresholds
below 15 dB HL at all frequencies tested suggestive of normal hearing thresholds. Bone
conduction thresholds were only tested at the earliest test date which revealed no air-bone gaps
greater than 5 dB. These results suggest no sensorineural or conductive hearing loss present. The
results also support that over the 8 years between the first and last test, there is no progression in
hearing loss as thresholds obtained at the age of 34.1 years of age were obtained at 5dB HL and
below at all audiometric frequencies tested. The advanced phenotyping procedures were
conducted at the age of 34.1 years.
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Figure 28. Audiometric thresholds obtained for family member A006. Conventional audiometric
symbols are used where x = left air conduction, o=right air conduction, <=right unmasked bone
conduction, and >=left unmasked bone conduction.
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Acoustic reflexes were present in all conditions when the probe was situated in A006’s
left ear (Figure 29). In A006’s right ear, reflexes were present in all conditions except at 4000 Hz
with ipsilateral and contralateral stimulation (Figure 30). A006 has measurable DPOAEs in both
ears and at all frequencies, with the exception of the distortion product at 4641 Hz in their left
ear (Figure 29). Power absorbance measurements for individual A006’s right ear fall outside of 1
standard deviation of the normative data reported in Chapter 4 and is considered abnormal given
the absence of acoustic reflexes also in the right ear. PA in A006’s right ear also demonstrates
the unusual peak around 960 Hz (Figure 30).
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Figure 29. Phenotypic results for left ear of individual A006. Results show most recent
audiogram, acoustic reflex thresholds (ARTs), standard tympanometry, distortion product
otoacoustic emissions (DPOAEs) and power absorbance (PA). DPOAEs meeting criteria to be
considered present are denoted by an asterisks (*).
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Figure 30. Phenotypic results for right ear of individual A006. Results show most recent
audiogram, acoustic reflex thresholds (ARTs), standard tympanometry, distortion product
otoacoustic emissions (DPOAEs) and power absorbance (PA). DPOAEs meeting criteria to be
considered present are denoted by an asterisks (*).
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Overall, the phenotype of A006 also suggests a case of non-penetrance, however there
may be some clinical signs of potential otosclerosis. Individual A006 was in her fourth decade at
the time of testing, which is older than the age of onset reported by the seven affected FOXL1
carriers. Therefore, we would expect her to start showing clinical signs of otosclerosis. While her
audiometric thresholds are normal, the DPOAE in her left ear at 4641 Hz was absent. Her right
ear is considered more abnormal as acoustic reflexes were also absent at 4000 Hz in her right ear
and she demonstrated a PA peak around 950 Hz which fell well outside of 1 standard deviation
of the normative values while demonstrating compliance 0.5 mL. This PA profile has been
linked with otosclerosis previously by Niemczyk, Lachowska, Tataj, Kurczak, & Niemczyk
(2018) as well as presented in the results of the subgroup presented in Chapter 4. Given these
sub-clinical signs of absent high-frequency DPOAEs and abnormal PA profile, we expect that
individual A006 may demonstrate early stages of otosclerotic development. Longitudinal studies
of this individual would be required in order to confirm the development of otosclerosis.

5.3.3

Phenotypic Summary
Two FOXL1 mutation carriers do not exhibit any typical clinical features of otosclerosis

(conductive hearing loss or evidence of cochlear otosclerosis). Results of the advanced
phenotyping may suggest the presence of some sub-clinical evidence of later onset otosclerosis
development. Individual A005 presents with a SNHL, however, the clinical profile, as well as a
history of workplace noise, suggest the presence of noise-induced SNHL. The other non-surgical
case, Individual A006, has audiometric thresholds within the clinically defined normal range of
20 dB HL at all frequencies tested, however she demonstrates a PA peak previously seen in four
of our otosclerotic ears in Chapter 4.
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A summary of the surgical interventions and clinical phenotype for all FOXL1 deletion
carriers is presented in Table 15. The interventions for these family members are quite variable,
where two family members, 0005 and 0002 have undergone unilateral cochlear implants to
correct their hearing loss. Four family members (0000, 0005, 0004 and 0035) have undergone
surgical intervention to treat bilateral conductive components. Two family members (0002 and
0016) present with mixed loss in one ear, and sensorineural hearing loss in the other, with both
undergoing stapes surgery to correct the conductive hearing loss component of their hearing loss.
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Table 15. Phenotypic summary of all family members in Family 2081 heterozygous for the FOXL1 deletion.

Individual

Diagnosis
(affected ear)

Affected Family Members
0000
Otosclerosis

Age of
Onset
(decade)
Early 3rd
Late 2nd early 3rd

Hearing Status before
Surgical Intervention
Right Ear
Left Ear

Surgical Interventions
(age in years)
Right Ear

Left Ear

Conductive

Conductive

Stapedectomy (51)

Stapedectomy (52)

Mixed

Mixed

Stapedectomy (36)

Canaloplasty (71)
Middle Ear Implant
(75)
Cochlear implant
(76)
None

0005

Otosclerosis

0002

Otosclerosis
(possibly cochlear)

2nd

Mixed

Sensorineural

Stapedectomy (60)
Cochlear Implant (61)

0004

Otosclerosis

Early 3rd

Conductive

Conductive

Stapedectomy (47)

Stapedectomy (22)

0016

Otosclerosis (left)

Early 3rd

Sensorineural

Mixed

None

Stapedectomy (42)

0035

Otosclerosis

Early 3rd

No data

No data

Stapedectomy (27)

Stapedectomy (52)

A001

Otosclerosis (bilateral)
Cholesteatoma (right)

Mid 2nd

Conductive

Conductive

3rd

Normal

Sensorineural

None

None

NA

Normal

Normal

None

None

Non-Penetrant Cases
A005
Hearing Loss (left);
possibly noise-induced

A006

Normal Hearing

Tympanotomy with stapes
mobilization (17)
Mastoidectomy (17)
Tympanoplasty with
ossicular chain re-mobilization
(18)

None
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5.4 Discussion
The rationale of this chapter was to investigate the advanced phenotype of Family 2081
in order to better understand the natural course of FOXL1-associated otosclerosis and to
develop a model of the associated hearing loss. Eleven family members of this family were
recently identified as gene carriers for the otosclerosis causing mutation in FOXL1, nine of
which were available for recruitment to this study.

5.4.1

Phenotypic Variability
Phenotypic analysis of Family 2081 revealed that although the FOXL1 deletion is

causative of otosclerosis in all affected family members, considerable variability in the auditory
phenotype exists for this family. Different audiometric profiles including bilateral conductive
hearing losses, unilateral mixed hearing loss, sensorineural hearing loss, and hearing within
normal limits was found for all gene mutation carriers. These findings are consistent with other
family studies of otosclerosis in which affected family members present with a broad range of
hearing loss, including unilateral or bilateral conductive hearing losses, mixed hearing loss, or
sensorineural hearing loss (Brownstein et al., 2006).
The identification of genetic causes of otosclerosis has been a challenge for researchers,
with the first causative genes identified just recently. While family studies are powerful in the
identification of genetics causes of disorders, they require an accurate identification of affected
versus unaffected family members for gene discovery. Family 2081 is a good example of how
the clinical features of an otosclerotic family can vary even in a monogenic inheritance of the
disorder. Traditionally, the gold standard for diagnosis of otosclerosis is confirmation of stapes
fixation at the time of stapes surgery. In the case of Family 2081, seven family members have
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been diagnosed with otosclerosis following surgery (Abdelfatah, 2014). This large number of
family members who underwent stapes surgery allowed for the identification of the FOXL1
mutation.
In future genetic studies of families with heritable otosclerosis, the incorporation of
non-surgically confirmed cases using a more comprehensive battery of auditory phenotyping
measures may be feasible since large families are rare. Future hypotheses of “affected” versus
“unaffected” family members should also account for the presence of cases without clinical
presentations of otosclerosis. This chapter reports the phenotypic analysis of two family
members, A005 and A006, who would not receive a surgical or clinical diagnosis of
otosclerosis since A005 demonstrates a unilateral sensorineural hearing loss which is
hypothesized to be due to noise exposure, and A006 has hearing thresholds within normal
limits at the age of 34.
Previous genetic research of otosclerosis has estimated the penetrance of otosclerosis
between 40-90% (Brownstein et al., 2006; Morrison, 1967; Van Den Bogaert et al., 2001).
While the true penetrance of otosclerosis remains unknown, larger studies into the prevalence
of the FOXL1 mutation in the otosclerotic population will help determine the true value of
penetrance of otosclerosis due to the FOXL1 mutation. The case study of individual A006
provides evidence that although no diagnosis of otosclerosis would be given, there may be subclinical signs of otosclerosis present in gene carriers. Therefore, the use of advanced
phenotyping including the use of DPOAEs and PA should be incorporated in future genetic
studies of otosclerosis as a method to potentially identify family members with normal hearing
thresholds, but who may be early in disease progression.
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5.4.2

Predictive Model for FOXL1-Associated Otosclerosis Progression
While the natural history of FOXL1-associated otosclerosis is quite variable, it is still

worth developing a predictive model for the hearing loss as a starting point to understand the
progression of FOXL1-associated hearing loss. Individuals of Family 2081 who present with
clinical otosclerosis, report their hearing loss beginning around the 3rd decade. The FOXL1associated hearing loss is predicted to progress into a mixed hearing loss, with air-conduction
thresholds in the severe to profound range by the age of 60, with air-conduction thresholds
progressing between 9.6-15.2 dB/dec and bone-conduction thresholds progressing between 5.018.6 dB/dec in the worse ear. The results of our analysis are similar to the progression results
reported in another large otosclerotic family, where air-conduction thresholds were estimated to
deteriorate at a rate of 8.1-13.2 dB/dec and bone-conduction thresholds at a rate of 3.7-8.2
dB/dec (Declau et al., 2007). The results of the predictive model can be used by audiologists
and clinicians as a guide to counsel any future individuals identified with the FOXL1 mutation
about the anticipated progression of the conductive and sensorineural components of their
hearing loss. A similar approach is used to predict the course of autosomal dominant forms of
sensorineural hearing losses caused by different gene mutations and made available to
clinicians and researchers by Smith and colleagues through their AudioGene website
(Hildebrand et al., 2009). The evidence from this Newfoundland pedigree with FOXL1associated otosclerosis will support counselling for individual family members regarding the
progressive sensorineural component of this auditory phenotype, allowing them to prepare for
appropriate interventions which may include the use of amplification devices, or cochlear
implantation if the sensorineural loss deteriorates substantially.
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Prospective research is recommended, with comprehensive, longitudinal monitoring of
the behavioural and physiological phenotype using ARTs, DPOAEs and PA in conjunction
with audiometric thresholds and thorough medical history questionnaires, providing insight into
the course of this genetic disorders over the lifespan. A limitation of using linear regression
analysis for the purpose of modeling FOXL1-associated hearing loss in Family 2081 is the
analysis assumes that the hearing loss progresses in a linear fashion. Reports of the pathology
of otosclerosis however suggest that the disorder progresses in stages, which are characterized
by varying enzymatic and bone remodeling (Crompton et al., 2019; Rudic et al., 2015).
Therefore, as additional types of data are collected in individuals carrying the FOXL1 mutation,
a more accurate model can be developed taking into account the various stages of the disorder.

5.4.3

Non-Surgical Cases
Studies investigating the genetic cause of otosclerosis have long suggested there are

cases of non-penetrance in dominantly inherited otosclerosis. There are two individuals in the
presently studied family who may be non-penetrant cases of the inherited form of otosclerosis
in their family; individuals A005 and A006. In the case of Individual A005, there is the
appearance of what might be described as noise-induced hearing loss appearing around 4 kHz,
especially in the left ear. This high-frequency hearing loss appears to begin by the age of 26
years and continues to worsen by the age of 53 years. The use of high-resolution imaging might
offer some clarity as to whether this case of non-penetrant otosclerosis might be a case of
histological otosclerosis. There are some potential sub-clinical features of otosclerosis present
in the case of A005. There is no measurable acoustic reflex with the probe in the participant’s
right ear, and the stimulation of the left ear (described in this study as “right contralateral”).
A005 also has absent otoacoustic emissions, which can be a feature of otosclerosis, either in the
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sensorineural form of the disorder or in the conductive form of the disorder (see Chapter 3 of
this thesis). In Chapter 3, DPOAEs were absent in otosclerotic ears with sensorineural hearing
loss (n=3), or ears with a conductive hearing loss (n=14).
A006 is also a carrier of the deletion in FOXL1, but by the age of 34, does not exhibit
any audiometric signs of otosclerosis. Despite normal pure tones thresholds, acoustic reflexes
were absent with the probe in her left ear with the stimulus presented in her right (left contra) at
frequencies of 500 and 4000 Hz. Acoustic reflexes were also absent with the probe in her right
ear for 4000 Hz. Wideband acoustic immittance testing revealed a PA peak around 950 Hz, a
profile which is linked to otosclerosis by Niemczyk et al. (2018) as and results of this thesis as
discussed in Chapter 4.
Without confirming the presence or absence of otosclerotic foci affecting the otic
capsule in these non-surgical cases of otosclerosis, it is difficult to determine whether these are
cases of true non-penetrance. Temporal bone studies suggest that histological otosclerosis is
more common than clinical or cochlear otosclerosis (Crompton et al., 2019; Karosi et al., 2012;
Schuknecht & Barber, 1985). Therefore, using advanced phenotyping in future genetic studies
that is sensitive to detect otosclerotic foci in histological otosclerosis cases, may improve the
chance of identifying causative genes. This study supports this idea since presented in this
chapter are 2 family members, heterozygous for the FOXL1 deletion, yet who would not meet
the standard clinical criteria of diagnosis for otosclerosis.

5.4.4

Conclusion and Future Direction
This large Newfoundland family presents as the first otosclerotic family with a known

mutation causing their heritable form of otosclerosis. This chapter describes in detail the
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phenotype of the individuals in this family and provides a predictive model based on
audiometric thresholds of family members presenting with FOXL1-associated hearing loss.
There are three family members of great importance for prospective study recruitment
(Individuals; A001, 0016 and B007). These three individuals are carriers of the FOXL1 deletion
but were unavailable to participate in the study at the time of prospective data collection. Only
retrospective audiometric thresholds were available for 0002, 0016 and A001. All three of these
individuals have had unilateral stapes surgery. Audiometric thresholds for 0002 and 0016
revealed a sensorineural hearing loss in their non-surgical ear, while A001 presents with a
conductive hearing loss in their non-surgical ear. At present, there is no retrospective
audiometric thresholds available for B007. Focusing future recruiting efforts for these
individuals will provide additional data for the physiological phenotype measurements of WAI,
ARTs and DPOAEs in non-surgical FOXL1 confirmed ears. B007 also serves as the first
identified carrier of the deletion in the younger generation. Therefore, they would serve as an
excellent case study to determine the longitudinal changes in audiometric thresholds as well as
the longitudinal changes in non-audiometric phenotyping measures in FOXL1 carriers.
Future research focused on gene discovery of mutations causing otosclerosis should
therefore look to broaden their definition of otosclerosis. The identification of gene carriers
solely based on surgical confirmation of stapes fixation could result in additional difficulty in
identifying the causative genetic mutations for the disorder since there is significant phenotypic
variability in otosclerosis, and specifically within a family with otosclerosis caused by the same
genetic mutation.
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Chapter 6
Advanced Phenotyping of an Otosclerosis Family of
Unknown Genetic Etiology

6

6.1 Introduction
The purpose of this chapter is to apply advanced phenotyping methodology to a family
with suspected hereditary otosclerosis. Advanced auditory phenotyping, using a comprehensive
battery of audiometry, DPOAEs, ARTs and PA was analyzed in order to generate an auditory
phenotype profile for each family member. Hierarchical cluster analysis was used to develop a
phenotype segregation map of auditory features. These methods were used to develop a
phenotype segregation hypothesis for this multiplex family. Phenotypic segregation and the
accurate determination of affection status (affected versus unaffected) is essential in order to
determine the most likely mode of inheritance in order to successfully identify new otosclerosis
genes.
In the population cohort of surgically confirmed cases, otosclerosis presented as a
unilateral or bilateral hearing loss and as conductive, mixed or sensorineural hearing loss
(Chapter 3). Acoustic reflexes and DPOAEs were absent in cases of conductive or mixed
hearing losses, while DPOAEs were absent in cases with SNHL. Although there was
insufficient data regarding the presence of ARTs in SNHL cases of otosclerosis in the study
presented in Chapter 3, the literature suggests that ARTs could be present in cases with SNHL
of unknown etiology, up to approximately 60 dB HL (Gelfand, 1994). It is unclear, beyond the
report of Chapter 3, regarding the presence or absence of DPOAEs in cases of cochlear
otosclerosis.
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In Chapter 4, another phenotyping tool, WAI, showed that PA was lower in otosclerotic
ears compared to normal ears. However, individual PA data from otosclerotic ears suggests
ears can be quite variable (Chapter 4, Niemczyk et al., 2018). Chapter 4 presents otosclerotic
ears with a peak in the PA measurement between 800-1100 Hz, as well as a more typical PA
profile of reduced absorbance in low frequencies, as previously reported in the literature (Keefe
et al., 2017; Shahnaz, Bork, et al., 2009). This variability could reflect various stages of
otosclerotic progression, as well as differences in the size and location of sclerotic foci in the
otic capsule, for example around the stapes footplate as opposed to the cochlea. One factor for
the presence of the peak, is the reported increase in PA around 1000 Hz correlated with ears
demonstrating a high compliance value of greater than 1.75 mL (Feeney et al., 2014).
Therefore, the presence of the PA peak will be considered as a potential indicator for
otosclerosis provided the individual presents with compliance values of less than 1.75 mL.

6.1.1

Aims of this Study
The aims of this study are to conduct a phenotypic analysis of members of Family 2143

using clinically available tools. More specifically, the aims are:
Specific aim 1: Collect advanced phenotyping and family history data on a
multiplex family (Family 2143) and develop a pedigree with segregation of family
members as affected, unaffected and possibly affected for otosclerosis.
Specific aim 2: Analyze auditory phenotype segregation on Family 2143 using
hierarchical cluster analysis.
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6.2 Methods
The test battery for participants in the previous studies consisted of audiometry,
tympanometry, DPOAEs, ARTs and PA measurements. The testing protocol for this study in
this chapter is a modified version based on the outcomes of the study presented in Chapter 4
and is described below.

6.2.1

Family 2143
A second multiplex family (2143) with suspected hereditary otosclerosis was identified

in NL (Figure 31). Twelve members spanning three generations, affected with various hearing
status, were recruited to this study (MUN Research Ethics Board #01.186). Their ages range
from 19 to 82 years at the time of testing and represent one individual from generation II, five
individuals from generation III and six individuals from generation IV (Figure 31). The family
pedigree was generated based on family history and audiometric thresholds obtained
retrospectively and/or prospectively. Genetic screening of recruited family members for the
FOXL1 deletion was conducted in the lab of Dr. Terry-Lynn Young at Memorial University
which confirmed that family members of Family 2143 are not carriers of the FOXL1 mutation
described in the previous two chapters.
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Figure 31. Family 2143 with suspected hereditary otosclerosis from NL. Pedigree based on audiometric thresholds and surgical
confirmation of otosclerosis.
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6.2.2

Advanced Phenotyping Protocol
The same advanced phenotyping protocol was used in this chapter as reported in Chapter

5. The advanced phenotyping protocol included the use of audiometry, tympanometry, acoustic
reflex thresholds, DPOAEs and WAI, specifically PA. The rationale for determine normal versus
abnormal PA is also reported in Chapters 4 (Study 2) and Chapter 5.

6.2.3

Statistical Analyses
A hierarchical cluster analysis using data from 11 members of Family 2143 with the

software R v.3.3.3 using the clustering of mixed variables (Szepannek, 2019). The hierarchical
cluster analysis and dendrogram was conducted with the assistance of Shailendra Singh, research
assistant at the University of Western Ontario, who developed appropriate R code. In order to
assess the fit of the individual data into the final clusters, a Silhouette width approach was
conducted as a method of validation of the final clusters (Lengyel & Botta-Dukát, 2019;
Rousseeuw, 1987). The silhouette width was calculated based on Euchlidean distance for each
cluster, where values of silhouette width will range from -1 to +1. A value closer to +1 idicates
euchlidean distance is closest to that of its own cluster compared to another cluster, while a value
closer to -1 indicates that the Euchlidean distance is more similar to that of a different cluster. It
is therefore suggested that a positive silhouette width is indicative of a good clustering result
(Lengyel & Botta-Dukát, 2019). Subject 1000, the proband, was removed from the analysis due
to bilateral stapes surgery. Cluster analysis was carried out to determine whether the clinical
features of family members cluster into distinct groups. Air-conduction thresholds, boneconduction thresholds, acoustic reflex thresholds, DPOAE amplitudes and associated SNRs were
used for analysis. Data was extracted at frequencies of 500, 1000, 2000 and 4000 Hz for all
measurements except DPOAE amplitudes and SNR at 500 Hz (data not elicited). Prior to
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analysis, ART, DP amplitudes and SNR data were normalized by subtracting the minimum value
of each measurement and dividing by the range of the data, allowing for a better visualization on
the phenotypic heatmap. A hierarchical dendrogram, representing the phenotypic heatmap, was
then created demonstrating Euclidean distances of individual ears based on their phenotype
features. A dendrogram was created based on the clustering analysis. The height of the vertical
bars, or leaves, of the dendrogram represents how similar or dissimilar each individual ear in the
cluster is from one another.
For the statistical analysis, a cutoff of three clusters was used for the repeated measures
ANOVA to determine whether specific auditory phenotype features were significantly different
between each cluster. The raw data was used to conduct three repeated measures ANOVA to test
for differences in clinical measures between clusters. The first repeated measures ANOVA was
conducted for air and bone conduction thresholds where Frequency (4 levels) and measurement
(2 levels) were used as within-subject factors, while cluster group (3 levels) was used as between
subject factor. The second repeated measures ANOVA was conducted for ipsilateral and
contralateral acoustic reflex thresholds where Frequency (4 levels) and measurement (2 levels)
were used as within-subject factures, while cluster group (3 levels) was used as a betweensubjects factor. Finally, the third repeated measures ANOVA was conducted for DPOAE
amplitude and SNR, where Frequency (3 levels) and measurement (2 levels) were used as
within-subject factors, while cluster group (3 levels) was used as a between-subject factor. When
appropriate, post-hoc analysis was conducted by completing a pairwise comparison following
Bonferroni correction.
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6.2.4

Individual Phenotyping and Genotyping Hypothesis
The rationale for determining whether the family member is considered affected, possibly

affected, or unaffected was based on the criteria shown in Table 16 and Figure 32. If a family
member presented with a hearing loss, then they were considered affected. As reported in this
thesis and by others, otosclerosis can present as conductive, mixed, or SNHL. Therefore, we
categorized all members with conductive, mixed, or SNHL as affected. Family members with
normal hearing thresholds and age-appropriate sub-clinical features were considered unaffected
(Figure 32). DPOAE amplitudes have been reported to decrease with age (Uchida et al., 2008),
and therefore, absence of DPOAEs in the highest frequencies in family members above the age
of 50 years were considered part of the normal aging process. Finally, a family member with
normal hearing and sub-clinical feature(s), either absent ARTs, absent DPOAEs or an altered PA
profile, was classified as possibly affected, based on our assumption that sub-clinical features
may be associated with otosclerosis.
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Table 16. Criteria for the classification of hearing status of family members based on bone
conduction (BC) thresholds, air-conduction (AC) thresholds and air-bone gaps (ABG).
Hearing Classification
Mixed Hearing Loss

BC Thresholds
> 20 dB HL at 2 or
more frequencies

AC Thresholds
> 20 dB HL at 2
or more
frequencies

ABG
> 10 dB at 2 or
more frequencies

High-Frequency
> 20 dB HL at 2 or
Sensorineural Hearing more frequencies at or
Loss
above 4000 Hz

> 20 dB HL at 2
or more
frequencies at or
above 4000 Hz

 10 dB at all
frequencies

> 20 dB HL at 2 or
Mid-Frequency
more frequencies
Sensorineural Hearing
between 1000 and 4000
Loss
Hz

> 20 dB HL at 2
or more
frequencies
between 1000 and
4000 Hz

 10 dB at all
frequencies

Low-Frequency
>20 dB HL at 2 or more
Sensorineural Hearing frequencies at or below
Loss
1000 Hz

>20 dB HL at 2 or
more frequencies
at or below 1000
Hz.

 10 dB at all
frequencies

 20 dB HL at all
frequencies

 10 dB at all
frequencies

Clinically Unaffected

 20 dB HL at all
frequencies

These sub-clinical signs include elevated (above 95 dB HL) or absent acoustic reflex
thresholds, absent otoacoustic emissions, reduced (below 0.3 mL) or elevated (above 1.4 mL)
static immittance, or compliance, measured via conventional 226 Hz tympanometry and
abnormal PA profile (as reported in Chapters 4 and 5).
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Figure 32. Decision tree for determining affection status of family members.

6.3 Results
6.3.1

Hierarchical Cluster Analysis
Results of the hierarchical cluster analysis reveal three distinct clusters (Figure 33).

Cluster 1 is comprised of cases with mixed hearing loss, consisting of both ears from individuals
0000 and 0009. Cluster 2 is comprised of all ears showing a SNHL, with both ears from
individuals 0002, 0003, 0004, and A011. Cluster 3 is comprised of all ears with family members
who audiometrically have thresholds within normal limits. This third cluster consists of both ears
of family members 0008, A000, A001, A002 and A006. Sihouette widths of Cluster 1, 2 and 3
generated values of 1, 0.314, and 0.0297 respectively, validating the clustering results. An
overall Sihouette score of 0.413 was calculated across all Clusters, further validating the stabile
configuration of clusters showing good intra-cluster cohesion and inter-cluster separation of data
points.
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Figure 33. Hierarchical dendrogram and phenotypic heatmap of auditory phenotype features for
members of Family 2143.
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Three repeated measures ANOVAs were performed to identify the measurements and
frequencies significantly different between clusters. The first repeated measures ANOVA
comparing differences in air and bone conduction thresholds was carried out using measurement
(2 levels), frequency (4 levels) as within-subject factors and cluster group (3 levels) as betweensubject factors. Mauchly’s Test of Sphericity indicated the assumption of sphericity was violated
for the within-subject factor of frequency 2(5) = 32.867, p < .001 and for the
frequency*measurement interaction 2(5) = 12.016, p = 0.035. Therefore, a Greenhouse-Geisser
correction was carried out for this factor. There was a significant effect of measurement [F(1, 19)
= 36.310, p < .001], as well as the interactions of measurement*cluster [F(2,19) = 8.301, p =
.003], measurement*frequency [F(2.283,43.371 = 9.544, p < .001], and
measurement*frequency*cluster [F(4.565,43.371) =5.252, p = .001]. Post-hoc analysis was
conducted using Bonferroni correction to determine the pairwise comparison of each
measurement at each frequency for each cluster. Results of the pairwise comparison (Table 17)
suggest a significant difference in air and bone conduction thresholds between all three clusters
at all four frequencies (p < .05). The second repeated measures ANOVA comparing differences
in ipsilateral and contralateral acoustic reflexes was carried out using measurement (2 levels),
frequency (4 levels) as within-subject factors and cluster group (3 levels) as between-subject
factors. Mauchly’s Test of Sphericity indicated the assumption of sphericity was not violated for
the within-subject factor of frequency (p = .177) or measurement*frequency (p = .443. There
was a significant effect of measurement [F(1, 19) = 10.565, p = .004], frequency [F(3, 57) =
3.719, p = .016], as well as the interaction of frequency*cluster [F(6,57) = 4.495, p = .001]. Posthoc analysis was conducted using Bonferroni correction to determine the pairwise comparison of
each frequency for each cluster. Results of the pairwise comparison (Table 17) suggest a
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significant difference in acoustic reflex thresholds between Cluster 1 and Cluster 2 at frequencies
of 500, 1000 and 2000 Hz (p < .05), a significant difference in ARTs between Cluster 1 and
Cluster 3 at all frequencies (p < .05), and a significant difference in ARTs between Cluster 2 and
Cluster 3 at 4000 Hz (p = .016). The final repeated measures ANOVA comparing differences in
DPOAE amplitude and SNRs was carried out using measurement (2 levels), frequency (3 levels)
as within-subject factors and cluster (3 levels) as between-subject factors. Mauchly’s Test of
Sphericity indicated the assumption of sphericity was violated for the within-subject factor of
frequency 2(2) = 6.722, p = .035 and therefore, a Greenhouse-Geisser correction was carried out
for this factor. There was a significant effect of measurement [F(1, 19) = 323.897, p < .001], as
well as the interactions of measurement*frequency [F(1.942,36.907) = 47.605, p < .001],
measurement*frequency*cluster [F(3.885,36.907 = 3.330, p = .021]. Post-hoc analysis was
conducted using Bonferroni correction to determine the pairwise comparison of each frequency
for each cluster. Results of the pairwise comparison (Table 17) suggest a significant difference in
DPOAE amplitude and SNR between Cluster 1 and Cluster 3 at frequencies of 1000 and 2000
Hz (p < .05) and a significant difference in DPOAE amplitude and SNR between Cluster 2 and
Cluster 3 at 4000 Hz (p < .05).
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Table 17. Pairwise comparison of auditory phenotype features in Family 2143 following Bonferroni correction for 3 repeated
measures ANOVA for six measurements at four frequencies between the three distinct clusters. Significant differences are highlighted
in bold.

Pairwise Comparison
Measurement
AC

BC

ARTs

DP

SNR

Frequency
(Hz)
500
1000
2000
4000
500
1000
2000
4000
500
1000
2000
4000
1000
2000
4000
1000
2000
4000

Cluster 1 - 2
Mean
Std
Sig.
Diff
Error
44.375
2.695
.000
36.875
5.878
.000
24.375
4.753
.000
30.625
8.488
.006
23.125
3.991
.000
17.500
5.167
.009
15.000
5.162
.027
23.125
7.829
.024
29.056
5.876
.000
27.500
4.448
.000
24.688
5.416
.001
8.125
6.604
.701
-1.226
4.289 1.000
-8.815
4.410
.180
-12.651 7.399
.311
-1.273
4.319 1.000
-6.241
3.413
.250
-5.271
4.978
.909

Cluster 1 - 3
Mean
Std
Diff
Error
62.750 2.604
59.250 5.679
53.000 4.591
58.250 8.201
48.000 3.855
46.500 4.991
50.000 4.987
47.250 7.564
25.00
5.676
26.500 4.297
26.00
5.232
24.250 6.380
-10.362 4.144
-14.525 4.261
-28.107 7.148
-8.868
4.172
-13.072 3.297
-16.389 4.810

Sig.
.000
.000
.000
.000
.000
.000
.000
.000
.001
.000
.000
.004
.065
.009
.003
.141
.002
.009

Cluster 2 - 3
Mean
Std
Diff
Error
18.375
2.088
22.375
4.553
28.625
3.681
27.625
6.575
24.875
3.091
29.000
4.002
35.000
3.998
24.125
6.064
-4.063
4.551
-1.00
3.446
1.312
4.195
16.125
5.116
-9.136
3.322
-5.708
3.416
-15.456 5.731
-7.595
3.345
-6.831
2.644
-11.118 3.856

Sig.
.000
.000
.000
.001
.000
.000
.000
.002
1.00
1.00
1.00
.016
.038
.333
.043
.105
.055
.029
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6.3.2

Phenotypic Segregation
A summary of the phenotype segregation of family members based on criteria in Figure

32 is reported in Table 18. The results of the hierarchical cluster analysis are also shown in the
far-right column of Table 18.
Seven family members were identified as affected based on the clinical definition of
audiometric hearing loss; three with mixed hearing loss and four with SNHL. Hierarchical
cluster analysis of these 7 family members revealed three distinct sub-phenotypes, Clusters 1, 2
and 3 based on the combined hearing threshold and physiological measures of the auditory
phenotype. This subdivision of the 7 affected family members into Clusters 1 and 2, is based on
significantly different patterns of threshold loss and acoustic reflexes (see Table 17) and
correlates with the clinical categories of mixed versus sensorineural hearing loss. Five family
members had normal pure-tone hearing thresholds with no significant conductive component and
were identified by the hierarchical analyses as a single cluster - Cluster 3. By applying the
additional criteria shown in Figure 32 to these five family members. three were designated as
affected (A000, A001, and A006) and two unaffected (0008 and A002). A detailed breakdown
of all data for each individual in Family 2143 are reported in the appendices (Appendices F-CC).
A summary of the phenotypic breakdown for all family members is reported in Table 18.
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Table 18. Phenotypic summary and associated cluster of Family 2143 members including diagnosis of otosclerosis via surgical
confirmation (*). Family members subcategorized into their segregated phenotype category of affected, possibly affected and
unaffected, based on phenotypic presentation. RE = right ear; LE = left ear; MFSNHL = mid-frequency sensorineural hearing loss;
HFSNHL = high-frequency sensorineural hearing loss; LFSNHL = low-frequency sensorineural hearing loss; HF = high-frequencies.
Individual

Onset

Age

Standard Phenotyping
Hearing thresholds
ARTs

(decade)
RE
Affected Family Members
1000*
3rd
82
Mixed
0000
3rd
54
Mixed
0009*
3rd
55
Mixed
0004
6th
57
MFSNHL
0002
6th
58
HFSNHL
0003
6th
57
HFSNHL
A011
3rd
25
LFSNHL
Possibly Affected Family Members
A000
26
Normal
A001
19
Normal
A006
32
Normal
Unaffected Family Members
0008
54
Normal
A002
20
Normal

Advanced Phenotyping
DPOAEs

Cluster
PA

LE

RE

LE

RE

LE

RE

LE

Mixed
Mixed
Mixed
MFSNHL
HFSNHL
HFSNHL
LFSNHL

Absent
Absent
Absent
Present
Present
Present
Present

Absent
Absent
Absent
Present
Present
Present
Present

DNT
Absent
Absent
Absent
Absent
Absent
Present

DNT
Absent
Absent
Absent
Absent
Absent
Present

DNT
Abnormal
Abnormal
Normal
Normal
Normal
Abnormal

DNT
Abnormal
Abnormal
Abnormal
Normal
Normal
Abnormal

N/A
1
1
2
2
2
2

Normal
Normal
Normal

Present
Present
Present

Absent
Present
Present

Present
Absent in HF
Absent in HF

Present
Absent in HF
Absent

Abnormal
Normal
Abnormal

Abnormal
Normal
Abnormal

3
3
3

Normal
Normal

Present
Present

Present
Present

Present
Present

Present
Present

Normal
Normal

Normal
Normal

3
3
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6.3.2.1

Mixed hearing loss

Three members of Family 2143, IDs 1000, 0000 and 0009 were diagnosed with mixed
hearing loss (Figure 34). Hierarchical cluster analyses also grouped these individuals into Cluster
1, although ID 1000 was not included in the cluster analysis. The proband (ID 1000) had stapes
surgery reportedly around the age of 50, and no pre-operative hearing tests were available for
this study. The proband’s offspring, 0000 and 0009, also with bilateral mixed hearing loss, with
self-reported onset in their 3rd or 4th decade, and both siblings describe the development of their
hearing losses as progressive. Individual 0009 was confirmed to have otosclerosis during
corrective stapes surgery of her left ear following the most recent audiogram.

Figure 34. Pre-operative audiograms for individuals in Family 2143 presenting with mixed
hearing loss.

6.3.2.2

SNHL

The second audiometric profile, SNHL, is present in four family members, also offspring
of the proband ID1000 (Figure 35). Two (IDs 0002, 0003) present with a high-frequency SNHL
(HFSNHL), one (ID 0004) with a mid-frequency SNHL (MFSNHL), and one (ID A011)
presents with a borderline low-frequency SNHL (LFSNHL). These 4 individuals were identified
statistically as Cluster 2.
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Figure 35. Audiograms for individuals in Family 2143 presenting with SNHL.

6.3.2.3

Normal Hearing

In total, five family members had measurable audiometric thresholds within the normal
range (IDs A000, A001, A002, A006 and 0008) and were grouped into Cluster 3. Individuals
A000, A001, A002 and A006 were all between the ages of 19-33 at the time of testing. Given the
reported later onset of hearing loss in this family, between the 3rd and 6th decade of affected
individuals, these four individuals may be at risk of developing the familial hearing loss.
Individual 0008 however had measurable thresholds within the normal range at the age of 54.6
years. All of Individual 0008’s affected siblings had measurable hearing loss by the 6th decade,
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meaning that Individual 0008 is considered unaffected since it is hypothesized that the heritable
hearing loss would have developed by this age. Results of the physiologic phenotypic analysis
suggest that individual A002 and individual 0008 do not exhibit any sub-clinical features of early
onset of hearing loss. Their audiometric thresholds are reported in Figure 36.

Figure 36. Audiograms for individuals in Family 2143 presenting with normal hearing and who
do not exhibit any sub-clinical features of early disease progression.
Physiological phenotypic analysis suggests that Individuals A000, A001 and A006 all
present with sub-clinical features of heritable hearing loss. They present with either absent
ARTs, absent DPOAEs or abnormal PA (Table 18). Therefore, we considered these individuals
to be possibly affected, as these physiological measures may represent early signs of either
conductive otosclerosis or cochlear otosclerosis.
Individual A000 presents with normal hearing thresholds, but absent ARTs with the
probe in their left ear and demonstrate a PA profile similar to otosclerotic ears where the PA in
the low-frequencies is below 1 SD of the normative mean (Figure 37).
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Figure 37. Audiometric thresholds for individual A000 along with sub-clinical features
hypothesized of indicating early stages of disease progression. Sub-clinical features include
absent acoustic reflex thresholds in left ear, and PA outside of 1 SD from normative mean below
1000 Hz demonstrating a low-absorbance profile in the low frequencies.
Phenotypic analysis of individual A001 suggests normal hearing thresholds, but subclinical feature of absent DPOAEs in the higher frequencies in her left ear (Figure 38).
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Figure 38. Audiometric thresholds for individual A001 along with sub-clinical features
indicating early stages of disease progression. Sub-clinical feature includes absent DPOAEs in
the high-frequencies (upper right) and poor DP SNR (lower right).
Finally, phenotypic analysis of individual A006 revealed normal hearing thresholds, yet
she presented with low or absent DPOAEs across the frequency range in both ears. The PA
profile had a peak at approximately 1000 Hz outside 1 SD of the normative mean (Figure 39).
This peak is similar to that reported in the otosclerosis sub-group in Chapter 4.
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Figure 39. Audiometric thresholds for individual A006 along with sub-clinical features
hypothesized to indicate early stages of disease progression. Sub-clinical features include absent
DPOAEs in both ears, and PA above 1 SD of the normative mean near 1000 Hz, demonstrating a
PA peak profile.

6.3.3

Phenotyping Summary and Pedigree Analysis
Twelve family members for Family 2143 were categorized as either affected, possibly

affected or unaffected based on their audiometric and advanced phenotyping results. Seven
family members (IDs 1000, 0000, 0009, 0002, 0003, 0004 and A011) were all considered
“affected” as each of them presented with hearing loss. Three family members (IDs A000, A001
and A006) were all considered as “possibly affected” based on the presence of advance
phenotyping measures which may suggest the presence of early otosclerosis development.
Finally, members A002 and 0008 were categorized as “unaffected”. These family members do
not have hearing loss or any signs of early otosclerotic development. These categorizations were
used to help determine the inheritance pattern of otosclerosis in Family 2143.
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The revised pedigree presented in Figure 40 (see initial pedigree in Figure 31 for
comparison) includes additional auditory phenotyping characteristics. Pedigree analysis
suggests an autosomal dominant transmission and variable types of hearing loss consistent
with otosclerosis. There are two individuals diagnosed with surgically confirmed otosclerosis,
the proband, ID 1000 and her daughter ID 0009.
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Figure 40. Five generation NL family (Family 2143) segregating an apparent autosomal dominant otosclerosis with variable
expression. Pedigree includes phenotypic segregation of sub-clinical features of otosclerosis.
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6.4 Discussion
6.4.1

Phenotypic Variability of Family 2143
Phenotypic analysis of Family 2143 revealed three distinct phenotypes, representing

mixed hearing loss, sensorineural hearing loss and normal hearing individuals. There were
three cases with mixed hearing loss (ID: 1000, 0000 and 0009). All three of these cases were
considered affected based on their audiometric thresholds. The eldest of the family members,
individual 1000, has previously undergone stapes surgery around the age of 50 years old. Due
to the length of time since the stapes surgeries, there were no retrospective hearing tests
available for the study. The proband’s two children, IDs 0000 and 0009 also present with
bilateral mixed hearing loss. The age of onset for their hearing losses were in their 3rd or 4th
decade, whereby both siblings describe the progression of their hearing losses as progressive.
At the age of 28, individual 0000 was diagnosed with noise-induced hearing loss represented
by a 4 kHz noise-notch in his left ear. The audiometric thresholds obtained at that time also
revealed a significant air-bone gap representing a conductive hearing loss in his right ear.
Individual 0000 demonstrated a slightly lower progression in bone conduction thresholds,
representing the sensorineural component to his hearing loss, whereby his hearing loss
progressed between 10 to 16 dB loss per decade. The octave frequency of 500 Hz had the
lowest sensorineural progression, with 2000 Hz exhibiting the highest rate of hearing loss
progression. This suggests that the sensorineural hearing loss component to his hearing loss
progressed at a slower rate in the low frequencies.
Individual 0009 reports obtaining a diagnosis of Meniere’s disease from an
otolaryngologist several decades prior to the study due to reported vertigo accompanied by
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hearing loss. She was recently diagnosed with otosclerosis and underwent successful stapes
surgery on her left ear confirming the presence of otosclerosis. Mixed hearing loss has been
associated with simultaneous stapes fixation and cochlear otosclerosis (Uppal et al., 2009). The
clinical profile of individuals 0000 and 0009 may involve otosclerotic foci attenuating stapes
mobility and causing the conductive hearing loss, while also invading the cochlea resulting in
cochlear otosclerosis.
In the second audiometric profile, SNHL is present in three family members (0002,
0003 and 0004). These three siblings were also considered affected based on their audiometric
thresholds. These siblings all had their hearing loss identified by an audiologist in their 6th
decade. Typically, the SNHL associated with cochlear otosclerosis occurs once the foci invade
the cochlear endosteum causing atrophy of the spiral ligament and a reduction of endocochlear
potential as well as cochlear hair cell damage. (Cureoglu et al., 2010). The SNHL typically
presents as a high-frequency SNHL as is the case with individuals 0002 and 0003, however the
presence of a mid-frequency sensorineural hearing loss, like that present in individual 0004, has
also been reported in otosclerosis. (de Souza & Glasscock, III, 2004).
There were five family members who had audiometric thresholds within the normal
limits. Given the later onset of otosclerosis, these normal hearing individuals are a challenge to
categorize, since four of them are relatively young (oldest is 32 years old).
Individual 0008 is considered unaffected since he is 54 years of age, has normal hearing
thresholds, and does not exhibit any other signs of otosclerosis. Individual A002 is also
classified as unaffected. He was 20 years old at the time of assessment and had no other
phenotype features with the exception of absent DPOAEs at 4000 Hz. He also has absent ARTs
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at 4000 Hz but ARTs at this stimulus frequency are often absent in normal hearing subjects
(Jerger, Jerger, & Mauldin, 1972). Longitudinal measures are needed to confirm the
designation of unaffected for this family member.
The remaining family members (A000, A001 and A006) with normal hearing
thresholds were categorized as possibly affected due to the presence of sub-clinical signs of
potential otosclerosis. Individual A000 may be demonstrating sub-clinical features of
otosclerosis in the left ear, with absent ARTs and DPOAEs. Furthermore, PA in both ears of
A000 is below 1 standard deviation from the mean in the low frequencies and follows a similar
PA peak as described otosclerotic subgroup presented in Chapter 4.
Individual A001 is also characterized as possibly affected due to the absence of
DPOAEs in the higher frequencies. The absence of DPOAEs in these frequencies may indicate
cochlear damage and/or possible changes to the middle ear mechanics (Gorga et al., 1997;
Lonsbury-Martin & Martin, 1990; Zhao, Wada, Koike, & Stephens, 2000). Individual A006 is
also considered possibly affected due to DPOAEs in the high frequencies in the right ear and
also absent across all frequencies in the left ear. PA from Individual A006’s left ear
demonstrates a similar profile to the PA peak around 1000 Hz which is present in several
otosclerotic ears from Chapter 4, and consistent with left PA profile of individual 0009, a
surgically confirmed case of otosclerosis in this family. In a gene hunt scenario, possibly
affected individuals are categorized as “unknown’ and left out of the initial genetic analysis.
Based on these results, evidence from previous chapters, and other reports in the
literature (Chapter 3, Chapter 4, Brownstein et al., 2006; Declau et al., 2007; Pauw et al., 2006;
Weegerink et al., 2011), a broad range of phenotypes, including those with normal hearing
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thresholds, must be considered as potentially affected and be studied using advanced
phenotyping measures. Since otosclerosis can present as conductive hearing loss, SNHL, mixed
hearing loss, or normal hearing (non-penetrant cases), advanced phenotyping for the purpose of
gene discovery will benefit the phenotyping segregation process if it increases the number of
identified affected individuals in a family and it if confirms those who are definitely unaffected.
If it can do both, the power of gene discovery will improve, and could mean the difference
between finding the gene or not. This point is illustrated by comparing the pedigrees in Figures
31 and 40. The pedigree reported in Figure 31 uses standard pure tone audiometry and surgical
confirmation to classify family members as affected. This method of phenotypic segregation is
consistent with previous literature reporting on other large families (Brownstein et al., 2006;
Chen et al., 2002; Thys, Van Den Bogaert, et al., 2007; Tomek et al., 1998; Van Den Bogaert et
al., 2001). By incorporating physiological phenotyping at multiple frequencies using a
combination of AR, DPOAEs and PA and combining this data with pure tone audiometry, the
phenotypic segregation added 3 members of Family 2143 in generation IV into the possibly
affected phenotype category, enhancing the revised pedigree in Figure 40. Although these three
individuals demonstrate normal hearing thresholds, each one exhibits sub-clinical features
based on the physiological findings. Additional longitudinal measures and high-resolution CT
could be used to confirm whether these subtle physiological phenotype measures are consistent
with the early development of otosclerosis.

6.4.2

Value of Advanced Phenotyping Measurements

6.4.2.1

DPOAEs

Sound-evoked DPOAEs depend on the transmission of two tones through the outer and
middle ear which evoke cochlear outer hair cell activity, which is then transmitted backward
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via the same route and recorded as an acoustic DPOAE response in the outer ear canal.
DPOAEs provide frequency-specific physiological phenotyping markers that may be valuable
in genetic research studies. Depending on frequency, DPOAEs are usually present in
individuals with normal hearing thresholds (below 20 dB HL), sometimes present when
audiometric thresholds are at a mild level (25-40 dB HL), and generally absent when hearing
thresholds are above 40 dB HL (Gorga et al., 1997). If the middle ear function is disrupted, as
is the case with stapes fixation due to otosclerosis, or if cochlear damage occurs due to cochlear
otosclerosis, DPOAES may be reduced or absent (Chapter 3).
These absent DPOAE findings for 2143 family members with hearing loss are similar to
those presented for the otosclerotic cohort in Chapter 3. However, in Family 2143 there are 2
cases (ID A001 and A006) with normal hearing thresholds who present with absent DPOAEs.
In conclusion, DPOAEs may be sensitive, non-specific physiological markers of middle ear
and cochlear dysfunction in ears affected by otosclerosis and are under-utilized in genetic
studies of this disease.

6.4.2.2

Acoustic Reflex Thresholds

Acoustic reflexes were absent in all members of Family 2143 presenting with mixed
hearing loss but present in family members with SNHL and those with normal hearing
thresholds. This is consistent with Gelfand (1994) who report that a significant SNHL greater
than 60 dB HL is required to exhibit absent acoustic reflex. Acoustic reflex thresholds provide
another sensitive physiological phenotype measurement in families with suspected otosclerosis
because acoustic reflexes are typically absent despite otherwise normal audiological findings
(Hannley, 1993; House & Cunningham, 2010; Keefe et al., 2017).
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ARTs in conjunction with audiometry have been used as phenotyping tools to aid in the
identification of three of the ten genetic loci responsible for monogenic otosclerosis, OTSC5,
OTSC 8 and OTSC10 (Bel Hadj Ali et al., 2008; Van Den Bogaert, 2004; Weegerink et al.,
2011). These three studies have used acoustic reflexes in non-surgical family members to
determine the presence or absence of clinical otosclerosis. However, identifying a family
member as affected required the individual to have both a hearing loss (conductive or mixed)
as well as absent reflexes, and a clinical diagnosis based on these findings. Future longitudinal
studies would be beneficial to confirm whether the family member with normal hearing
thresholds and absent reflexes (ID A000) is in the early stages of otosclerosis development.

6.4.2.3

Wideband Immittance

Family 2143 demonstrates how wideband absorbance can be used in the advanced
phenotyping of families with inherited forms of otosclerosis. Three cases with normal hearing
and no conductive component exhibit an abnormal PA profile consistent with an increase in
middle ear stiffness, where the absorbance was lower in the low-frequencies compared to
normative values (IDs 0000, A000 and A001). This profile was reported in the pre-surgical
otosclerotic ears with conductive hearing losses in Chapter 4 as well as in studies focused on
PA changes also in ears with conductive hearing loss due to otosclerosis (Feeney et al., 2003;
Merchant et al., 2016; Shahnaz, Longridge, et al., 2009).
The presence of a low frequency PA peak has also been shown in the otosclerotic
population in Chapter 4 as well as in other otosclerotic populations (Nakajima et al., 2012;
Niemczyk et al., 2018; Shahnaz, Bork, et al., 2009). In family member 0009 with bilateral
conductive hearing loss, the left ear pre-operative results provide further evidence that
otosclerosis can cause a low frequency PA peak. While the conductive component was not as
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large, a similar PA peak was also present in her right ear. This PA profile was present in three
other affected individuals (0000, 0004 and A011) with hearing impairment. Finally, the
presence of low frequency PA peak around 1000 Hz was also identified in one normal hearing
possibly affected individual (A006) without overt signs of otosclerosis.
Although promising, the use of PA in isolation may be misleading given the limited
research in pathological middle ears and no specific guidelines for differentiating normal
versus abnormal PA profiles in individual subjects. In this chapter, while most ears of 2143
family members had PA values outside 1 standard deviation of the normative mean, only three
ears demonstrated PA values that were 2 standard deviations outside of the normative mean.

6.4.3

Value of Hierarchical Cluster Analysis
Hierarchical cluster analysis was a valuable method for analyzing the phenotype

features of Family 2143 and confirmed the non-statistical segregation of members into affected
versus unaffected. There were three distinct clusters which correlated with the audiometric
thresholds (mixed HL, SNHL and normal hearing thresholds) as well as the presence/absence
of ARTs and the presence/absence of DPOAEs either across the frequency range (mixed HL),
or in the high-frequencies (SNHL).
For Cluster 3, the 10 ears presenting with normal audiometric thresholds, other features
may also serve as markers of early onset of the heritable otosclerosis. A subgroup within the
normal hearing Cluster 3, including both ears of individuals A006 and A001, and the right ear
of individual A000, formed a sub-cluster; these are the same ears which were identified as
possibly affected ears using non-statistical analyses of the of the advanced phenotyping
features. A000’s left ear is the most distant from all the other ears within the Cluster 3
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apparently due to absent acoustic reflexes in both the ipsilateral and contralateral stimulus
conditions and may represent an early case of otosclerosis despite the normal audiogram.
Longitudinal audiometric thresholds and continued phenotyping are needed to confirm
otosclerotic progression in these Cluster 3 cases.

6.4.4

Phenotype Segregation using Advanced Phenotyping
The family members were separated into three categories of affected (n=7), possibly

affected (n=3) or unaffected (n=2). For the purpose of gene discovery, this breakdown of
categories based on phenotype will be used as a way to compare genetic commonalities among
affected individuals and contrast them to commonalities with the unaffected family members.

6.4.5

Conclusion and Future Direction
Guided by previous work on the variability of otosclerosis reported in the otosclerotic

population (Chapter 3 and 4) as well as within families (Chapter 5), an advanced phenotyping
approach using frequency-specific physiological measures not typically used in genetic studies
of otosclerosis, was used for segregation of a large multiplex family and will be used in future
gene discovery studies.
The identification of novel genes causing otosclerosis has been challenging. Although 8
OTSC loci have been identified in large families, these studies have failed to identify any
causative genes with the exception of FOXL1. One barrier is the availability of large families
with enough affected family members to increase the power of the genetic analysis. It is
challenging to identify new genes when conductive or mixed hearing loss or stapes surgery are
the only method classifying “affected” versus “unaffected” individuals, as is the current
convention. (Bel Hadj Ali et al., 2008; Brownstein et al., 2006; Chen et al., 2002; Thys, Van
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Den Bogaert, et al., 2007; Tomek et al., 1998; Van Den Bogaert et al., 2001; Weegerink et al.,
2011). By relying solely on audiological thresholds and surgical confirmation of the sclerotic
bone growth, identification of otosclerosis is limited to individuals with advanced otosclerosis.
Comprehensive phenotyping methods outlined in this chapter, to provide alternative hypothesis
of phenotype segregation analysis, may facilitate the next gene discovery phase in Family
2143. If successful, similar methods may be applied in yet unidentified families (Bel Hadj Ali
et al., 2008; Brownstein, Goldfarb, Levi, Frydman, & Avraham, 2006; Chen et al., 2002; Pauw
et al., 2006; Schrauwen et al., 2011; Thys, Van Den Bogaert, et al., 2007; Tomek et al., 1998;
Van Den Bogaert et al., 2001). In summary, this chapter provides a statistical approach to
phenotypic segregation analysis, and the incorporation of physiological features beyond the
clinical audiogram, to characterize a multiplex family with heritable otosclerosis. Hierarchical
cluster analysis has not been used in hearing loss gene discovery research and could be tested
in future genetic studies of auditory system dysfunction.
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Chapter 7

7

Conclusion

7.1 Overall Contributions
For many decades genetic linkage analysis has been an extremely successful method for
mapping otosclerosis loci. However, only recently has the first causative gene (FOXL1) for
autosomal dominant otosclerosis been identified (Abdelfatah, 2014).A barrier to gene
identification for heritable otosclerosis has been the lack of sensitive phenotyping and
understanding of the disease progression, which in turn limits the accurate segregation of
family members available for linkage analyses. This thesis focused on advanced phenotyping
with the goal to improve our understanding of otosclerosis in families of known and unknown
genetic etiology, and a clinical population with this disorder, and to determine whether the
Newfoundland founder mutation in FOXL1 is present in this unrelated clinical cohort.
Overall contributions of this thesis included:
1. The identification of the FOXL1 deletion outside of the Newfoundland family where
it was identified.
2. The confirmation of a strong family history of otosclerosis within the Ontario
population.
3. An advanced phenotyping analysis of an Ontario population confirming the absence
of acoustic reflexes and DPOAEs in ears with a conductive hearing loss and postsurgical ears.
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4. The identification of instrument and stimulus level effects on power absorbance and
it’s test-retest reliability
5. The initial predictive model of a progressive mixed hearing loss due to the FOXL1
deletion.
6. The application of advanced phenotyping for the purpose of future gene segregation
analysis and the identification of potential early onset otosclerotic cases within a
large family.

7.2 Conclusion, Limitations and Future Directions
Genetic screening of FOXL1 in the Ontario otosclerotic population confirmed that this
FOXL1 deletion (976¬990het_del) was present in an unrelated individual from Ontario,
Canada. This suggests that the gene and specific mutation discovered by Abdelfatah (2014) is
not isolated solely to the large Newfoundland family. This study was limited in that only the
deletion in FOXL1 was genotyped in the Ontario population. Future research should proceed
with screening other otosclerotic populations for this deletion and other potentially pathogenic
variants in FOXL1. Additional work should also include the advanced genotyping of
otosclerosis in the Ontario population, since 22 unique families with later-onset hearing loss,
and 9 unique families with otosclerosis were idenitifed in the study sample recruited for this
thesis Gentoype-phenotype evaluation of these Ontario families may unveil new causative
genes and mutations for otosclerosis.
Prior to the discovery of the FOXL1 gene, there were up to 10 genetic loci (8 published)
associated with the monogenic form of otosclerosis (Bel Hadj Ali et al., 2008; Brownstein,
Goldfarb, Levi, Frydman, & Avraham, 2006; Chen et al., 2002; Schrauwen et al., 2011; Thys et
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al., 2007; Tomek et al., 1998; Van Den Bogaert et al., 2004; Van Den Bogaert et al., 2001). So
far, none of these genetic loci have yielded the identity of the underlying gene causing
otosclerosis (Bittermann et al., 2014).
Genetic studies of autosomal dominant otosclerosis rely on careful phenotyping in order
to determine who in the family is affected and who is unaffected by this slowly progressive,
late-onset disease. There is no gold standard diagnostic test for otosclerosis, and so
determination of affection status has relied heavily on surgical confirmation in patients with
already significant hearing loss (Bel Hadj Ali et al., 2008; Brownstein et al., 2006; Chen et al.,
2002; Thys, Van Den Bogaert, et al., 2007; Tomek et al., 1998; Van Den Bogaert et al., 2001;
Weegerink et al., 2011), or impaired audiometric thresholds in conjunction with abnormal
acoustic reflexes (Bel Hadj Ali et al., 2008; Van Den Bogaert, 2004; Weegerink et al., 2011),
or in one case high-resolution imaging of the temporal bone (Bel Hadj Ali et al., 2008). All of
these genetic studies required substantial hearing loss and therefore relatively advanced disease
for their phenotyping methods. Furthermore, not all affected family members are candidates for
stapes surgery even if they have hearing loss and may be excluded from genetic analyses.
Besides the study by Bel Hadj Ali et al. (2008) who use high-resolution CT scanning as a
phenotypic tool for histological otosclerosis, none of these have taken advantage of advanced
physiological phenotyping, outside of acoustic reflexes, to explore younger generation family
members with normal hearing or mild impairments, in order to segregate affected from
unaffected family members during the early course of the disease.
WAI has shown promise for the clinical diagnosis of conductive hearing loss etiology
(Feeney et al., 2003; Nakajima et al., 2012; Prieve et al., 2013), and therefore hypothesized to
be a potentially useful phenotyping tool for genetic studies of otosclerosis. In this thesis WAI,

187

particularly PA, was evaluated for its value as a phenotypic tool in otosclerosis and was
measured using two systems, the Mimosa HearID and the Interacoustics Titan. Given the lack
of standards for this new acoustic immittance technique, a comparison of these systems was
completed and revealed that although both exhibit good test-retest reliability, the recording
instrument and testing protocol can affect PA outcomes. Therefore, instrument and stimulusspecific normative data should be used when including PA as a phenotyping tool.
In this thesis, phenotyping outcomes using WAI agree with previous literature showing
that otosclerotic ears may have lower PA in the low-frequencies than normal ears (Feeney et
al., 2003; Nakajima et al., 2012; Niemczyk et al., 2018; Prieve et al., 2013; Sanford et al., 2012;
Shahnaz, Bork, et al., 2009). However, not all otosclerotic ears exhibit this low frequency, low
absorbance profile. A sub-group of otosclerotic ears in both the small clinical cohort and in 2
multiplex families have a different profile, with a PA peak near 1 kHz. These preliminary
results are in agreement with other literature (Nakajima et al., 2012; Niemczyk et al., 2018;
Shahnaz, Bork, et al., 2009) and require further investigation to determine whether they
correlate with early stage otosclerosis, or histological variations of otosclerosis that could be
investigated through high resolution CT imaging studies (Naumann, Porcellini, & Fisch, 2005;
Quesnel et al., 2013; Redfors et al., 2012). In future, longitudinal phenotyping including PA,
and the use of temporal bone imaging may be used to detect the presence of histological
otosclerosis in the two non-penetrant FOXL1 carriers in this family. Longitudinal phenotyping
studies using PA may also provide evidence for progressive changes in PA correlating to
otosclerotic progression in early cases of the disease.
Since otosclerosis is a bone disorder characterized by abnormal bone growth, candidate
genes will be considered if they are involved in the bone remodeling process. Recently, the first
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gene causing otosclerosis was discovered in FOXL1 (Abdelfatah, 2014). FOXL1 is a
transcription factor gene, which is responsible for regulating other genes, and potentially downregulates several genes including ILIA, CXCL10, IL29, IFNB1, IFIT1, FEN1 and SP4.
Therefore, these down-regulated genes as well as other transcription factors may potentially be
involved in the development of otosclerosis and should be considered candidate genes for
future gene discovery research.
The goals of advanced phenotyping are three-fold: (1) to better understand the clinical
presentation of a specific disorder, (2) to better understand the clinical presentation of a specific
gene mutation, and (3) to support gene discovery through improved phenotypic segregation.
Future genetic studies into the genetic causes of otosclerosis should consider multiple
phenotype measures when attempting to determine genetic carriers of the affected alleles.
Cluster analysis was used for the first time in this thesis for studying genetic hearing loss, to
assist with segregation analyses. Hierarchical cluster analysis was a useful statistical technique
for analyzing multiple phenotyping measures in the preliminary investigation of auditory
phenotypic segregation in large families with heritable hearing loss. Studying the physiological
phenotype will have a positive impact on the understanding of the natural course of otosclerosis
across the lifespan and variation in the presentation of this disease. A broader understanding of
the otosclerosis disease process will support early identification and the development of new
treatments.
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Appendix A: Sequencing protocol for FOXL1 screening. Protocol retrieved from PhD thesis of
Nelly Abdelfatah (2014).
Cycle Sequencing protocol
Reagent
dH20
BDT 5x Buffer
BDT Sequencing Mix
Primer
Purified PCR Sample
Total Volume

Volume (uL)
15.68
2
0.5
0.32
1
20

Thermocycling Protocols for Cycle Sequencing
94°C for 1 min
25 cycles of:
1.
96°C Denaturation for 10s
2.
50°C Annealing for 5s
3.
60°C Extension for 4 mins
Hold at 4°
Cycle Sequencing DNA Precipitation Protocol
This step was performed after Cycle sequencing was completed, as a second purification step
before being placed on the ABI 3130xl of ABI 3730.
Step 1) DNA precipitation
• Add 65uL of 95% Ethanol (EtOH) to each well
• Add 5uL of 125mM Ethylenediaminetetraacetic acid to each well
• Let precipitate for 15 mins to overnight in dark o Can place at -20°C if preferred or if
not using plate for a few days.
Step 2) Ethanol mixture Removal
• Place plate in centrifuge, spin at 3000 RPM for 30 mins
• Remove plate from centrifuge and decant ethanol mixture onto a dry paper towel by
inverting the plate.
• Leave plate inverted on paper towel and place back in centrifuge. Spin up to 200 RPM,
and then immediately stop the spinning.
• Remove and discard paper towel.
Step 3) Rinse step
• Add 150uL of 70% EtOH to each well, and place in centrifuge.
• Spin plate at 3000 RPM for 5 mins.
• Remove plate from centrifuge and decant EtOH mixture onto a paper towel
• Leave plate inverted on paper towel and place back in centrifuge. Spin up to 200 RPM,
and then immediately stop the spinning.
• Remove and discard paper towel. Let plate dry in dark and uncovered for 20 mins
Step 4) Sample Resuspension
• Add 15 uL of Hi-Dye Formamide (HDF) to each well
• Place plate in thermocycler on ‘denat’ program o
▪ 95°C for 2 mins
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▪

Hold at 4°
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Appendix B: Results of interpretation of FOXL1 deletion pathogenicity based on guidelines
reported by the American College of Medical Genetics (Richards et. al. 2015)
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Appendix C: Family History Questionnaire

FAMILY HISTORY QUESTIONNAIRE-ADULT
Interviewer:____________________ Participant #_________________
Date: Day: ___________Month: ________________Year:__________

PARTICIPANT INFORMATION
Birth History:
Did the participant’s mother have any of the following illnesses or problems during her pregnancy (check all that apply):
Fever
Infection:
Rubella
Quinine
Cytomegalovirus
Maternal Diabetes
Retinoic Acid
Oligohydraminos Toxoplasmosis
Other:
If any selected, please specify at what stage of pregnancy the exposure occurred and the duration:
weeks for
days
Participant’s Infant Hearing Screen result:
Pass
Refer
Unknown
If refer, please specify:

Personal History:
Do you have a known medical condition, or were you born with any physical differences? If so, please describe:
Is the participant adopted?
No
Yes
Is the participant and his/her partner related by blood? (e.g. cousins?)
No
Yes
Are parents of participant related by blood?
No
Yes - If ‘Yes’ please explain how parents are related:
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FAMILY HISTORY INFORMATION
PARTICIPANT’S CHILDREN
Please continue any other important information on the back of this page
Full Name

Sex

(Please include miscarriages, stillbirths &
deceased individuals)

Date of Birth

Partner’s Name

(yyyy/mm/dd)

(Other Parent)

PARTICIPANT SIBLINGS:
Please continue any other important information on the back of this page
Full Name
(Please include deceased
individuals)

Sex

Date of
Birth
(yyyy/mm/dd)

Father’s Name

Mother’s Name

Children’s Full Name

(If different from
participant’s)

(If different from
participant’s)

( Please include miscarriages,
stillbirths & deceased
individuals)

Sex

Date of
Birth

Partner’s Name
(Other Parent)

(yyyy/mm/dd)
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MATERNAL INFORMATION
Please continue any other important information on the back of this page
Full Name

Date of Birth
(yyyy/mm/dd)

Age of
Death

If deceased
Cause of Death

(If Applicable)

Mother
Maternal
Grandmother
Maternal Grandfather

MOTHER’S SIBLINGS
Please continue any other important information on the back of this page
Full Name
(Please include deceased
individuals)

Sex

Date of
Birth
(yyyy/mm/dd)

Father’s Name

Mother’s Name

Children’s Full Name

(If different from
participant’s maternal
grandfather)

(If different from
participant’s maternal
grandmother)

( Please include miscarriages,
stillbirths & deceased
individuals)

Sex

Date of
Birth

Partner’s Name
(Other Parent)

(yyyy/mm/dd)
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Are any of the individuals listed above adopted?

Yes

No - If ‘Yes’ please list their names:

MATERNAL ETHNICITY AND AFFILIATION
Participant’s Mother
Please indicate ancestry and/or ethno religious affiliation (if
applicable)- check all that apply:

Participant’s Father
Please indicate ancestry and/or ethno religious affiliation (if
applicable)- check all that apply:

English
Polish
Portuguese
Italian
Dutch
German
Chinese
Columbian

English
Polish
Portuguese
Italian
Dutch
German
Chinese
Columbian

Mennonite
Amish
Jewish
Conference

Indian
South Korean
French Canadian
Other:

Indian
South Korean
French Canadian
Other:

Mennonite
Amish
Jewish
Conference
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PATERNAL INFORMATION
Please continue any other important information on the back of this page
Full Name

Date of Birth
(yyyy/mm/dd)

Age of
Death

If deceased
Cause of Death

Father
Paternal Grandmother
Paternal Grandfather

FATHER’S SIBLINGS
Please continue any other important information on the back of this page
Full Name
(Please include deceased
individuals)

Sex

Date of
Birth
(yyyy/mm/dd)

Father’s Name

Mother’s Name

Children’s Full Name

(If different from
participant’s maternal
grandfather)

(If different from
participant’s maternal
grandmother)

( Please include miscarriages,
stillbirths & deceased
individuals)

Sex

Date of
Birth

Partner’s Name
(Other Parent)

(yyyy/mm/dd)
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Are any of the individuals listed above adopted?

Yes

No - If ‘Yes’ please list their names:

PATERNAL ETHNICITY AND/OR AFFILIATION
Participant’s Mother
Please indicate ancestry and/or ethno religious affiliation (if
applicable)- check all that apply:

Participant’s Father
Please indicate ancestry and/or ethno religious affiliation (if
applicable)- check all that apply:

English
Polish
Portuguese
Italian
Dutch
German
Chinese
Columbian

English
Polish
Portuguese
Italian
Dutch
German
Chinese
Columbian

Mennonite
Amish
Jewish
Conference

Indian
South Korean
French Canadian
Other:

Indian
South Korean
French Canadian
Other:

Mennonite
Amish
Jewish
Conference
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FAMILY HEALTH INFORMATION
Please complete the following table. Does anyone related to the participant currently have or has had a history of the following medical conditions? For each medical condition in
the table below please select ‘Yes’, ‘No’ or ‘Unsure’. If ‘Yes’ please write the name of the person(s) and how the person(s) is/are related to the participant, in the space provided.
Please write any additional family members and information on the back of this page.

Physical Conditions

Eyes
Physical
Hypertelorism (wide spaced), Eyelid Coloboma (“notched” eyes), Ptosis (drooping
eyelids), Heterochromia (different coloured eyes), Blue sclerae (white of eyes has blue
tint), Dystropia Canthorum

Visual Problems
Progressive/Stable? Glaucoma, Cataracts, Retinitis Pigmentosa, Optic
Atrophy/Neuropathy, Severe myopia, Retinal detachment

Yes

No

Unsure





































Names of Family Members
and How they are Related to
Participant

Ears
Bony labyrinth abnormality, Malformation? –describe physical shape and size (cupped,
crumpled, ect), Absent, Low set/Rotated Placement, Ear tags/pits, Mondini dysplasia,
Dilated Vestibular Aqueduct, Abnormal/Loss of Vestibular Function

Nose
Anosmia (“Inability to smell”)

Mouth
Cleft lip/Cleft Palate, High Arched Palate, Lip Pits

Chin
Abnormalities of the Jaw Bones, Micrognathia (undersized jaw)

Neck
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Esophageal Dysfunction, Brachial Cleft Cysts or Fistulae

























Head/Face
Abnormalities of Facial Bones, Microcephaly, Macrocephaly, Midface Hypoplasia

Skin/Hair
White Streaks, Sparse or Patchy, Pigmentary Abnormalities

Teeth
Conical, Malocclusion (abnormal growth), Discoloration, “Brittle”

Other physical differences at birth (specify):_______________







Yes

No

Unsure

























Renal (Glomulonephritis, Failure)
Skeletal







Tall/Short stature, disproportionate limbs, scoliosis, congenital hip dislocation,
osteoarthritis, multiple fractures, loose joints, spondyloepiphyseal dysplasia



















Health Conditions:

Elliptocytosis
Goiter (enlarged thyroid gland)
Movement Disorders

Names of Family Members
and How they are Related to
Participant

Ataxia (episodic or progressive), Dystonia

Cardiovascular
Conduction Defects (Prolonged Q-T interval), Syncopal Episodes (fainting)

Gastrointestinal
Hirschprung disease, Enlarged liver or spleen

Tumors
Vestibular schwannoma, other rare tumors: meningioma, astrocytoma, ependymomas,
meningioangiomatosis, genital leiomyomas

Other health conditions
(specify): ____________
Developmental Delay:
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Intellectual disability (describe):


















Learning Delay (describe):
Other inherited
condition:

If there are there any additional health concerns in the family that have not previously been mentioned, please list them:

FAMILY MEMBERS WITH HEARING LOSS
Name of
Family Member:

Relation to
Participant:
Birth History

Did the individual’s mother have any of the following illnesses or
problems during her pregnancy (check all that apply):
Fever
Infection:
Rubella
Quinine
Cytomegalovirus
Maternal Diabetes
Retinoic Acid
Oligohydraminos Toxoplasmosis
Other: :
If any selected, please specify at what stage of pregnancy the
exposure occurred and the duration:
weeks for
days

Date of Birth:
(yyyy/mm/dd)
Environmental Exposure

Was the individual exposed to any of the following (check
all that apply):
Noise (occupational/environmental) Trauma to Ear
Chronic Ear Infections Aminoglycoside use
Meningitis Mastoidtis Kericterus (bilirubin
encephalopathy) Myxedema (hypothyroidism)
Surgical Procedure on Ear
Other:_____
If any selected, please specify:

Infant Hearing Screen result:
Pass
Refer
Unknown
If refer, please specify:

Devices Used
Hearing Aid
Cochlear Implant
Other: :

Speech/Language Difficulties
Yes
No
Unknown
If yes selected, please specify:

Description
Age of Onset
Congenital
Child
Adult
Unknown

Progressive?
Yes
No
Unknown

Type
Conductive
Sensorineural
Mixed
Unknown

Physical Features?
Yes
No
Unknown
If yes selected, please
specify:

Previous Medical Evaluations Performed

Audiogram(s)

ABR

BAER

Other evaluations:
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Has anyone in your family previously been referred for genetic counseling and/or genetic testing?
If Yes, please state where:
For what reason?

Yes

No

Unsure
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Appendix D: Mean (M) and standard deviation (SD) air conduction thresholds and air-bone gaps (ABG) for surgical ears (n=42),
suspected otosclerotic ears (n=14), normal ears (n=11) and SNHL ears (n=3).

Surgical
Air

Suspected Otosclerotic
ABG

Air

Normal

ABG

Air

SNHL
ABG

Air

ABG

Frequency
(Hz)

M

SD

M

SD

M

SD

M

SD

M

SD

M

SD

M

SD

M

SD

250

30.70

14.94

25.38

14.02

39.64

10.46

33.85

7.40

13.18

6.03

16.00

6.15

36.67

18.93

18.33

7.64

500

30.81

17.21

16.98

15.85

42.86

9.94

28.21

7.99

11.36

5.52

10.00

6.32

45.00

13.23

6.67

7.64

1000

28.12

16.28

15.91

12.46

39.64

10.82

20.71

8.29

10.91

4.37

9.09

4.91

38.33

16.07

8.33

5.77

2000

30.70

17.81

8.95

8.77

33.57

13.07

9.64

7.20

8.18

4.62

1.36

5.52

36.67

17.56

1.67

5.77

4000

33.14

22.52

8.60

9.84

35.36

15.99

12.14

8.02

8.18

9.02

0.00

4.47

36.67

16.07

5.00

5.00

8000

49.07

24.74

45.71

18.49

20.00

18.03

41.67

17.56
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Appendix E: Mean power absorbance (PA) for Mimosa HearID and Interacoustics Titan (n=50
ears) obtained at 65 dB SPL. Error bars represent standard deviations. Significant differences
in PA between instruments are bolded.
95% Confidence Interval
Mean
Frequency

Lower Bound

Upper Bound

Mimosa

Titan

Mimosa

Titan

Mimosa

Titan

250

0.090

0.195

0.071

0.167

0.109

0.223

315

0.122

0.213

0.098

0.178

0.145

0.248

397

0.177

0.317

0.145

0.275

0.209

0.358

500

0.251

0.381

0.207

0.331

0.294

0.431

630

0.366

0.480

0.310

0.423

0.422

0.537

794

0.491

0.597

0.429

0.535

0.554

0.659

1000

0.575

0.671

0.521

0.616

0.629

0.726

1260

0.631

0.717

0.579

0.672

0.684

0.762

1587

0.645

0.677

0.594

0.627

0696

0.726

2000

0.663

0.682

0.616

0.634

0.709

0.730

2520

0.713

0.642

0.666

0.581

0.760

0.704

3175

0.703

0.579

0.654

0.506

0.752

0.652

4000

0.604

0.399

0.535

0.309

0.673

0.489

5040

0.349

0.419

0.232

0.352

0.466

0.486

(Hz)
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Appendix F: Results of 1000’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance. Acoustic reflex thresholds results represent probe in the right ear. ‘A’
denotes ‘absent’ reflex, and WBN denotes “wideband noise”. Acoustic immittance results
report ear canal volume, tympanometric peak pressure (TPP) and compliance.
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Appendix G: Results of 1000’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance. Acoustic reflex thresholds results represent probe in the right ear. ‘A’
denotes ‘absent’ reflex, and WBN denotes “wideband noise”. Acoustic immittance results
report ear canal volume, tympanometric peak pressure (TPP) and compliance.
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Appendix H: Results of 0000’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix I: Results of 0000’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix J: Results of 0009’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix K: Results of 0009’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix L: Results of 0002’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix M: Results of 0002’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix N: Results of 0003’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix O: Results of 0003’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix P: Results of 0004’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix Q: Results of 0004’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix R: Results of A011’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix S: Results of A011’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix T: Results of A000’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix U: Results of A000’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix V: Results of A001’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix W: Results of A001’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix X: Results of A002’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).

228

Appendix Y: Results of A002’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix Z: Results of A006’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).

230

Appendix AA: Results of A006’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix BB: Results of 0008’s left ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).
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Appendix CC: Results of 0008’s right ear audiometric thresholds, acoustic reflex thresholds,
acoustic immittance, distortion product otoacoustic emissions (DPOAE) and power absorbance
(PA). Acoustic reflex thresholds results represent probe in the right ear. ‘A’ denotes ‘absent’
reflex, and WBN denotes “wideband noise”. Acoustic immittance results report ear canal
volume, tympanometric peak pressure (TPP) and compliance. Distortion product otoacoustic
emissions meeting the criteria to be considered present are denoted by an asterisk (*).

233

Appendix DD: Western University Research Ethics Approval Documentation.
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Appendix EE: Memorial University of Newfoundland Research Ethics Approval
Documentation.
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Appendix FF: Letter of Information and Consent Forms
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